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ABSTRACT 
DAVID B. WEI: Economic Evaluation of Biological Therapy Use  
among Patients with Crohn's Disease 
(Under the direction of Dr. Joel F. Farley) 
 
 Crohn’s disease (CD) is a chronic inflammatory disorder that substantially impairs 
quality of life for patients and entails enormous economic burden to the US society. 
Biological therapies can effectively treat Crohn’s disease. The treatment strategy of using 
biological therapy for CD is currently shifting from the conventional 'bottom-up' approach 
that reserves biological therapy as the last medical resort to a more aggressive 'top-down' 
approach that endorses early use of biological therapy. This dissertation sought to evaluate 
the impact of this shift in treatment on healthcare utilization by CD patients and healthcare 
costs to payers.  
 First, we examined healthcare utilization and costs for CD patients  in a large claims 
database dating from 2005 to 2009. We found that early biological users had lower utilization 
of inpatient services and higher prescription drug costs than late biological users. Annual 
medical costs for both biological user groups were comparable. We constructed a decision 
tree model and conducted budget impact analysis to predict the financial ramifications for 
third party payers of the change in prescription drug costs resulting from top-down treatment 
approach. Our results showed that the top-down approach of biological therapy was 
associated with increased prescription drug costs in the first year of disease. Incremental drug 
costs from top-down approach were significantly reduced in the second and third years 
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following CD diagnosis. Last, we conducted a cost analysis to compare total healthcare costs 
for patients who adopted biological therapy following top-down or bottom-up approach. We 
found that patients following the top-down strategy incurred higher healthcare costs in the 
first year of disease. In the second and third years, the top-down strategy appeared to be cost 
neutral, which was mainly attributed to a cost reduction in non-drug services.  
 In conclusion,  novel biological therapies have been increasingly used among CD 
patients, and the new top-down treatment strategy can affect allocation of healthcare costs. 
Top-down treatment approach resulted in higher prescription drug costs for patients, 
especially in the first year of disease, when compared to patients following the conventional 
bottom-up approach. The top-down strategy for CD is projected to be cost neutral in the long 
term. 
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CHAPTER I: 
INTRODUCTION 
1.1 Overview 
Crohn’s disease (CD) is a chronic inflammatory disorder that affects around a half 
million Americans.[1] Despite its relatively low prevalence compared to other common 
gastrointestinal disorders, CD substantially impairs quality of life for patients and entails 
enormous economic burden to the US society.[2] In 2006, total direct medical costs were 
estimated at $18,000 per patient and over $10 billion to the US healthcare system.[3] 
Prescription drug expenditure accounted for the largest proportion of medical costs (35.3%) 
in 2003, an increase of almost 25% since 1990's.[4-6] Costs for prescription drugs may 
increase even more with several novel drug therapies entering the market that are FDA-
approved for clinical use. 
Biological therapy is a novel drug class approved by the FDA for treatment of 
Crohn’s disease. Biological agents (including infliximab, adalimumab, natalizumab and 
certolizumab pegol) are clinically effective for moderate to severe disease, resulting in rapid 
onset of mucosal healing, better quality of life, and maintenance of remission.[7-9] The 
beneficial effects of these biological therapies have resulted in a notable change of CD 
treatment options since the approval of infliximab (Remicade®, Centocor) by the FDA in 
1998.  
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Prior to the era of biological therapy, first-line treatment for patients with moderate 
and severe disease consisted of low-dose steroids and/or antibiotics, then followed with 
azathioprine and 6-mercaptopurine (6-MP) as maintenance therapy. These traditional 
therapies were not clinically satisfactory, and often caused serious side effects. As many as 
75% of CD patients required surgery for management of their disease after failing to respond 
to these pharmacological therapies, and more than 40% of CD patients needed subsequent 
surgeries.[10]  
With a growing number of new biological agents under investigation, these biological 
drugs play a more important role in the therapeutic regimen for Crohn’s disease. Biological 
therapies have proven to be potent and effective disease modifiers, and are widely prescribed 
to CD patients. However, treatment strategy has been under debate in recent years as 
clinicians determine the optimal stage of the disease to introduce biological therapy. Under 
current Crohn’s disease management guidelines, biological therapies are generally reserved 
for patients who fail to respond to first-line therapy.[11] This conservative approach entails 
starting treatment with conventional drugs, then moving to more advanced biological 
therapies as the disease progresses. This approach, referred to as 'bottom-up' therapy, has 
long been the mainstay of clinical practice with regard to biological therapies for CD patients. 
A new and more aggressive approach promotes the use of biological therapies at the early 
stage of disease before patients become glucocorticoid dependent and possibly even before 
glucocorticoid treatment is initiated. This approach, noted as 'top-down' therapy, has gained 
more popularity in recent years. Clinical evidence from newly published studies has shown 
that patients adopted biological therapies early in disease course had experienced superior 
mucosal healing, more rapid remission, and a higher rate of remission when compared to the 
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late adopters.[12, 13] It is believed that the early use of biological therapies may alter natural 
disease progression, and provide great benefits to patients. Thus, the treatment paradigm for 
Crohn’s disease is currently shifting from the conventional bottom-up approach to a more 
aggressive top-down approach.  
Despite their clinical efficacy, innovative biological therapies are associated with 
substantial drug cost. The annual drug costs of biological therapies are three to four times 
higher than conventional, non-biological drugs.[10] Because treatment strategy for CD is 
shifting to include biological therapies in the first-line treatment, a surge of biological 
therapy use is anticipated in the next few years. This rapid increase of high-cost medications 
raises concerns about the extent of reimbursement that payers will provide for these drugs in 
the long term. To contain healthcare costs, payers may practice a variety of strategies, 
including prior authorization, closed formulary, tiered copayments and coinsurance.[14] 
These policy changes can potentially affect the access to these novel drugs, and limit the 
therapeutic benefits to patients in need. Therefore, in order to understand the financial 
implication to payers, it is imperative to study the economic outcomes of CD patients due to 
the shifting treatment strategy.  
In the literature to date, no studies evaluated the economic outcomes for CD patients 
during the transition of treatment strategy changes from bottom-up to top-down approach. 
Recent economic studies have commonly used cost-utility or cost-effectiveness analysis 
(CUA/CEA) to demonstrate the value of novel biological therapies, but the validity of the 
data sources is questionable, providing limited generalizability and usefulness. The cost data 
were outdated and did not account for the increasing trend of drug cost and new biological 
therapies approved for CD treatment in recent years. Additionally, the effectiveness data 
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were often based on the results from clinical trials, instead of 'real-world' patient data. In this 
dissertation, I will take a real-world data approach based on a large administrative database 
to assess the economic impact from the top-down therapy for CD. 
 
1.2 Specific Aims 
A potential surge in the use of biological therapies among CD patients due to the 
treatment strategy change from bottom-up to top-down approach raises concerns about the 
affordability and sustainability of third party payers, and, in the long run, the well-being of 
CD patients. To cope with the overwhelming financial burden, payers may potentially change 
their policies, thereby limiting patients access to novel biological therapies.  Lack of 
information about the economic outcomes from CD patients hinders further research 
regarding the affordability and sustainability of payers in the healthcare system. In this 
dissertation, I will evaluate the effect of this treatment strategy change on : a) the short-term 
and long-term economic outcomes of CD patients; b) payer's affordability, determined by 
conducting a budget impact analysis, and c) long-term sustainability, assessed by conducting 
a  comprehensive cost analysis. To ensure the validity of these analyses, this dissertation will 
use a real-world large database that contains healthcare service information for millions of 
patients over time.  From this large database, two comparison cohorts will be formed 
according to their clinical utilization data in recent years: a) bottom-up users with late 
adoption of biological therapies; b) and top-down users with early adoption of biological 
therapies. The economic outcomes of both patient cohorts are evaluated annually based on 
claims data from 2005 to 2009, and will be used to estimate their outcomes in the first three 
years following CD diagnosis. Economic evaluations for payers, including a budget impact 
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analysis and cost analysis, will be based on the predicted outcomes of CD patients.  The 
specific research aims are as follows: 
Aim 1: To estimate the utilization and costs of healthcare services used by CD patients, 
and to compare the utilization and costs between early and late biological users     
This aim will be addressed by analyzing the commercial medical and pharmacy 
claims of CD patients from 2005 to 2009. Utilization and costs associated with different 
healthcare services, including inpatient hospitalization, outpatient visits, emergency room 
visits and prescribed medications, will be extensively examined. More specifically, 
utilization rates and costs of healthcare services will be compared between different CD 
patient cohorts, which are designated below. 
Cohort Comparison 1: Biological Therapy Users vs. Non-Biological Therapy Users 
Patients will be classified as biological therapy users if they used any amount of 
biological therapies following a confirmed diagnosis of CD. Non-biological therapy users are 
CD patients who used no biological therapies at any time during the course of their disease. 
For each year from CD diagnosis, healthcare utilization and costs in these two patient groups 
are summarized for comparison. 
Cohort Comparison 2: Top-down Biological Users vs. Bottom-up Biological Users 
Biological therapy users are categorized according to their treatment strategy. Under 
conventional bottom-up approach, biological therapies are reserved as the last 
pharmacological resort after patients failed in other pharmacotherapies, including 5-
aminosalicylic acid (5-ASA), 6-mercaptopurine(6-MP) and glucocorticoids. Thus, patients 
who used biological therapy following any conventional non-biological drugs are considered 
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bottom-up biological users. Top-down biological users are those who directly used any 
biological therapy in the first line treatment.  
Aim 1a: To calculate the utilization and costs of healthcare services for all CD 
     patients by cohort from 2005 to 2009 
Descriptive statistics will be calculated for healthcare utilization and cost variables 
for CD patients in four different cohorts according to the claims data from 2005 to 2009. 
Healthcare utilization is measured by the following outcome variables: number of outpatient 
visits, number of inpatient visits, total length (in days) of inpatient stays, number of 
emergency room visits, and number of prescriptions. Healthcare costs include the total 
amount paid by payers in the following service sectors: outpatient visits, inpatient visits, 
emergency room visits, and prescription medications. 
Aim 1b: To compare utilization and costs between early and late biological users 
     from 2005 to 2009, and estimate the utilization and costs for patients in 
     both cohorts in the first three years of disease  
Multivariate regression models are employed to examine all individual utilization and 
cost variables between top-down and bottom-up biological users. The between-group 
differences will be adjusted by a number of covariates, including patient characteristics, 
health plan type and healthcare service provider types. The patient characteristics in the 
regression model include demographic characteristics (age, gender, race, region, and 
insurance coverage), and patient’s general health condition (comorbidity). Health plan type 
contains patients' healthcare insurance information, including health plan type (PPO, POS, 
and HMO). Healthcare service provider characteristics include provider specialty. The 
following outcomes will be calculated: a) the differences in healthcare service costs between 
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early and late biological users - the economic outcomes for the new treatment strategy 
change; b) the differences in prescription drug costs between the two biological user groups 
in the first year of disease - the short-term economic outcome; and c) the differences in 
overall healthcare services between the two groups in the coming three years - the long-term 
economic outcome. Predictions for both short and long-term economic outcomes are 
provided in subsequent economic evaluations under Aim 2 and Aim3. 
 
Aim 2: To assess the impact of short-term economic outcome for CD patients on third 
party payers based on the changing treatment strategy for disease management 
Based on the prediction of short-term economic outcomes for CD patients in both 
early and late biological users, a budget impact analysis (BIA) will be used to estimate the 
financial implications of the new CD treatment paradigm to third party payers, in particular, 
the prescription drug expenditures to pharmacy benefit managers (PBMs) in managed care 
organizations (MCOs). The change in prescription drug costs from the current late adoption 
treatment approach to the new early adoption approach will be predicted for the first year of 
disease, and the second and third years of disease as well. A decision tree will be constructed 
to compare the accumulated prescription drug costs, including costs for biological therapies, 
between these two treatment approaches. In addition, probabilistic sensitivity analyses will 
be performed to examine the robustness of the estimation from the variation of input 
parameters. The result of the budget impact analysis can be used by PBMs to forecast the 
incremental cost or savings in the first three years of disease due to the changing treatment 
strategy. 
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Aim 3: To evaluate whether or not the top-down approach for CD management is more 
cost-saving than the bottom-up approach  for third party payers when 
accounting for the long-term economic outcomes of CD patients 
To address this aim, the costs associated with a broader range of healthcare services, 
including inpatient visits, emergency room (ER) visits, outpatient visits, and prescription 
drugs, will be collectively examined to determine whether or not the new treatment paradigm 
is cost-saving in both the short (one-year) and long (three-year) term. A decision tree is 
designed to model the two treatment approaches according to disease severity and treatment 
response. 
An accurate assessment of budget impact from the aggressive top-down treatment 
approach can facilitate third party payer decisions regarding whether or not formulary 
changes are needed to cope with the change of treatment strategy. Unfavorable modifications 
to the formulary could prevent patients from accessing the novel therapy, and further reduce 
their well-being in the long term. A reliable prediction of the impact on total medical costs 
can inform payers, as well as healthcare administrators and providers, regarding the long-
term benefits associated with the top-down approach. 
 
1.3 Dissertation Outlines 
 Following the Introduction (Chapter I), Chapter II provides further background 
information and a systematic review of related literature. In Chapter III, theoretical and 
conceptual frameworks are established, and Chapter IV provides a detailed discussion of the 
research methods. Chapters V, VI and VII are each dedicated to one research manuscript. 
Study findings and limitations are summarized in Chapter VIII. 
   
 
 
 
 
CHAPTER II: 
BACKGROUND AND LITERATURE REVIEW 
 
 This chapter consists of two sections. The first section provides the background 
information related to Crohn's disease, including disease epidemiology, disease management, 
medical treatments, and economic data. The second section is a rigorous review of related 
literature.   
 
2.1 Background 
2.1.1  Disease Epidemiology 
Crohn’s disease (CD) is a major inflammatory bowel disease (IBD) that can affect 
any portion of the gastrointestinal (GI) tract from the mouth to the perianal area, but 
primarily the small intestine and colon.[10]  The disease is relapsing and characterized by 
diarrhea, abdominal pain, fatigue, fever, clinical symptoms of bowel obstruction, and passage 
of blood and mucus. Patients may also develop strictures, abscesses, or fistulas.[15] This 
chronic GI disorder affects around a half million Americans with incidence rate at 
5.8/100,000 person-year and prevalence rate of 144/100,000.[1, 16] The peak incidence of 
CD occurs in patients between the ages of 15 and 25 years.[17] With regard to gender, more 
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studies show a male predominance. [18] The risk for Crohn's disease is influenced by genetic 
factors, and elevated by cigarette smoking, however, the etiology and pathogenesis of CD 
remain obscure.[19] Crohn’s disease continues to be among the most challenging chronic 
illnesses in clinical practice.[20] 
 
2.1.2  Disease Morbidity and Mortality 
 Crohn's disease is characterized with an elevated mortality rate and significant 
morbidity. Population-based epidemiological studies showed that the mortality rate of CD is 
20-70% higher than that in the general population.[21, 22] Recent studies reported that 
exposure to new biological therapy, such as infliximab, did not significantly change the 
mortality rate and relative risk of death. The mortality rate was 0.53 per 100 patient-year for 
patients who were treated with infliximab, a biological drug, which is similar to 0.43 for 
those who were not.[23, 24]  
 Surgery is inevitable for the majority of CD patients after all other medical 
interventions have failed.  Cohen et al. reported that 79% of CD patients will need surgery at 
some point in their lives, and 45% of these patients require a second surgery. The annual rate 
of surgery recurrence is 8-10%.[10] 
Corticosteroids are only used for patients with more severe disease, particularly those 
requiring hospitalization due to potential side effects and long-term dependency. Therefore, 
use of corticosteroids is an important indicator of disease severity. A population-based study 
reported that 43% of patients from Olmsted County, Minnesota used steroids.[25] Two 
studies conducted in Europe showed that higher percentages of patients have used 
steroids.[26, 27]    
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2.1.3  Disease Management 
At present, CD is neither medically nor surgically curable. Therapeutic goals for CD 
are to induce and maintain disease remission, improve quality of life, and minimize long-
term effect from toxicity and complications.[11] Although the disease management plan for 
individual patient is tailored according to his or her response and tolerance to medical 
interventions, disease severity, disease location, and disease-related complications are the 
key factors prompting medical and surgical treatment decisions in clinical practice. Severity 
of Crohn's disease is often measured by the Crohn’s Disease Activity Index (CDAI), a 
research tool quantifying symptoms. The CDAI consists of eight clinical components, such 
as the number of liquid or soft stools each day for seven days. Each component is weighted 
based on a point system, and the CDAI is the sum of all points for each component. 
According to the CDAI score, disease severity is separated into four categories: a) 
asymptomatic remission (CDAI<150); b) mildly to moderately active (CDAI 150-220); c) 
moderately to severely active (CDAI 220-450); and d) severe-fulminant (CDAI>450). 
Generally, the therapeutic approach consists of the following sequential steps: a) treat acute 
disease; b) induce clinical remission; c) maintain response/remission; and d) if necessary, 
surgery. However, medical therapy can be quite different depending on disease severity.[11] 
Mild to moderate active disease is commonly treated with oral mesalamine or sulfasalazine 
daily. Moderate to severe disease is often treated with prednisone daily. Azathioprine, 6-
mercaptopurine (6-MP), and methotrexate are prescribed for steroid-induced remission or 
steroid-refractory disease. Anti-TNF monoclonal antibodies can be considered for patients 
who have not responded to corticosteroids and immunosuppressive agents. For patients with 
severe or fulminant disease, higher doses of corticosteroids, broad-spectrum antibiotics, and 
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immunosuppressants (e.g., tacrolimus) are indicated. Surgical intervention is recommended 
for patients who have failed to respond or experience worsening symptoms. Below are the 
current guidelines for patients with mildly to moderately active and severe Crohn’s 
disease.[11]  
 
2.1.4  Medical Therapies 
Aminosalicylates (sulfasalazine or mesalamine) are the most common drugs prescribed for 
Crohn’s disease to prevent or control inflammation. In patients with mild to moderate disease 
activity, aminosalicylates have been shown to be effective up to 80% of the time. The 
primary active component is 5-aminosalicylic acid (5-ASA). Most of 5-ASA drugs (eg. 
sulfasalazine) are delivered to the colon, so the aminosalicylates are more effective for 
patients with active colonic or ileocolonic disease, but are relatively ineffective for patients 
with isolated small bowel disease. The 5-ASA drugs have a number of side effects, and are 
not helpful in patients with more severe disease. 
Antibiotics (ciprofloxacin or metronidazole) are suggested when aminosalicylates can not 
control symptoms. 
Steroids (prednisone or budesonide) are used to treat the disease if symptoms persist. 
Steroids can not achieve long-term remission, and are associated with a large number of side 
effects, and can cause dependency.  
Immunomodulators (azathioprine, 6-MP, methotrexate) are used as maintenance therapy to 
keep patients in remission, however, the overall response rate is not satisfactory. 
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Figure 2.1   Bottom-up Treatment Guidelines 
 
Mild to Moderate Disease 
 
Source:  Lichtenstein et al, Management of Crohn's disease in adults.
 
Severe Disease 
 Am J Gastroenterol, 2009.
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Biological therapies (infliximab, adalimumab, natalizumab, and certolizumab pegol) are 
biological therapies that have demonstrated efficacy in multiple clinical trials for patients 
with moderate to severe Crohn’s disease.  
Immunosuppressants (cyclosporine, tacrolimus) are occasionally used  to treat CD patients 
who have not responded to conventional drugs (e.g., steroid resistance). Concerns about their 
long-term toxicity (especially high risk of renal injuries) have restricted the use of 
immunosuppressants to CD patients.[28]  
 
2.1.5  Biological Therapy 
Conventional drug therapies for CD treatment, including 5-ASA, corticosteroids and 
immunomodulators, have a relatively low response rate and only 50% of patients achieve 
sustained remission. Those treatments also cause many side effects, such as toxicity from 
corticosteroids and cytopenia from azathioprine.[29, 30] Although the etiology of CD 
remains unclear, dysregulated immune responses are believed to play an important role in the 
process of CD development.[31] Monoclonal antibodies can be specifically designed to 
modulate immune cell proliferation and, indeed, biological therapies that target immune 
pathways have emerged as a novel and effective therapeutic class for many immune 
mediated disorders, including rheumatoid arthritis, psoriasis, cancer, and Crohn’s disease. 
For example, infliximab, adalimumab and certolizumab pegol are anti-tumor necrosis factors 
(Anti-TNFs). They can inhibit over production of TNF, which is an important pro-
inflammatory cytokine involved in the pathogenesis of Crohn’s disease.[32] Four biological 
therapies have been approved by the FDA for treatment of Crohn’s disease. 
 15 
 
Infliximab (Remicade®) is a chimeric monoclonal antibody directed against tumor 
necrosis factor (TNF)-α that has shown efficacy in the treatment of patients with moderately 
to severely active Crohn’s disease that fail to respond to other treatment options or those with 
fistulising disease. Infliximab treatment is generally initiated with a single intravenous 
infusion at a dosage of 5 or 10 mg/kg as induction therapy, and followed by repeated doses 
every four weeks at a dosage of 5 mg/kg to sustain clinical remission. 
Adalimumab (Humira®) is a recombinant human IgG1 monoclonal antibody specific 
for human TNF. In randomized clinical trials, a greater percentage of patients treated with 
160/80 mg of adalimumab achieved induction of clinical remission versus placebo after four 
weeks of treatment. A greater portion of patients, who experienced a clinical response after 
induction treatment, achieved clinical remission with a dose of 40 mg in the bi-weekly 
maintenance group compared to the placebo maintenance group. Adalimumab is 
administered by subcutaneous injection, and initial dose (Day 1) was 160 mg, followed by 80 
mg two weeks later (Day 15). At Day 29, patients began a maintenance dose of 40 mg every 
other week. 
Natalizumab (Tysabri®) is a recombinant humanized IgG4κ monoclonal antibody 
produced in murine myeloma cells. The safety and efficacy of natalizumab were evaluated in 
three randomized trials. Induction of clinical response was assessed at Week 10 in the first 
trial, and at Week 8 and 12 in the second. Maintenance of response was evaluated at Months 
9 and 15 in the third trial. The recommended dosage is 300 mg intravenous infusion in every 
four weeks. 
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Table 2.1    Biological Therapies for Crohn's disease 
Brand 
Name 
Generic 
Name Manufacturer 
FDA 
Approval 
Dosage & 
Route Co-Indications 
Remicade® infliximab Centocor 8/24/1998  Intravenous 
Infusion, 
5mg/kg at 0, 
2, and 6 
weeks, then 
every 8 
weeks. 
Ulcerative Colitis, 
Rheumatoid 
Arthritis, 
Ankylosing 
Spondylitis, 
Psoriatic Arthritis, 
Plaque Psoriasis 
Humira ®  adalimumab Abbott 2/27/2007 
(12/31/2002 
for RA) 
Subcutaneous 
Injection, 160 
mg on Day 1, 
80 mg on Day 
15, 40 mg 
every 2 
weeks.  
Rheumatoid 
Arthritis, 
Ankylosing 
Spondylitis, 
Psoriatic Arthritis, 
Plaque Psoriasis, 
Juvenile Idiopathic 
Arthritis 
Tysabri ®  natalizumab Biogen Idec 
and Elan 
1/14/2008 
 
Intravenous 
infusion, 300 
mg, every 4 
weeks.  
Multiple Sclerosis 
Cimzia ® certolizumab 
pegol 
UCB 4/22/2008 Subcutaneous 
injection, 400 
mg at weeks 2 
and 4, then 
400 mg every 
4 weeks 
Rheumatoid 
Arthritis 
Source: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/   (Labeling information) 
 
Certolizumab pegol (Cimzia®) is a recombinant, humanized antibody Fab’ fragment 
with specificity for human tumor necrosis factor alpha (TNF-α). The efficacy and safety of 
certolizumab pegol were assessed in two randomized clinical trials. Compared to patients in 
the placebo group, a greater proportion of certolizumab pegol-treated patients achieved 
clinical response at Week 6 (induction) and Week 26 (maintenance).  The recommended 
initial adult dose of certolizumab pegol is 400 mg (given as two injections), and following by 
the same dose at Weeks 2 and 4. In patients who exhibit a clinical response, the 
recommended maintenance regimen is 400 mg every four weeks. 
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A growing number of new biological therapies are under investigation. More 
biological therapies may be approved by the FDA and added to the therapeutic pyramid for 
the treatment of Crohn’s disease. 
 
The advent of new drug therapies has not only brought more treatment options to 
patients, but has also changed the landscape of the treatment strategy. All four biological 
agents (see Table 2.1) demonstrated therapeutic benefits to patients in multiple clinical 
trials.[7-9] These benefits included: a higher response rate in the induction for patients with 
more severe disease, rapid onset of clinical response within 2 weeks, greater effectiveness in 
maintaining long-term remission, and significant improvement in health-related quality of 
life. Due to the lack of a long-term safety profile, however, the use of novel biological 
therapies has been controversial in clinical practice in recent years. 
 
2.1.6  Revolution of Disease Treatment Approach 
The introduction of biological therapies in the past decade has resulted in 
considerable changes in the Crohn’s disease treatment paradigm. Prior to the approval of 
infliximab, therapeutic options for CD patients were limited. Most patients underwent 
surgeries once they failed to respond to conventional treatments. While novel biological 
therapies have been prescribed to patients with active Crohn’s disease, treatment algorithms 
emphasizing on the optimal time to introduce biological therapies have been evolving as 
more efficacy data become available. 
The conventional treatment approach advocates biological therapies as the last 
medical resort. Biological therapies are generally used in patients who are refractory or 
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intolerant to conventional drugs. This so-called 'bottom-up' or 'step-up' approach has been 
recommended in most CD management guidelines worldwide. Toxicity, immunogenicity, 
and lack of efficacy data about biological therapies as first-line treatment have been major 
concerns that limit their use for CD patients. 
A new and more aggressive ‘top-down’ treatment approach has gotten considerable 
attention from inflammatory bowel disease (IDB) specialists.[33] Early introduction of 
biological therapies into the CD treatment regimen can increase their therapeutic benefit, 
partly by changing the natural course of disease progression. Compared to the bottom-up 
approach, the top-down therapy introduces biological therapies as first-line treatment, either 
in combination with immunomodulators or as monotherapy alone. A flow chart depicting 
both treatment approaches is shown in Figure 2.2. 
Two recent studies, SONIC1 for infliximab[12] and an open randomized study [13], 
have shown that the top-down approach is superior to the bottom-up approach among CD 
patients who were naïve to steroids and biological therapies. Study treatment arms including 
patients who received biological therapies early in course of their disease were found to have 
a more rapid remission and higher remission rate than those who received standard therapy. 
Evidence in these two recent studies will substantially change the perspective of the use of 
biological therapies. The treatment paradigm for Crohn’s disease is shifting from the 
conventional therapeutic algorithm to early aggressive treatment approach. 
In regards to the notation of CD treatment strategy, 'bottom-up' (or 'step-up') and 'top-
down' are frequently used in the literature to represent the conventional and early aggressive 
approaches respectively. These notations are rather conceptual with no consensus about their 
                                                 
1
 Study of Biologic and Immunomodulator Naive Patients in Crohn's disease (SONIC) was a Phase III trial 
comparing infliximab and infliximab and azathioprine in the treatment of Patients with Crohn's disease. 
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definition in clinical practice. In this dissertation, we simply consider patients who adopted 
biological therapy early in disease course as top-down users, and those who used biological 
therapies later after attempting conventional drugs as bottom-up users. 
 
Figure 2.2   Comparison of CD Treatment Approaches 
 
2.1.7  Economics of Crohn’s Disease  
In 2007, U.S. healthcare spending increased by 6.1 percent to $2.2 trillion, or $7,421 
per person. The healthcare portion of the gross domestic product (GDP) reached 16.2 
percent.[34] Despite its relatively low prevalence compared to other common GI disorders, 
CD substantially impairs quality of life for patients, and entails high morbidity and  
Flare with mild to moderate 
activity: 
• Oral corticosteroids 
• 5-ASA 
• Oral antibiotics 
Flare with severe activity: 
• IV corticosteroids, plus 
• 6-MP/AZA 
• MTX 
NO remission 
• Consider other medical 
therapy, or 
• Consider surgical 
intervention 
 
NO remission, with severe activity 
• AZA/6-MP + anti-TNF 
• MTX + anti-TNF 
• Anti-TNF alone 
Bottom-up Approach 
NO remission 
• Consider other medical 
therapy, or 
• Consider surgical 
intervention 
 
Flare with active disease 
• AZA/6-MP + anti-TNF 
• MTX + anti-TNF 
• Anti-TNF alone 
Top-down Approach 
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enormous economic burden.[2] The average annual direct cost of healthcare per patient was 
estimated at $8,727 in 1992[4], $12,417 in 1994[5], and $8265 in both 2003 and 2004[6]. 
Although the annual direct cost was relatively stable, the cost distribution for different 
healthcare services has changed significantly.  In 1992 and 1994, drug costs only accounted 
for a small percentage of the total direct costs, and were 4.6% and 3.5%, respectively. 
Hospital costs contributed to the majority of expenses at 55.8% in 1992 and 57.3% in 1994.[4, 
5] In both 2003 and 2004, pharmaceutical claims accounted for the largest proportion of 
direct cost (35.3%), then followed by hospitalization (31.4%).[6] This drastic change in cost 
distribution is primarily attributed to the emergence of biological therapies for the treatment 
of CD in the past decade. The annual drug cost, including the drugs themselves, as well as 
drug administration and wastage, was estimated at $17,176 for adalimumab-treated patients, 
and $18,214 for infliximab-treated patients in 2007.[35] With the treatment strategy shifting 
from the bottom-up to the top-down approach, biological therapies will be used among a 
larger portion of patients, and will likely be used for long-term maintenance. A massive 
increase in the use of these expensive drugs will add to the financial burden for third party 
payers and patients. However, these highly effective drugs might potentially be cost-saving if 
patient utilization of health care resources is reduced. For example, a study conducted with 
the CD population at the University of Chicago showed that one year's use of infliximab was 
associated with significant decreases in many areas, such as: surgery (38%), gastrointestinal 
surgeries (18%), endoscopies (43%), radiographs (12%), ER visits (66%), and 
hospitalizations (59%).[36] This dissertation is therefore enlightened to overcome the lack of 
information about long-term economic value of novel biological therapies. 
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In addition to direct medical costs, indirect costs can constitute a substantial portion 
of total costs incurred by Crohn’s disease. Indirect costs include expenses associated with 
disability, days off from work, transportation, and time spent with family. It has been 
estimated that 5-10% of CD patients each year are unable to work.[4] There is great 
anticipation that the clinical effectiveness of novel biological therapies will be translated into 
a substantial reduction of disability and overall indirect costs. 
 
 
2.2 Literature Review 
2.2.1  Overview 
In this section, peer reviewed journal articles from the past fifteen years are rigorously 
reviewed for the development of this dissertation. This review focuses on the following 
major areas corresponding to the research aims: a) use of biological therapies among Crohn's 
disease patients; b) healthcare costs related to Crohn's disease; and c) economic evaluation of 
biological therapies targeted for the treatment for Crohn's disease. After a thorough review of 
the literature, research gaps in each targeted area are identified, which support the research 
aims of this dissertation. 
 
2.2.2  Use of Biological Therapies in Crohn's Disease Patients 
 Conventional medical therapies (including aminosalicylates, corticosteroids, 
antibiotics, and immunosuppressors) for Crohn's disease can help patients achieve and 
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sustain remission only 50% of the time, and entail serious side effects.[32] In contrast, 
biological therapies (e.g., infliximab and adalimumab) have proven to be novel and effective 
nonsurgical treatment in clinical trials, and have been prescribed to Crohn's disease 
patients.[37]  However, under current CD management guidelines, the mainstays of medical 
therapy for active disease are corticosteroids, antibiotics for fistulized disease, and 
immunosuppresants when patients are steroid-dependent or steroid-refractory. Biological 
therapies are reserved as the last medical resort, and are limited to patients with severe 
symptoms. To have a better understanding of how patients and clinicians adapted to these 
innovative therapies, a literature review was conducted utilizing a PubMed search and the 
following key words: ((use) OR (utilization)) AND  ((biological) OR (infliximab) OR 
(adalimumab) OR (tumor necrosis factor)) AND (crohn's). Only four studies were identified 
involving information about the use of biological therapies in CD patients from 2000 to 2010 
(see Table 2.2). 
 Results of the literature search were inadequate and inconsistent. Only two studies 
were conducted with the US patient populations, and one of them used a small sample from a 
Veterans Affairs (VA) medical center. Due to the differences in patient cohorts and study 
time frames, the proportion of patients who used biological therapies in these studies is 
notably different. Hilsden et al. conducted a national survey in 2001 on all members of the 
Crohn's and Colitis Foundation of Canada. Among 1,787 CD patients, nearly 6% of them 
reported having used infliximab, even though the survey was conducted three years after 
approval of the drug. Patients with more severe disease, as evidenced by increased 
hospitalizations, surgeries, and steroid use, were more likely to receive infliximab (21.1% for 
severe disease, 5.4% for moderate disease, 2.3% for mild disease, and 1.8% for patients with 
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inactive disease). Patients between age of 16 and 24 had the highest use of infliximab 
(11.6%), and older patients (age > 55 years) were least likely to use infliximab (2.7%). 
Significant differences in infliximab use based on region of residence, gender, and income 
level were not observed.[38] 
Table 2.2   Studies Related to the Use of Biological Therapies in Crohn’s Disease Patients 
Study Setting Findings Limitations 
Hilsden 2003 1,787surveyed in 
Canada in 2001 
6%  of patients used 
infliximab; younger patients 
used more. Variations 
in infliximab use based on 
region of residence and 
income were not seen. 
Canada study, early days, 
descriptive analysis 
Jewell 2005 205 patients in a 
retrospective audit at 7 
centers in UK 
72% of patients received one 
infusion initially; 19% of 
patients received 6-month 
infusion. 
UK sample in different 
healthcare system, small 
sample, and short follow-up 
(6 month) period 
Pressman 
2008 
2,964 patients from a 
community setting, 
cohort study from 
1998 to 2006 
494 (16.7%) initiated 
infliximab, younger patients 
used more. Infliximab use 
continuously increased. 
High discontinuation rate 
Community setting, 
matching algorithm by 
outpatient visits 
Feagins 2010 127 patients from VA 
medical center; 
retrospective cohort 
study 
Biologic use varied 
inversely with age of onset. 
55.5% at 21, 0% for >70yrs 
VA setting, small sample, 
majority of patients were 
male,  
 
 
 Jewell et al. assessed infliximab use via a retrospective study that was undertaken at 
seven medical centers in the U.K. between August 2002 and September 2003. Among 205 
patients with moderate and severe Crohn's disease, the majority (72%) received a single 
infusion, 4% had two infusions, 23% had three infusions, and 19% of patients received 
infliximab continuously during the 6-month follow-up period. Since the primary objective of 
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the study did not include assessing the predicting factors of infliximab use, no further 
analyses were conducted.[39] 
 Pressman et al. undertook a retrospective cohort study to investigate the patterns of 
infliximab use among CD patients in a community setting. The study population consisted 
data from 4,780 patients in Kaiser Permanente database from 1998 to 2006, and 537 (11.2%) 
of these same patients received infliximab at any time during the study period. In a cohort 
study, the case cohort included 494 patients who began receiving infliximab and met 
enrollment criteria. The control cohort was randomly chosen from the non-infliximab users,  
matched by the number of outpatient visits in the preceding quarter at a ratio of 1:5 (e.g., 1 
case to 5 controls). The authors found that 29% of patients began receiving infliximab during 
a hospitalization. Significant predictors of infliximab use were age, number of inflammatory 
bowel disease (IBD) drugs, and comorbidity (Charlson Comorbidity Index). Gender, race and 
ethnicity were not statistically significant predictors. The authors also noticed that a large 
number of patients received only a single infusion of infliximab, i.e., 18% of patients in the 
overall population. High discontinuation and low drug persistency appeared to have 
controversial effects on healthcare utilization, which includes surgeries, hospitalizations, and 
immunomodulator use. It was also reported that the number of infusions for CD patients has 
been rapidly increased, and had not leveled off by the end of the study. The percentage of 
infusions that occurred in outpatient setting increased from 50% in 2001 to 97% in 2006.[40] 
 More recently, Feagins et al. conducted a retrospective review of the Dallas V.A. IBD 
database. They identified 127 veterans with CD from 2000 to 2008 and, for each identified 
patient, demographics (e.g., age, race, and gender) and disease characteristics (e.g., disease 
duration, location, disease behavior, and drug use) were obtained from his or medical records. 
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Overall, 34% of patients received treatment with a biological agent. Among younger patients 
(<21 years old), 55.5% used biological therapies, whereas no patients >70 years of age used 
these novel treatments. Use of biological therapies varied inversely with age at disease onset.  
In addition, disease severity and inflammatory arthritis had significant association with the 
use of biologics. There were no significant differences in disease duration, smoking status, 
and comorbidity.[41] 
 In summary, the literature provides some important information regarding the use of 
biological therapies in Crohn's disease patients. Biological therapies have been increasingly 
prescribed to patients with severe Crohn's disease. In addition to disease severity, younger 
age and comorbidity of arthritis contribute to patient use of biological therapies. There are 
also several significant limitations with these studies. First, patient samples of these studies 
were based on small (Feagins), regional (Pressman), or non-US populations (Hilsden and 
Jewell), which hampers generalization of results into the larger U.S. population. Second, with 
the exception of the small study conducted with veterans (Feagins), these studies took place 
during the early years of biologic availability. The results from Pressman and others cannot 
be extrapolated to recent years without mentioning several study limitations. Pressman's 
study failed to take into consideration the important fact that adalimumab was approved by 
the FDA in 2007, and both natalizumab and certolizumab pegol were approved in 2008, 
offering more biological treatment options to CD patients. Third, there are some serious 
methodological issues with these studies. None of these studies established an analytical 
model upon any theory, so their analyses were primarily data driven. Many important factors, 
such as insurance status, were not controlled. In Pressman's study, a matching algorithm 
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based on the number of outpatient visits is insufficient when controlling for potential 
confounders between patients groups. 
 In order to obtain valid information about the use of biological therapies among CD 
patients, we plan to conduct a cohort study (Aim 1) that is based on a large sample containing 
real-world data for more than seventy million insured individuals from 2005 to 2009, and 
employs a rigorous analytical model based on economic and behavioral theories. 
 
2.2.3  Costs of Crohn's Disease 
 Crohn's disease is characterized by a high disease morbidity and financial burden to 
patients and society. The prohibitive costs of Crohn's disease are attributable to several 
factors: a) disease onset in early life; b) increased needs for surgical resections; and c) high 
drug costs. The U.S. economy is still recovering from a recession, and healthcare costs are 
under more scrutiny than ever. In order to better understand the economic burden of Crohn's 
disease and, more specifically, the medical costs and trend of medical costs among CD 
patients, I conducted a literature search in PubMed. Several important studies were identified 
that provided cost information specific to Crohn's disease in the U.S. spanning the past two 
decades (see Table 2.3). 
 The annual direct medical costs incurred by CD patients were high, and relatively 
stable from the 1990s to the early 2000s. The total annual cost was $6,561 in 1988-89[4], 
$12,417 in 1994-1995[5], $10,952 in 2003-2004[6], and $18,962 in 2005[42]. When adjusted 
for inflation according to the medical consumer price index, total annual costs of $6,561 in 
1988-89 and $12,417 in 1994-95 became equivalent to $14,670 and $18,253 in 2005. Due to 
different methodologies and source data among these studies, these estimates appeared 
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inconsistent but can be useful in demonstrating the gross change in overall cost. Both 
infliximab and adalimumab are very costly, as a result, the trend in direct medical costs may 
have changed in recent years because biological therapies have been more frequently 
prescribed to CD patients. Ollendorf et al. estimated that the average cost for infliximab was 
$2,793 per infusion.[43] Kane et al. reported that the annual medical costs for patients treated 
with infliximab were $36,675, including a cost of $25,284 for infliximab alone.[44] 
Sandborn et al. estimated that the annual medical costs can be as high as $32,688 for CD 
patients receiving adalimumab weekly or every other week.[45] No recent studies have 
reported the direct medical costs of Crohn's disease in the U.S.  This, it is imperative for 
third-party payers in the private sector or in the government healthcare system to know total 
medical expenditures for CD to facilitate budgeting and planning. 
 While total direct medical costs stayed relatively stable, the distribution of costs for 
different healthcare services has changed significantly. The proportion of costs attributable to 
inpatient and surgical services decreased from nearly 80% in 1988-89, to 57% in 1994-95, 
and further down to 31% in 2003-04. At the same time, the proportion of costs for outpatient 
medications drastically increased from 4% in 1994-95 to 35% in 2003-04.[5, 6] The shifting 
pattern of medical costs from inpatient services to outpatient medications has occurred with 
the simultaneous entry of biological therapies into treatment regimen for CD patients. It is 
believed that the increasing expenditure on pharmaceuticals, especially novel biologics, has 
offset the costs of hospitalization and surgeries.[46] However, there is a lack of evidence 
supporting this hypothesis. In clinical trials, biological therapies have demonstrated a lower 
utilization rate of inpatient services, but the results have not been confirmed in large, 
population-based studies over time.[47]  
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Figure 2.3   Comparison of Proportions of Medical Costs of Crohn’s Disease 
 
1988-89              1994-95 2003-04 
 
 
$6,561 in 1989 $12,417 in 1995 $10,952 in 2003 
$12,205 in 2010*   $19,345 in 2010*   $13,470 in 2010* 
Source: Hay et al, 1992; Feagan et al, 2000; Kappelman et al, 2008 
* Adjusted with annual inflation rate at 3% 
 
 
 While previous research provides evidence about overall medical costs and 
distribution of costs for different healthcare services, there are still several important, 
unanswered questions regarding cost trends and patterns in recent years, as well as the cost 
difference between biological therapy users and non-biological therapy users. 
 First, the trend of total medical costs for Crohn's disease in recent years is unknown. 
Gibson, Ollendorf, and Kappelman used different claims databases from 1999 to 2005 in 
their studies, so little is known about the trend of total medical costs after 2005. While 
infliximab has continuously diffused into the clinical and patient communities, its use may 
have steadily increased in recent years. FDA approvals of adalimumab in 2007, natalizumab 
and certolizumab pegol in 2008 should also have boosted the use of biological therapies as 
more treatment alternatives became available to CD patients. In addition, the trend of 
medical expenditures for CD patients can be affected by changes in the healthcare system 
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and economic environment, such as the enactment of Medicare Part D in 2006 and the 
economic recession from December 2007 to June 2009. Medicare Part D may not have a 
direct impact on the majority of patients aged 64 or younger, with exception of those who are 
dually eligible for both Medicare and Medicaid. However, Medicare Part D can indirectly 
affect younger patients (<65 years) by influencing manufacturers' pricing strategy and third 
party payers' benefit structure. The economic recession could have greatly reduced patients' 
ability to pay for high-cost medications, such as biological therapies for CD treatment. In the 
U.S., the increase in total healthcare costs has appeared to slow down in recent years[34], but 
the trend in medical costs for Crohn's disease remains unknown. 
 Second, the distribution pattern of total medical costs in recent years is also unknown. 
It is impractical to extrapolate the empirical results based on data before 2005 to estimate the 
proportion of drug costs. The increase in drug expenditures may out-pace the costs of 
inpatient and outpatient services if innovative biological therapies are rapidly adapted by 
clinicians and patients. However, no confirmative data are available in the literature.   
 Third, the difference in total medical costs between biological therapy users and non 
biological therapy users is unknown. Studies in recent literature have paid little attention to 
differing the costs for these two subgroups of patients with Crohn's disease. The majority of 
studies summarized costs by services without delineating expenses for CD patients. While 
biological therapies are considered as the major contributor to total medical costs, little 
information is available about how much biological therapy users spent for different medical 
services, such as inpatient, outpatient, ER services as well as prescription drugs. The 
difference in costs between biological therapy users and those CD patients who have never 
used biological therapies, is also unknown. A fair comparison between biological users and 
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non-biological users may be hindered by confounding factors, such as disease severity. 
However, it is worth the effort to study the cost patterns between these two groups if their 
medical costs are categorically different. The difference in sub-groups among biological 
users is also worth noting. Persistent users (>3 months of continuous use) can experience 
increased medical costs than episodic users (occasional use of biological therapies).  No 
information is available in recent literature about medical costs and cost patterns of patients 
in these two sub-groups.  
 In summary, while total direct medical costs have remained relatively stable in the 
past two decades, the proportion of costs associated with different services (e.g. inpatient 
hospitalization/ surgery, outpatient visits, ER visits, and prescribed medications) has changed. 
There has been a clear shift in medical spending from inpatient services to outpatient 
medications, which was presumably affected by the introduction of novel biological therapies.  
In the pre-biologics era, aminosalicylic acid drugs and corticosteroids were the mainstay of 
medical treatment for CD, with stable costs and cost proportions.[48] Since the first 
biological agent, infliximab, was approved by the FDA for CD patients' use, drug costs have 
increasingly accounted for a larger portion of total medical costs. Previous studies provided 
valuable information about the cost trend mentioned above, however, they have two 
important limitations: a) patient data utilized in these studies were prior to 2005, so little is 
known about the trend of total costs and cost patterns in recent years; b) no studies have 
compared costs and cost patterns between biological users and non-biological users. 
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Table 2.3   Summary of Studies Related to Costs of Crohn’s Disease 
Study Setting Perspective Findings Limitations 
Hay 1992 Medical decision costing 
algorithm, augmented by 88-89 
claims data 
Health system Total: $6561; Outpatient: $192; 
Diagnostic: $98; Inpatient: $5241; Rx: 
$671 
Strong method but disease 
management out-dated. 
Feagan 
2000 
607 patients  from medical 
claims database from  10/94 to 
9/95;  
Payer & 
Patient 
Inpatient: $7,115; outpatient: $2,936; 
MD office: $1,054; Rx: $444; ER: $202; 
Total: $12,417 
Claims data,  early years 
 
Cohen 
2000 
147 patients in one hospital from 
7/96 to 6/97 
Hospital 
& Payer 
charge: $35,378 (surgical  46,354; 
medical  $20,744) 
Reimburse: 21,968 (Sur: 28,946, Med 
12,666) 
Sample from one institution 
Ollendorf 
2006 
2230 CD patients treated with 
infliximab from Pharmetrics 
Claims database (6/00 to 12/03) 
Payer & patient Charge: $4441/infusion 
Paid: $2793/infusion 
Commercially insured, early 
years of biologics, not per 
member cost 
Gibson 
2008 
6569 CD patients from 
MarketScan claims data base from 
1999 to 2005 
Employers Inpatient: $8679; Outpatient/MD: $7722; 
ER:$ 316; Rx: $2243.56 
Total:$18,962 
No data after 2005 
Kane 2009 571 CD patients treated with 4+ 
infusions of infliximab from  
claims database (1999 to 2006) 
Payer 
 
CD-related costs:  Inpatient: 2,185; 
Outpatient: $2,282; ER: $93;Rx (no 
inf.):$6,987;Rx (inf): $25,284 
All-cause costs: Inpatient: $3,718; 
Outpatient: $5,383; ER: $258; Rx (no 
inf.): $11,391 
Differentiate CD-related costs 
from all-cause cost. 
Unknown about the no-
infliximab patients 
Kappelman 
2008 
9056 CD patients + 24,829 
controls from Pharmetrics claims 
database (2003 and 2004) 
Payer Total cost: $10,952 (CD);  $2,898 (other) 
Cost diff (CD-control): Inpatient: $2,593 
ER: $97; Rx: $2,919 
Pediatric and adults mixed 
together; not current data 
Sandborn 
2011 
260 CD patients received 
adalimumab EOW or weekly 
Payer $15,981 - 32,688 Adalimumab patients only 
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 In this dissertation, we sought to comprehensively examine the direct medical costs 
incurred by Crohn's disease patients using a large and nationally representative database with 
healthcare utilization and expenditure data from 2005 to 2009. Analyses focus on trends and 
patterns of costs for CD patients in recent years, and the comparisons of cost trends and 
patterns between biological therapy users and non-biological therapy users. Based on recent 
data, we predict costs and trends for these groups in the first three years of disease, and 
conduct economic evaluations on prescription drug costs and total healthcare costs from the 
perspective of third party payers. 
 
2.2.4  Cost-effectiveness of Crohn's Disease 
 Since the movement of evidence-based medicine in the mid-1980s, 
pharmacoeconomics has gained more and more popularity. In the past decade, 
pharmacoeconomic studies have been on the rise as third party payers faced budgetary issues 
due to the rapid growth of healthcare costs.[49] Crohn's disease is associated with a 
substantial financial burden to both patients and society at large. The financial burden is 
further increased when costly biological therapies became available for CD patients as 
alternative medical therapies. Due to the high costs and lack of sufficient safety data and 
clinical evidence, biological therapies have been fraught with controversies and critics.[32] 
Several pharmacoeconomic studies from the past ten years were identified after searching 
PubMed with the following key words: economic evaluation, cost benefit analysis, Crohn's 
disease, biological therapy, and anti-tumor necrosis factor. Study setting and the main results 
of these studies are summarized in Table 2.4. Most of these investigations made great effort 
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to demonstrate the cost effectiveness of biological therapies, mostly infliximab, among CD 
patients, and provided important information. 
 First, medical treatments with biological therapies, both infliximab (Remicade®) and 
adalimumab (Humira®), are associated with a very high incremental cost compared with the 
treatments with non biological therapy. In 2001, Arseneau et al. used Markov modeling to 
assess the cost-utility of infliximab by comparing infliximab combined with 6-
mercaptopurine (6MP) and metronidazole (Met). The incremental cost-effectiveness ratio 
(ICER) ranged from $355,450 to $377,000 per quality-adjusted life-years (QALY) while 
infliximab was administered in combination therapies or as mono therapy. The findings of 
this early study indicated that infliximab interventions are more costly than other 
interventions that are already pricey, such as bone marrow transplant and peritoneal dialysis. 
Because clinical efficacy data were scarce, the ICERs were likely over estimated.[50] In 
2003, the Health Technology Assessment program in UK reported that the cost per QALY in 
the treatment of chronic active Crohn's disease was £6700 ($10,953 in 2003 U.S. dollar) for a 
single-dose treatment, £10,400 (or $17,002) for episodic re-treatment,  £84,400 (or $13,798) 
for maintenance treatment, and £102,000–£123,000 (or $166,750-$201,080) for initial 
treatment of fistulising disease.[51]  Since the economic model was based on information 
submitted by the manufacturer and effectiveness data were obtained from randomized 
clinical trials (RCTs), the above results are likely downward biased.[51] Jaisson-Hot et al. 
compared the cost utility between infliximab and surgery among patients with severe Crohn's 
disease. The ICERs varied from €63,700 (episodic re-infusions) to €762,245 (maintenance 
therapy).[52] In a more recent study, Lindsay et al. evaluated the cost-effectiveness of 
maintenance treatment with infliximab among patients with active luminal and fistulising 
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disease. Compared to standard care in 2008, the incremental cost per QALY gained was 
£26,128 ($48,397 in U.S. dollar) for luminal CD, and £29,752 ($55,110) for fistulising 
CD.[53]  Similar results were obtained in Bodger's investigation, which compared infliximab 
treatment for one year with standard care. From a Markov simulation, the ICER was £19,050 
per QALY gained.[54] In summary, the cost-effectiveness ratio of infliximab treatment to 
standard care was around $50,000 per QALY gained among patients with severe CD disease, 
and this cost-effectiveness ratio could be even higher among patients with mild to moderate 
Crohn's disease.  According to the unofficial cost-effectiveness threshold of $50,000 per 
QALY gained in the U.S., infliximab treatments do not appear to be cost-effective.  
 Head-to-head comparisons of adalimumab with infliximab have suggested that 
adalimumab is more cost-effective than infliximab, but still not cost-effective in comparison 
to the cost-effectiveness threshold. Kaplan et al. compared the cost-effectiveness of 
adalimumab as rescue therapy with high dose infliximab among patients who failed to 
respond to low dose infliximab. The cost per patient was $35,908 per QALY for patients 
receiving a dose escalation of infliximab, and $23,782 per QALY for patients receiving 
adalimumab. Even though adalimumab showed favorable cost-effectiveness, the costs of 
adalimumab were still considerably high.[55] In a recent study by Yu et al., adalimumab was 
only marginally more cost-effective than infliximab.[35] Compared with standard care, the 
incremental cost per QALY gained was £16,064 ($25,148 in 2009 US dollar) in severe CD 
patients, and £33,731($52,806) in patients with moderate-to-severe disease.[15] 
 Second, most analyses were conducted from the perspective of a third-party payer or 
healthcare system. In principle, the societal perspective is generally considered most 
appropriate and comprehensive when framing pharmacoeconomic studies because it 
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encompasses all costs and health effects of an intervention regardless of who incurs the costs 
and who obtains the effects in the entire society.[56] However, there are many technical 
obstacles in accruing the effects and costs from all members in society, and in assessing the 
effects and costs quantitatively when conducting studies from a societal perspective. For 
example, indirect costs, such as productivity loss, are usually difficult to measure monetarily. 
More importantly, the perspective of economic evaluation should reflect the viewpoint of the 
key audience (e.g. healthcare decision makers) who are primarily intended to inform. The 
payer's perspective, either from a third-party payer or from national healthcare service, is 
common in economic studies conducted in the U.S. and abroad despite the differences in 
healthcare systems.[35, 50, 55] Compared to a broad societal perspective, a more narrow 
perspective can not only ease the determination of relevant healthcare services and costs, but 
also provide measureable values for decision makers. In this dissertation, I intend to inform 
the decision-makers who are responsible for budgeting health benefit plans in the third-party 
payers in the private sector of US healthcare system. It is not my intention, however, to 
inform the budget administrator of each individual health benefit plan. Instead, all health 
plans will be considered together as a single payer. The analyses in my dissertation will be 
based on the perspective of this joint single payer, which provides health benefits to all 
commercially insured non-elderly Americans. 
 While many economic studies have evaluated the cost-effectiveness of biological 
therapies in different patient groups using various analytic methods, (e.g. Markov modeling), 
and different data source, there are several important limitations that are worthy of comment: 
1. The effectiveness of medical interventions with biologics in CUA or CEA was assessed 
by using data from clinical trials. As a result, the clinical effectiveness of biological 
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therapies was likely over-stated because patients enrolled in clinical trials are generally 
healthier. Also the assessment based on small samples in clinical trials can hardly be 
generalized to the CD patient population. Given the short follow-up time in clinical trials 
(6 months to 1 year), the long-term benefits or risks of biological therapies can not be 
evaluated accurately. It is interesting to note that the difference in utility values, the 
denominator of the incremental cost-effectiveness ratio, was small in several studies. For 
example, Yu et al. reported that utility indices for treatment with infliximab and 
adalimumab were 0.865 vs 0.851 respectively.[35] The small difference in these utility 
indices can increase the magnitude of the incremental cost-effectiveness ratio. This is a 
controversial issue with methodology of CUA or CEA.[56] If credible long-term 
effectiveness data are not available, CUA and CEA are not the ideal approach for 
evaluating the novel drug therapies.   
2. Cost data are not up to date, or are not based on real-world data. Several studies 
approximated the costs by using cost information, such as wholesale acquisition costs in  
Redbook® (Thomson Reuters, Ann Arbor, MI), and average costs published in other 
studies. Only a few studies used patient level data to calculate direct medical costs. 
Bodger et al. used data from the UK to derive total cost.[54] Yu et al. used patient level 
data in the US to estimate total costs, but patients were limited to the enrollees in the 
Medicare program.[35] 
3. Selection bias and publication bias are threats to validity of the study results because of 
the influence from the sponsor in pharmaceutical industry. Most economic evaluation 
studies have been funded by the pharmaceutical companies, who are required to submit 
economic data about medical products to regulatory agencies in European countries for 
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market authorization. In the U.S., it is not mandatory for pharmaceutical companies to 
include the economic evaluation data as part of submission dossier. Thus, pharmaceutical 
companies have not incentive to conduct large scale economic studies, or publish those 
studies if the findings are not favorable to their products. Unsurprisingly, results in the 
literature unanimously favor therapies manufactured by sponsoring company, and against 
competing products. Due to this conflict of interest, economic studies purely designed as 
marketing tools by the pharmaceutical companies may not provide valid information to 
the public.  
 
 Because of a lack of data regarding the effectiveness of biological therapies among 
patients with Crohn's disease, we strive to evaluate costs associated with these biological 
therapies and,  more broadly, the total medical costs of patients with Crohn's disease. Unlike 
existing studies in the literature, our research will use current patient level data from a large 
pharmacy and medical claims database to estimate costs from the perspective of third-party 
payers. With no conflict of interest to declare, we do not assume any proposition during the 
research. 
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Table 2.4   Summary of Pharmacoeconomic Studies Related to Crohn’s Disease 
Study Setting Perspective / Time Horizon Findings Limitations 
Arseneau, 
2001 
CUA: inf vs. 6MP/met 
Markov modeling of 3 treatments 
Efficacy data: literature review 
Cost data: hospital billing 
Third party payer, 
1 year 
ICER (3 tx vs. 6MP/met): 
Tx 1 (inf+6MP/met): $355,450 
Tx 2 (inf): $360,900 
Tx 3 (6MP/met+inf): 377,000 
Efficacy data were scarce back in 
2001; hypothetic interventions 
(eg. 3 infusions of infliximab). 
Clark, 
2003 
Health Technology Assessment 
by NICE, revised from the 
company model in submission 
UK NHS Cost: £1,800 per dose 
CE: £6,700 for single dose, £10,400 
for episodic retreatment, £84,400 
for maintenance. (per QALY) 
Fistulizing CD, more costly 
Strictly limit infliximab to severe 
patients, not for episodic 
treatment in UK setting 
Jaisson-
Hot, 2004 
CUA: infliximab vs. surgery 
Markov modeling 
Efficacy data: literature+expert 
Cost data: literature  
Payer, lifelong (2-
month cycle) 
ICER: (2 tx vs surgery): 
Tx 1 (relapse): €63,700 
Tx 2 (maintain): €762,245  
No patient-level data;  
Kaplan, 
2007 
CEA: inf vs ada (rescue therapy) 
Decision tree modeling 
Efficacy data: clinical trials 
Cost data: literature, Redbook 
Payer, 1 year ICER: inf (5mg--> 10mg) vs ada 
$332,032/QALY 
Not real-world data; only the sub-
cohort lost response to 5mg/kg 
infliximab 
Lindsay, 
2008 
CEA: inf vs standard care 
Markov modeling 
Data source: literature 
 
UK NHS, 5 years ICER (inf vs standard care): 
Severe luminal CD: £26,128 
Fistulizing: £29,752 
Sponsor funded, not based on 
patient data. 
ada = adalimumab, inf = infliximab, TNF = tumor necrosis factor, WAC=wholesale acquisition cost, QALY=quality-adjusted life year 
(Continued on next page)
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                (Continued) 
Table 2.4 Summary of Pharmacoeconomic Studies Related to Crohn's Disease 
Study Setting Perspective / Time Horizon Findings Limitations 
Loftus, 
2009 
CEA: ada vs standard of care 
Efficacy data: clinical trials 
Cost data: literatures 
UK NHS, 1 year ICER (ada vs standard of care): 
Severe CD: £16,064/QALY 
Moderate-to-severe:£33,731/QALY 
Abbott funded, not real world 
patient data, strong assumptions 
(perfect adherence, etc) 
Bodger, 
2009 
CEA: inf / ada vs standard care 
Markov cohort analysis 
Efficacy data: clinical trials 
Cost data: UK patient-level data 
UK NHS, 1 year ICER (ada /inf vs Standard care): 
Inf (1yr, 2 yr): £19,050, £21,300 
Ada (1yr, 2yr):  £7,190, £10,310 
Rigorous assumptions for 
Markov model, source of efficacy 
data 
Yu, 2009 CUA: ada vs inf (maintenance) 
Efficacy Data: clinical trials 
(CHARM and ACCENT I) 
Cost Data: WAC, Medicare 
Payer, 1 year 1-year remission: 47.2% vs 37.1% 
TNF cost: $17,176 vs $18,214 
Total cost: $34,193 vs $39,045 
QALY: 0.865 vs 0.851 
Pharma (Abbott) sponsored, 
Small sample from clinical trials, 
Short time frame 
ada = adalimumab, inf = infliximab, TNF = tumor necrosis factor, WAC=wholesale acquisition cost, QALY=quality-adjusted life year 
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2.2.5  Other Economic Evaluations of Crohn's Disease 
 In addition to cost-effectiveness studies, other formats of economic evaluation of drug 
therapies for Crohn's disease have been scarce in the literature. Although CEA has 
commonly been used to indicate value, researchers have also shown that CEA results are 
rarely used by decision-makers to inform formulary decision.[57] Budget impact analysis and 
resource consequence analysis are two complementary techniques that can be used to assess 
the impact of a new treatment on costs and resource use for a specific group of individuals.  
Budget Impact Analysis 
 No budget impact analysis studies on biological therapies for Crohn's disease patients 
were identified in the literature search. However, budget impact analysis has been 
implemented in other disease areas. Sorensen and Andersen used this approach to assess the 
potential impact on the Danish healthcare budget of prescribing infliximab or etanercept for 
patients with rheumatoid arthritis.[58]   
Resource Use Analysis 
 In 2002, Rubenstein et al. reported that infliximab decreases resource use among 
patients with Crohn's disease, and suggested potential cost savings. However, healthcare 
resources were not expressed in monetary terms, so the magnitude of cost saving is 
unknown.[36] Study patients (79 in total) were only followed for one year, and the long term 
effect on healthcare resources use was not addressed. 
 In 2007, Saro et al reported that infliximab appeared to be effective in routine practice 
by reducing hospital stays, but increased overall budgetary costs. However, the study sample 
was based on patients admitted to a single hospital in Spain, and the cohort of patients 
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receiving infliximab only included 34 patients. Thus, thus, the results can not be generalized 
to the larger US.S population.[59] 
 In 2009, Nugent et al conducted a population-based study of healthcare resource use 
among infliximab users beginning in 2001, and found that the number of physician visits, 
hospital visits, and surgeries was different between infliximab users and patients receiving 
other drugs.[47] This is the first population-based study to report resource utilization in 
multiple years under the 'bottom-up' treatment approach, however, these results are not easily 
translated into practice because resource use was assessed in natural unit of different 
healthcare service (e.g. number of hospitalizations), instead of a common monetary unit for 
comparison. 
 In 2010, Kappelman et al used a large claims database to estimate healthcare resource 
(inpatient, outpatient, ER, and endoscopy services) utilization occurring between 2003 and 
2004, and found that utilization varied by gender, geographic region, and insurance type.[46] 
Although data analysis was not stratified by use of biological therapies, the study results still 
provided valuable information about the entire CD patient population. 
 In summary, the above studies prove that a budget impact analysis on medications 
and a cost saving analysis on resource use is feasible when using large administrative 
databases to evaluate the economic consequence of biological therapies under different 
treatment approaches. Kappelman et al showed that large administrative databases contain 
adequate information to investigate healthcare utilization. Additionally, Saro et al 
demonstrated that budgetary costs can be estimated when units of healthcare resources are 
priced correctly.[59] 
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2.3 Summary 
 The treatment strategy for Crohn’s disease is now shifting from the conventional 
‘bottom-up’ to a more aggressive ‘top-down’ approach, which promotes novel biological 
therapies as first-line treatment for CD patients. The rapid change in the treatment algorithm 
could extend greater clinical benefits to patients, but simultaneously incur greater financial 
burden for both payers and patients. Economic evaluation of novel biological therapies, 
especially during this transition period, is necessary. From recent literature, cost-
effectiveness analysis studies did not demonstrate the value of these new therapies due to a 
lack of effectiveness data. Therefore, from the methodological point of view, it is more 
practical to conduct economic evaluations that focus on medical costs.  
 In this dissertation, budget impact analyses are used to evaluate the financial 
implications to payers by comparing the use of biological therapies under different treatment 
strategies. To the best of my knowledge, no budget impact analysis has been conducted to 
address costs related to the new treatment approach from the payers’ perspective. 
Furthermore, a comprehensive cost analysis including all healthcare resources is conducted 
to evaluate the long-term sustainability of the new treatment paradigm by examining the 
difference in costs of healthcare resources between patients under the two different treatment 
approaches.
   
 
 
 
 
 
CHAPTER III: 
THEORETICAL AND CONCEPTUAL FRAMEWORK 
  
 Modern research is often based on multiple theories from different disciplines. The 
theoretical framework encompasses the linkage between theories and specific research 
questions in a given setting. In this dissertation, Andersen's Behavioral Model of Health 
Services Use (Andersen's model), and Grossman's Model of Health Demand (Grossman's 
model) serve as the backbone for constructing the theoretical framework.  
 The conceptual framework outlines an operational roadmap for the research direction, 
and the relationships of different constructs. In this chapter, a conceptual framework is 
presented to demonstrate the theory-based approaches to addressing the proposed research 
aims. 
 
3.1 Theoretical Framework 
 Important life goals for most individuals are to maintain or improve health status, and  
prevent injury or illness. While health is affected by any acute or chronic condition, it is 
natural for people to seek advice from healthcare professionals, and make use of healthcare 
facilities and services. Admittedly, all healthcare resources are not free and unlimited for all 
members to access, but rather, are constrained and shared in society. Therefore, using health 
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care is not only a process of health behavior undertaken to achieve optimal health status, but 
also a series of economic activities that produce health at certain opportunity costs. Health 
outcomes and economic consequences can reinforce or undermine the use of healthcare 
services. Figure 3.1 describes the relationships among health, health care, health outcomes 
and health economics. Andersen's Behavioral Model provides in-depth reasons as to why 
patients use health care from a health behavior point of view. Grossman's model purports that 
the ultimate purpose of using health care is to produce better health, and demand of health 
care is derived from the demand for health, and can be affected by many factors. 
 
 
 
 
3.1.1  Andersen's Model 
 Andersen's Behavioral Model of health services was developed in the 1960s. It has 
been widely utilized in the research of healthcare access and healthcare services utilization. 
The original model was designed to assist in understanding why families use health services, 
Grossman 
Model 
Andersen 
Model 
Health 
Health care Health economics 
Health 
outcomes 
Patient 
Figure 3.1   Theoretical Framework 
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define and measure equitable access to health care, and facilitate in developing policies to 
promote equitable access. After several revisions, the model, shown in Figure 3.2, 
incorporates the dynamic and recursive nature of health services.[60] The essence of 
Andersen's behavioral model is that the use of health services is a function of patient 
characteristics, which are delineated into three major components: a) predisposition to use 
services; b) factors that enable or impede use; and c) the need for care.  
Predisposing characteristics refer broadly to everything that might predispose patients 
to need and use healthcare services. In Andersen's model, predisposing variables include 
demographic variables (age and gender), socio-economic status variables (education, 
occupation, race, ethnicity, etc) and health beliefs (attitude, value, and knowledge). These 
variables have proven to be risk factors for healthcare utilization, however, not all variables 
are readily available in the source data for secondary analysis.  Among the predisposing 
characteristics, demographic and socioeconomic variables are usually collected in healthcare 
research databases, but variables representing health beliefs are often difficult to quantify and 
measure, even though health beliefs are believed to have substantial influence on patients' 
perception of need and use of healthcare services.  
Enabling factors are variables that represent the adequacy of healthcare resource use. 
Healthcare resources include personal level resources (e.g., income, employment status, 
health insurance,  and generosity of insurance coverage) and community level resources (e.g., 
per capita amount of healthcare personnel and facilities, and the quality of healthcare 
personnel and related facilities). 
Need variables represent the necessity and importance of healthcare to patients. 
Needs can be self-perceived needs explained by social structure and health beliefs, or 
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evaluated needs judged by healthcare professionals regarding patients' health status. They are 
often the most immediate causes of healthcare service use. 
In addition to the three major components listed above, Andersen's model also 
recognizes the external environment, both political and economic changes, as an important 
input for healthcare services. The model takes into account the influence of personal health 
practices, such as exercise, on the use of health services. Health outcomes, e.g., perceived 
and evaluated health status, in turn, can reinforce or impede the use of healthcare services. 
 
 
 
 
 
Source: Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc 
Behav 1995;36:1-10 
 
3.1.2  Grossman's Model 
 Grossman's model is a theory of demand for healthcare with great influence from the 
health economics field. The basic model was developed in the 1970’s,[61] and revised to a 
more generalized model in the 1980’s.[62] Grossman used the theory of human capital to 
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Figure 3.2    Andersen's Behavioral Model 
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explain the demand for health and healthcare, and show how consumers allocate resources 
for health. According to human capital theory, consumers invest in themselves through 
education, training, and health to increase their earnings. Since health can be capitalized, 
healthcare is demanded as a means for consumers to produce a larger stock of 'health capital'.  
Therefore, the demand for healthcare is considered to be a derived demand from the demand 
for health. This is the key element in Grossman's model.  
 In addition, the model also highlighted several other important aspects of health 
demand that distinguishes health and healthcare from other traditional goods. First, each 
individual is viewed as both a producer and consumer of health. Consumers do not merely 
purchase health passively from the market, but, instead, the consumer produces health, for 
example, by devoting time to health-improving activities. Second, health is treated as a stock 
which degrades over time in the absence of investments in health, so that health is viewed as 
a sort of capital. Third, healthcare is a consumption good that yields direct satisfaction and 
utility as well. It is also an investment good which yields satisfaction to consumers indirectly 
through increased productivities, such as fewer sick days, and better quality of life. In the 
health capital model, it is assumed that individuals inherit an initial stock of health that 
depreciates over time, particularly, at an increasing rate, after some stage in the life cycle, 
and can be increased by investment. The optimal level of health investment can be reached 
upon equilibrium where the marginal cost of health capital is equal to the marginal benefit 
from health outcomes. The following factors were found to be determinants of predicting the 
optimal level of health investment. 
• Age: In general, the health of older people is likely to deteriorate faster than the 
health of younger people, so the optimal stock of health varies with higher 
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depreciation rates in later periods of the life span. Higher depreciation rates increase 
the cost of holding health capital stock. Therefore, elderly people purchase a greater 
amount of medical care, even as their health declines. 
• Wage rate: The rewards of being healthy are greater for higher-wage workers, so 
increased wages will be likely to increase optimal capital stock. Higher wage not only 
implies increased return on health investment, but also implies increased opportunity 
cost in producing health. 
• Education: Higher education is most often related to better health. Economists believe 
that education can improve the efficiency and productivity of health investment, so a 
given health investment can be generated at less cost for educated people. Educated 
people can better recognize the benefits of improved health and, thus, have a greater 
demand for health and healthcare.  
 
While emphasizing the effect from age, education and wage rate, Grossman's model 
did not exclude the impact of environmental variables. Instead, the effect of other variables 
was hypothesized to be static. Grossman’s model can help us identify key variables as 
determinants of the use of medical care, and understand how profoundly their effect can be 
expressed in mathematical terms. 
 
3.1.3  Model Synthesis 
 In this dissertation, the research goal is to investigate the economic outcomes of CD 
patients while the treatment paradigm is shifting from the late to early adoption treatment 
approach. The effect of the treatment strategy change can be observed in greater utilization of 
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biological therapies and other healthcare services. Determinants of healthcare utilization can 
be conceptualized by the theoretical models discussed in the previous section. According to 
both Andersen's behavior model of health services and Grossman's model of demand of 
health care, the use of healthcare services among CD patients is determined by internal 
factors (e.g., patient's characteristics), and influenced by external factors (e.g., provider's 
characteristics and features of health plans provided by payers). 
 In the context of Andersen's model, the use of biological therapies is determined by 
three major categories of patient characteristics, including predisposing, enabling and need 
variables, and a number of external environmental factors. These external factors are often 
related to parties who have direct interaction with patients, including providers and payers. In 
clinical practice, major medical decisions are made jointly between patients, providers, and 
payers. Therefore, providers' characteristics, such as medical specialty, and features of health 
plans offered by payers (e.g., formulary and deductibles) are important external factors that 
influence on healthcare utilization.   
 When considering Grossman's model, the use of healthcare services is mainly 
determined by the effects of age, education, and wage rate. Although Andersen’s model has 
recognized these three variables as predictors of healthcare service utilization (e.g., age and 
education are predisposing variables, and wage is an enabling variable), no empirical 
information is provided to guide the analytic model construction. Grossman’s model provides 
complementarily information about the effect as in mathematical expression, which suggests 
that predicting effects are likely non-linear and certain transformation may be needed in the 
model specifications. 
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3.2 Conceptual Framework 
 The theoretical models in the previous section provide the rationale and logic to 
determine why patients demand healthcare, how patients cope with their needs, and what 
factors can affect the decision to convert needs into health behavior. The conceptual 
framework for the current project, shown in Figure 3.3, presents a pictorial pathway of the 
research goals when the theories are implemented, and the relationships between causal 
factors. The research goals are to: a) investigate the impact of the treatment strategy change 
on the use of biological therapies in patients with Crohn's disease (Aim 1); b) estimate the 
change on economic outcomes of patients; and c) predict the financial impact on payers 
(Aims 2 and 3). The pathways in Figure 3.3 illustrate the following relationships:  
1. The treatment strategy change from the bottom-up to top-down approach is the key 
environmental variable for CD patients that can directly impact the utilization of 
biological therapies, or indirectly influence CD patients via the providers. The top-down 
approach will increase the use of biological therapies among CD patients. 
2. Besides the treatment strategy change, the use of biological therapies is also associated 
with patient's characteristics, and provider's characteristics, and features of health plans. 
3. The short-term economic outcome of the treatment strategy change results from the 
increase in prescription drug costs since biological therapies are expensive medications. 
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Figure 3.3   Conceptual Framework 
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4. Clinical benefits of biological therapies will be reflected by a gradual decrease in 
utilization of other healthcare services, for example, fewer inpatient and ER visits. The 
long-term economic outcome of the treatment strategy change is the decrease of costs for 
other healthcare services. 
5. Both short-term and long-term economic outcomes of the treatment strategy change for 
CD patients can have direct financial implications to payers. Short-term economic 
outcome about prescription drug costs can be used to predict the budget increase in the 
first year of disease, and long-term economic outcomes can be used to demonstrate 
whether or not the treatment paradigm change is cost-saving when drug costs are offset 
by a decreased use of other healthcare services after the first year of disease. 
6. Financial implication for third-party payers can be related to the future formulary change, 
which can potentially affect the use of biological therapies by CD patients. 
 
 Based on the conceptual pathways, research for this dissertation will be conducted in 
the following steps.  
1. The first part of this dissertation will focus on an empirical study of the claims database 
to determine the utilization of healthcare services, either prescription drugs alone or all 
healthcare services combined, among CD patients who are classified into different 
cohorts according to their use and usage pattern of biological therapies in previous years. 
The primary goal is to determine the differences in utilization between patients who are 
early and late biological users.  Differences between these two patient cohorts will be 
adjusted using a wide range of covariates, which contribute to healthcare utilization 
according to the theories presented in section 3.1.   Covariates include patient 
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characteristics (e.g., age, sex, race, ethnicity, region, education level, income, 
employment status, disease severity, and comorbid conditions), provider characteristics 
(e.g., treatment preference, specialty, and affiliated organization), and health plan features 
(e.g., coverage/generosity, reimbursement/copayment, and formulary). Admittedly, some 
variables, such as ethnicity, education level, income, and formulary, are not available in 
the primary data source (MarketScan claims database). Other variables, such as disease 
severity, and comorbidity, can only be approximated by healthcare utilization data 
records. Despite these limitations due to unobserved variables and potential 
misinformation, the covariates with adequate information in the claims database represent 
many important characteristics about patients, providers, and payers. 
2. Next, the research focus shifts to the economic outcomes of CD patients. More 
specifically, I will predict both short- and long-term economic outcomes for top-down 
and bottom-up therapy users in three years following CD diagnosis by using empirical 
data from early and late biological therapy adopters in previous years (from 2005 to 
2009). Short-term economic outcomes are represented by the prescription drug costs in 
the first year of disease. Long-term economic outcomes are represented by total 
healthcare costs, including expenditures for drugs, outpatient services, inpatient services, 
and emergency room services in the second and third years after CD diagnosis. 
3. Lastly, the financial impact on payers will be estimated based on the aggregated 
economic outcomes of CD patients, who use either top-down or bottom-up strategy, at 
the population level. A budget impact analysis will be employed to predict the financial 
impact of top-down treatment approach on third party payers by comparing the short-
term economic outcomes between top-down and bottom-up users of biological therapies 
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in the first year of disease. A cost analysis will be conducted to demonstrate the 
differences in total healthcare service costs for the long term.  
  
3.3 Construction of Analytical Models  
 The conceptual framework guides the operation of this dissertation research by 
building the analytical models upon theories. These theories imply that patients' health 
behavior in healthcare utilization is largely determined by both internal (e.g., patient 
characteristics) and external factors (e.g., health plans provided by payers). Internal factors 
include three sets of characteristics: a) demographics (e.g., age, gender, race, and region); b) 
socioeconomic status (e.g., income, and education); and c) health status (disease severity, and 
comorbidity).  External factors include the features of health plans (premiums, deductibles, 
formulary coverage, and copayments) and provider characteristics (specialty, knowledge, 
institution, and patient communication).  
 
Patient Demographics 
 Both the Andersen and Grossman models suggest that age is a key determinant for 
healthcare demand and health behavior. Older patients incur a greater demand on health care, 
and likely use more healthcare resources. Crohn's disease is often diagnosed at a young age 
and does not significantly short the life span, so younger patients with CD may also sustain a 
high demand for health care.  Gender, race, geographic region and urban residence are 
predisposing variables in the Andersen model, and are considered to be factors for predicting 
health demand in the Grossman model.  
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Socioeconomic Status 
  Income, education level, and ethnicity, are another set of important predisposing 
variables in Andersen's model. In economic models, income (i.e., wage rate) and education 
are two key factors that affect an individual's health demand. Higher income means greater 
ability to purchase better or more healthcare services. From an economic perspective, higher 
income gives people more incentive to improve or maintain their health by seeking 
healthcare resource or changing their lifestyle in order to keep well-paying jobs. Both 
behavioral and economic models assert that education is an important factor relevant to the 
need and use of healthcare. Higher levels of attained education can improve the efficiency of 
received healthcare. Educated people can better recognize the benefits of health and the value 
of healthcare, and seek more healthcare services. However, there is no socioeconomic status 
variable in the Marketscan claims database, so the socioeconomic variables are omitted in the 
analytical models. 
Health Status and Disease Severity 
 In Grossman's model, current health status represents the initial health capital that 
patients inherit as baseline when determining their demand for healthcare in the future. In 
Andersen's model, health status is an important need factor that either stimulates or delays 
healthcare seeking. Patients with more severe disease symptoms and comorbid conditions are 
more likely to use increased healthcare resources. 
Health Plan Features 
Most people do not pay providers directly for health care, but instead, pay indirectly through 
health plans of insurance provided by insurance companies, or third party payers, which are 
either private financed systems or government subsidized public programs. Health plans, or 
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insurance plans, are designed with different benefit structures. Characteristics of health plans, 
such as premiums, deductibles, formulary coverage, and copayment, have financial 
implications that can affect the demand for healthcare, and subsequent health decisions. More 
generous health plans with low deductibles and low copayments can increase health demand 
and the likelihood of using healthcare. 
Provider Characteristics 
 In the U.S., healthcare providers, mostly physicians, have a great deal of influence on 
patients' use of healthcare. Health decisions are often jointly made by patients and their 
providers. Providers' knowledge, specialty, affiliated institution, and patient communication 
style can have a substantial effect on the use of healthcare, and the level of usage. 
 
3.4 Summary  
 Both health behavior and economic theories suggest that healthcare utilization is 
jointly determined by a wide range of internal patient characteristics and external factors 
related to payers and providers. These variables can be potential confounders, which need to 
be controlled for when examining the true effect of the treatment strategy change. The 
conceptual framework depicts the pathways and variable sources, and translates theories to 
an operational roadmap.  
  
 
 
 
CHAPTER IV:  
METHODS 
  
 This chapter presents the methodology applied to address the study aims for this 
dissertation, including the data source (Section 4.1), study sample (Section 4.2), study 
methods for Aim 1 (Section 4.3), study methods for Aim 2 (Section 4.4), and study methods 
for Aim 3 (Section 4.5). 
 
4.1 Data Source 
 The MarketScan® Commercial Claims and Encounters Database (CCAE) (2005-2009) 
from Thomson Reuters (Healthcare) Inc. serves as the central data source for this dissertation.  
This database contains de-identified, person-specific health data including clinical utilization, 
expenditures, insurance enrollment/plan benefits, inpatient, and outpatient services, and 
outpatient prescription information. The data include over seventy million individuals, and 
include private sector health data from approximately 100 payers, and can be linked to track 
detailed patient information across sites and types of providers over time.  
 MarketScan CCAE is a major administrative database, and has been widely utilized 
by healthcare researchers to understand disease progression, treatment effect, healthcare 
utilization, health outcomes, and healthcare costs to patients, employers, and health plans.  
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4.2 Study Sample 
 All patients in the MarketScan CCAE database need to meet the following inclusion 
criteria for the study: 
• A confirmed diagnosis of Crohn’s disease, which requires at least one 
encounter from either an inpatient or outpatient setting with a diagnosis of 
Crohn’s disease (ICD-9 codes: 555.0, 555.1, 555.2, 555.9) (Source: HCUP 
CSS tools for ICD-9-CM). 
• Age between 18 and 64 (inclusive) at diagnosis of Crohn's disease. Older 
patients aged 65 and above are eligible for the Medicare program. Nearly 30% 
of children under age 18 are insured by  public insurance programs like 
Medicaid and the State Children's Health Insurance Program (SCHIP). [63] 
Pharmacy and medical claims from elderly adults and children from low-
income families, except those covered by supplemental insurance, are not 
included in the commercial claims and encounters database. As a result, only 
non-elderly adults are included in the study sample. 
• At least two years continuous enrollment following the diagnosis of Crohn's 
disease between 2005 and 2009. More specifically, eligible patients are 
required to have at least six months of enrollment prior to their diagnosis of 
Crohn's disease, and have at least one year of enrollment after the diagnosis. 
• Enrollee health plans must be network-based managed care programs, which 
can be one of the following: a) HMO (health maintenance organization); b) 
POS (point-of-service), c) PPO (preferred provider organization);  and d) EPO 
(exclusive provider organization). 
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Patients meeting the following exclusion criterion are not eligible for the study: 
• A diagnosis of any co-indicated condition where a patient used an FDA- 
  approved biological therapy, including ulcerative colitis (ICD-9 codes: 556, 
  556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9), rheumatoid  
  arthritis (ICD-9 codes: 714.0, 714.1, 714.2, 714.30, 714.31, 714.32, 714.33, 
  714.4, 714.81, 714.89, 714.9), ankylosing spondylitis (ICD-9 code: 720.0), 
  psoriatic arthritis (ICD-9 code: 696.0), plaque psoriasis (ICD-9 code: 696.1), 
  multiple sclerosis (ICD-9 code: 340), and juvenile idiopathic arthritis (ICD-9 
  code: 714.3) (Source: ICD9Data.com).  
 
4.3 Study Methods for Aim 1 (cohort studies) 
4.3.1  Study Cohorts 
Healthcare utilization and costs for all eligible CD patients in the study sample are 
summarized annually to demonstrate trends from 2005 to 2009. In each year, utilization and 
costs are examined by healthcare service type, including inpatient services, outpatient 
services, emergency room services, and outpatient prescription drug use. Moreover, 
retrospective cohorts are constructed to compare healthcare utilization and costs associated 
with CD patients who are stratified by use and usage pattern of biological therapies in all 
years after the first confirmed diagnosis of Crohn's disease. A diagnosis was confirmed if at 
least one prescription of any essential CD drugs (listed below) was filled after a medical 
claim with CD as primary diagnosis. In addition to the inclusion and exclusion criteria 
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specified in section 4.2, CD patients are required to have a six-month washout period to 
fulfill new user design for this study. Under new user design, prevalent users with existing 
condition are excluded. To ensure a clean disease history, all eligible CD patients should be 
free of medical and pharmacy claims during the six-month washout period prior to the first 
CD diagnosis. Specifically, before their first CD diagnosis, patients are required to have no 
use of any essential CD drugs, including: a) aminosalicylates (i.e., sulfasalazine and 
mesalamine); b) antibiotics (i.e., ciprofloxacin and metronidazole); c) steroids (prednisone 
and budesonide); d) immunomodulators (i.e., azathioprine, 6-mercaptopurine, and 
methotrexate); e) biological agents approved for CD (i.e., infliximab, adalimumab, 
natalizumab, and certolizumab pegol); and f) immunosuppressants (i.e., cyclosporine, and 
tacrolimus). Two types of cohorts are designated for comparison as shown in Figure 4.1.  
 
Figure 4.1   Sample Selection for Cohort Studies 
 
 
 
All qualified new CD Patients 
Non-biological users  Biological users 
Early biological users Late biological users 
Cohort  
Comparison 1 
Cohort  
Comparison 2 
All eligible CD Patients 
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Biological therapy users vs. non-biological therapy users 
 New CD patients are dichotomized into biological therapy users and non-biological 
therapy users, according to whether or not biological therapies were introduced into their 
treatment plan. Patients in the biological cohort are those who used any type of biological 
therapy after their first diagnosis date between January 1, 2005 and December 31, 2009. 
Non-biological users are those patients who have never used any biological therapies before 
and after the diagnosis date.  
 
Early biological users vs. late biological users 
 Biological users are further divided into two sub-groups, early and late users, 
according to their treatment strategy. Early biological users are patients who used biological 
therapies as first-line treatment in the early stage of disease. Late biological users are those 
patients who used a biological therapy after any of, or a combination of, the following drugs: 
aminosalicylates, antibiotics, steroids, immunomodulators, regardless the amount of use. We 
presume that the early and late biological users followed the top-down and bottom-up 
treatment strategies respectively. The annual estimation of healthcare utilization and costs for 
both early and late biological users from 2005 to 2009 will be referenced in predicting the 
utilization and costs in the first three years of CD for the budget impact analysis (Aim 2) and 
cost saving analysis (Aim 3). 
 
4.3.2  Outcome Variables 
 Outcome variables in the analysis are utilization of healthcare services and associated 
costs. Healthcare services include inpatient visits, outpatient visits, emergency room visits, 
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and outpatient prescription drugs. All-cause healthcare services of each type are inclusive 
when utilization and costs are calculated. No attempts are made to differentiate Crohn's 
disease related services and costs due to technical difficulties in separating these services 
from services for other conditions. Crohn's disease is often characterized by gastrointestinal 
involvement and extraintestinal manifestations (e.g., arthritis, eye involvement, skin 
disorders, malnutrition, etc.), and is often associated with significant co-morbid conditions, 
however, their causal relationship with CD is unclear.(www.uptodate.com) The treatments 
for extraintestinal and co-morbid conditions are not categorized as specifically related to 
Crohn's disease in the claims database. Thus, it is impractical to accurately group the claims 
into those related to CD and those that are not. Since the focus of this dissertation is to 
determine the financial impact of the treatment strategy shift on payers, overall medical costs 
are more meaningful than medical costs specific to CD. Lastly, the economic evaluation is 
based on the difference in costs for CD patients utilizing either early or late adoption of 
biological treatment approach. When all other variables are controlled for in the analyses, the 
economic impact can be attributed to the treatment strategy change. Thus, all-cause 
healthcare utilization and costs are the outcome variables for this dissertation. 
 For eligible CD patients in four different cohorts (i.e., biological users, non-biological 
users, early biological users, and late biological users), outcome variables are defined to 
constitute healthcare utilization and costs for each individual patient based on their claims 
data from 2005 to 2009.  Three sets of outcome variables are used to quantify healthcare 
utilization: a) healthcare utilization variables, representing the quantity of individual 
healthcare services; b) gross cost variables, depicting the total healthcare costs for payers, 
patients (e.g., out of pocket costs), and coordination of benefits (COB); and c) net cost 
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variables, representing the costs for payers only. The definitions for outcome variables are 
provided below. 
Healthcare Utilization Variables  
• Total number of unique inpatient admissions 
• Total length of stay (in days) for all inpatient admissions 
• Total number of visits to a doctor's office or using other outpatient facilities 
• Total number of emergency room visits 
• Total number of outpatient drug prescriptions (including refills) 
Gross Cost Variables 
• Total gross payment for all inpatient services and admissions, including facility and 
professional payments 
• Total gross payment for all outpatient services rendered in a doctor's office, hospital 
outpatient facility, or other outpatient facility 
• Total gross payment for all emergency room services 
• Total gross payment for all outpatient prescription medications, including mail 
ordered prescriptions 
• Total gross payment for all inpatient, outpatient, emergency room, and prescription 
medication services 
Net Cost Variables 
• Total net payment made by third party payers for all inpatient admissions and 
services, including facility and professional payments 
• Total net payment made by third party payers for all outpatient services rendered in 
a doctor's office, hospital outpatient facility, or other outpatient facility 
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• Total net payment made by third party payers for all emergency room services 
• Total net payment made by third party payers for all outpatient prescription 
medications, including mail ordered prescriptions 
• Total net payment made by third party payers for all inpatient, outpatient, 
emergency room, and prescription medication services 
  
 All outcome variables are standardized to annual rates or annual costs according to  
the amount of utilization or costs incurred from CD diagnosis date to the end of enrollment. 
Therefore, values of outcome variables are prorated by dividing by the number of enrolled 
months from CD diagnosis, then multiplying by twelve. All costs are adjusted with annual 
inflation rates for medical care, and expressed in 2010 US dollar ($). 
 
4.3.3  Independent Variables 
 As the analytical models are constructed to compare outcomes between early and late 
biological users, the key independent variable is the user cohort indicator. The value of the 
indicator is set to '1' for patients in the early user cohort, and '0' for patients in the late user 
cohort.  
 Covariates are included in the analytical models to control for potential confounding 
effects. The following variables are designated as covariates in the analyses according to the 
theoretical framework (see Chapter 3): 
• Age (at the year of diagnosis) 
• Gender (female or not) 
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• Geographic region (northeast, north central, south, or west) 
• Urban residence (metropolitan statistical area or not) 
• Employment status of primary beneficiary (full time, part time, or others) 
• Relationship to employee (non-dependent employee, or dependent) 
• Size of employer (large US employer or not) 
• Charlson Comorbidity Index (CCI) score (based on claims data in the washout 
period, six months prior to diagnosis) 
• Number of prescriptions filled in the washout period, six months prior to 
diagnosis 
• Health plan type (EPO, HMO, POS, or PPO) 
• Principal provider specialty (gastroenterologist, or others). 
 
4.3.4  Regression Models 
 In the cohort comparisons, multivariate regression models are constructed to evaluate 
the cross-group effect on healthcare utilization and costs while controlling for a variety of co-
variates. The regression model is expressed in the following form: 
εβββββββ +++++++= − yearmproviderlplaninskhealthjdemogiBioRx XXXXXXY 10  
where Y is an outcome variable, YBioRx is a dichotomous key variable that indicates the 
treatment strategy of the use of biological therapies. Xdemog represents a group of 
demographic variables (e.g., Age, Gender,  Region, MSA, Employ, LargeEmp, and EmpRel), 
Xhealth represents health status (indicated by CCI, Charlson Comorbidity Index  and RxNum, 
number of prescriptions used in the washout period (six months prior to diagnosis)), Xins-plan 
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represents type of insurance plan (i.e., PlanType), Xprovider represents the characteristics of the 
provider (i.e., Specialty),  Xyear represents the number of years from 2005 to the observed 
year. The definitions for all predicting variables are provided in Table 4.1. 
 The generalized estimation equation (GEE) regression model is used to examine 
group differences in a series of outcomes variables (mainly costs, and number of events). The 
GEE model is an extension of the generalized linear model (GLM) to accommodate 
correlated data with a focus on estimating the aggregate response for the population.[64] The 
GEE model has been more and more frequently applied in cohort studies involving 
longitudinal data.[65] Empirically, GEE is most suitable for estimating the effect when 
outcome variables do not exhibit a normal distribution, and an unknown correlation is present. 
The outcome variables in this study can be categorized into two types, i.e., cost and event 
count. Cost data in healthcare are usually highly skewed from the normal distribution, often 
require transformation (e.g., log or inverse) before fitting regression models. Event count 
likely has a gamma or Poisson distribution. In the GEE model, the underlying data 
distribution of outcome variable can be specified by a suitable choice of the link function to 
fit the model. A test method developed by Park et al. can be used to facilitate the choice of 
link function.[66] For each outcome variable, observed values for the same patients in 
multiple years are likely correlated. GEE can easily handle the regression setting with 
longitudinally repeated measures. Therefore, the GEE model is used in this dissertation 
because it can analyze non-normal data and handle the within-patient correlation 
appropriately. 
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Table 4.1   Definitions of Independent Variables in the Regression Models 
Variable Type Definition 
XBioRx Key independent variable 
(Dichotomous)  
1 for early users, 0 for late users 
Age* Numeric (continuous, or 
discrete) 
Age of patient at initial diagnosis of 
Crohn's disease 
Gender Categorical (male, female) Gender of patient 
Region Categorical (northeast, north, 
south, or west) 
Geographic region 
MSA Dichotomous Metropolitan statistical area: 1 = urban, 
0 = non-urban 
Employ Dichotomous 1 for full time employment status, 0 for 
part time or others 
EmpRel Dichotomous 1 for non dependent employee, 0 for 
dependent  
LargeEmp Dichotomous 1 for large US employer, 0 for other 
health plans 
CCI Numeric, continuous Charlson Comorbidity Index score 
RxNum Numeric Number of Rx in washout period 
PlanType Dichotomous 1 for PPO, 0 for others (POS, HMO, 
EPO) 
Specialty Dichotomous 1 if principal provider is a GI specialist 
(STDPROV = 275), 0 for others 
Year Numeric Number of years from 2005 
* Age is also grouped as 18 to 39 years, and 40 years and above. 
 
 
 Multivariate logistic regression model is used to examine group differences when the 
outcome variables are binary, such as whether or not any inpatient services (or emergency 
room services) were used during the disease course. The multivariate logistic regression 
models estimate the effect of each covariate (predicting factor) on the likelihood of 
dichotomous outcome (e.g. any use of inpatient services) while other covariates are 
controlled for.  
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4.3.5  Data Analysis and Data Security 
 Source data and analysis data are stored on a secure data server with restricted access 
in the Sheps Center for Health Services Research at UNC. Data analyses are performed on a 
designated computer with password protection. Study results are communicated with caution 
to the Advisory Committee and others. No patient data are exchanged via email. All 
programming tasks pertaining to data management and statistical analyses are conducted 
with SAS (version 9.1.3, Cary NC).  
 An application was submitted to the Institutional Review Board (IRB) at the 
University of North Carolina at Chapel Hill. IRB approval was obtained prior to the data 
analysis for this study. 
 
4.4 Study Methods for Aim 2 (budget impact study)  
 Budget impact analysis (BIA) is commonly used to address the financial 
consequences related to new health care technologies. In this study, it is extended to assess 
the financial impact of the change of use of new health care technologies. In the Aim 2 of 
this dissertation, a BIA is conducted to evaluate the financial impact of change in treatment 
strategy for Crohn's disease. More specifically, the BIA aims to evaluate payers' affordability 
of the increased use of biological therapies as CD treatment shifts from the conventional 
bottom-up to the aggressive top-down approach. 
 While cost-effectiveness analysis (CEA) evaluates both costs and outcomes of 
alternative technologies to determine their economic efficiency, BIA focuses on costs 
associated with alternative technologies. Since BIA is often used for budget planning and 
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forecasting by decision makers for health plans or third party payers, the BIA is conducted 
from the perspective of payers who manage and plan the budget of a specific healthcare 
program in a given time frame. According to the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Task Force principles of good 
research practice for BIA, the model does share many important methodological elements 
with CEA. Some key elements of the analytical framework for BIA are introduced in 
subsequent sections. 
 
4.4.1  Decision Tree  
 A decision tree model, as schematized in Figure 4.2, is designed as the analytical 
framework for the budget impact analysis in this dissertation. BIA compares prescription 
drug costs for CD patients use two treatment strategies, 'bottom-up' as base case  scenario 
and 'top-down' as alternative scenario. Under the base case (reference) scenario, CD patients 
are compliant to existing treatment guidelines (2009 version) that follow the late adoption 
approach. All CD patients in the alternative (new) scenario are adapting to the early 
aggressive treatment approach that promotes the use of novel biological therapies in the early 
stage of disease. On the decision tree, the two scenarios are listed after the decision node 
(square). 
 In both treatment scenarios, CD patients are allocated into four exclusive outcome 
events according to disease severity, which includes remission, mild/moderate, 
moderate/severe, and severe/fulminant. Each outcome event, or a branch on the decision tree, 
is assigned a probability and associated with a certain amount of costs.  The calculation for 
the probability and costs for each outcome (branch) is detailed in the following sections. On 
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the decision tree, possible outcomes are listed after the chance nodes (circle). Death is not 
included as an outcome  for two reasons: 1) the death rate for CD patients is only slightly 
higher than the general population;[21] and 2)  no death information for patients is available in the 
claims database to provide an estimation. 
 Prescription drug costs associated with each scenario (choice) is the summation of 
costs for each branch (outcome) multiplied by the assigned probability. The net difference in 
drug costs between two scenarios represents the financial impact on the annual budget for 
prescription drugs in a given year. 
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Figure 4.2   Decision Tree (schematic) for Budget Impact Analysis 
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4.4.2  Time Horizon 
 The BIA is conducted on an annual basis for the first, second and third year of CD to 
provide information on financial consequences of drug costs due to the treatment strategy 
change from the bottom-up to top-down approach. The costs and outcomes are evaluated and 
assigned annually. 
 
4.4.3  Perspective 
 The perspective of the budget impact analysis is conducted primarily from that of 
pharmacy benefit management organizations (PBMOs), who are contracted by payers to 
manage prescription drug benefits. In the private sector of the US healthcare system, 
managed care organizations (MCOs) play a major role in providing healthcare to patients. 
Most MCOs use PBMOs to administer the pharmacy benefits. PBMOs negotiate drug price 
with manufacturers and purchase discounted drugs on behalf of MCOs. PBMOs also play a 
pivotal role in formulary design and provision of competitive benefit package to patients.  
When more and more specialty drugs (e.g., biological therapies) became available, PBMOs 
have evolved their function from the pharmacy counter to other sites, e.g., the infusion center. 
To cope with the complexity of specialty drugs, PBMOs usually develop specialty pharmacy 
programs to provide services to individual patients. Traditionally, all prescriptions filled at 
pharmacy counters are reimbursed by PBMOs under pharmacy benefits, and specialty drugs 
are administered by specialty pharmacy programs, but paid directly by payers under medical 
benefits.[67] Since the purpose of BIA is to predict the change in drug costs due to the 
treatment paradigm shift from the bottom-up to top-down treatment approach. We conduct 
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the BIA from a broader view of PBMOs to capture the drug costs for both conventional drugs, 
which are covered by pharmacy benefits, and biological therapies and costs associated with 
drug administration, which are covered by medical benefits. 
 
4.4.4  Outcome Definition by Disease Severity 
 For an individual CD patient, the outcome of a particular treatment intervention can 
be measured in many different ways, such as treatment response, mucus healing, and quality 
of life. However, the outcome of a treatment for a large population cannot be measured 
simply due to the variety of treatment regimens, and the heterogeneity of treatment effects 
among CD patients. Usually, bedside clinical information is not readily accessible for 
researchers to conduct studies for outcome assessment. Without complications from 
individualized treatment and personal clinical experience, disease severity has been used by 
researchers to approximate treatment outcomes at the patient population level.[2] [68] 
 Disease severity is a key determinant in treatment planning for CD patients, although 
other factors, such as disease location, cost of therapy, patient compliance, and individual 
susceptibility to drug toxicity, can also be relevant in making therapeutic decisions. 
Therefore, patients with similar disease severities are presumably treated similarly. For 
example, it is recommended that patients with moderate/severe disease be treated with more 
than two doses of biological therapies. The change in disease severity can then represent the 
outcome of the recommended treatments.  Given the heterogeneity of the disease, however, 
there is no 'gold standard' for the measurement of Crohn's disease severity. Crohn's Disease 
Activity Index (CDAI) is a disease-specific instrument used to quantify the symptoms of CD 
patients. According to the working definition of Crohn's disease activity in the practice 
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guidelines for adults published by the American College of Gastroenterology, Crohn's 
disease is classified into the following stages: a) remission (CDAI: <150); b) mild-moderate 
disease (CDAI: 150-300); c) moderate-severe disease (CDAI: 300-450); and d) 
severe/fulminant disease (CDAI: > 450).[11, 69] The CDAI-based classification system has 
been widely used in clinical trials for Crohn's disease.[8, 9] However, information on disease 
severity for individual patient is not readily available in claims databases for outcomes 
research.  
 Claim-based medical and pharmacological utilization information is used to 
approximate disease severity. Silverstein et al. used both type of therapy and patient response 
to therapy to define disease severity in their Markov model analysis from a population-based 
cohort.[2] Recently, Malone et al. modified the definitions for CD severity by incorporating 
both medical and pharmaceutical claims.[68] Classification of CD severity, as shown in 
Table 4.2, enables the definition of outcomes based on medical and pharmacological claims. 
In this dissertation, disease severity of Crohn's disease patients under either the bottom-up or 
top-down treatment approach is evaluated annually using pharmacy and medical claims. All 
claims within an observed year are checked with the criteria for severe/fulminant disease first, 
then with moderate-severe disease if not met severe disease, and so forth.  This method has 
not been verified in an actual patient population. It is unknown how accurate the definition of 
disease severity is when compared with standard way in clinical practice. Due to the lack of 
direct medical information about patients' disease progression, the algorithm proposed by 
Malone et al. is used as a reasonable proxy for severity classification in this dissertation. 
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Table 4.2   Classification of Severity for Crohn’s Disease 
Severity Stage Clinical Manifestations Claims for Classification* 
Severe/fulminant persistent symptoms despite the 
introduction of conventional 
corticosteroids or biologic agents 
(infliximab, adalimumab, certolizumab 
pegol, or natalizumab) as outpatients, 
or individuals presenting with high 
fevers, persistent vomiting, evidence of 
intestinal obstruction, significant 
peritoneal signs such as involuntary 
guarding or rebound tenderness, 
cachexia, or evidence of an abscess 
• Inpatient hospitalization 
admission with CD diagnosis; or 
• Diagnosis: obstruction, acute 
suppuration, perforation, 
refractory disease; or 
• Procedures: hyperalimentation; or 
• CD related procedures: surgical 
resection, stricturoplasty, 
colectormy ileostomy; or 
• Rx drugs: immunosuppressant, IV 
steroid  
Moderate-severe failed to respond to treatment for mild 
– moderate disease, or those with more 
prominent symptoms of fever, 
significant weight loss, abdominal pain 
or tenderness, intermittent nausea or 
vomiting (without obstructive 
findings), or significant anemia 
Does not meet criteria for 
severe/fulminant, and 
• Diagnosis: fistulas, abdominal 
mass, haemorrhage; or 
• Procedures: absess drainage; or 
• Rx drugs: biological agents (>2 
doses), Prednisone, azathioprine, 
mercaptopurine, methotrexate; or 
• Symptoms: high fever, significant 
weight loss, abdominal 
pain/tenderness, anaemia 
Mild-moderate ambulatory and able to tolerate oral 
alimentation without manifestations of 
dehydration, systemic toxicity (high 
fevers, rigors, and prostration), 
abdominal tenderness, painful mass, 
intestinal obstruction, or >10 % weight 
loss 
Does not meet criteria for 
severe/fulminant and Moderate-
severe, and: 
• Rx drugs: mesalazine, 
sulfasalzine, metronidazole, 
ciprofloxaxin, budesonide, 
rifaximin 
Remission asymptomatic or without any 
symptomatic inflammatory sequelae 
Does not meet criteria for 
severe/fulminant, Moderate-severe, 
and Mild-moderate. 
   CD: Crohn's disease  
* Source: Malone, D.C. et al., A claims-cased Markov model for Crohn's disease. Aliment Pharmacol. 
ther. 2010; 32: 448-458 
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4.4.5  Prescription Drug Costs 
 Due to a  lack of recent data regarding medical costs for CD patients with different 
disease severities, prescription drug costs for each disease severity classification for each 
year of disease are derived from the claims data from 2005 to 2009. In the decision tree for 
budget impact model, annual drug costs in the first three years of CD are the payoff values 
for each branch.    Drug costs are not limited to the drugs prescribed to treat CD, but instead, 
costs for all-cause prescription drugs are included. Additionally, drug administrative costs 
(e.g., intravenous infusion costs) are also included for biological therapies that are 
administered intravenously or subcutaneously. 
 In MarketScan CCAE database, there are two types of prescription drug claims: a) 
traditional drug claims adjudicated with valid national drug codes (NDC), e.g., 00186070210 
for Entocort (Budesonide); and b) specialty drug claims adjudicated with HCPCS J codes, 
e.g., J1745 for infliximab, J0135 for adalimumab, J2323 for natalizumab, and J0718 for 
certolizumab pegol. The following two financial variables, 'payment' and 'net payment', are 
used to calculate gross costs and net costs for prescription drugs. Gross drug costs are the 
sum of 'payment', and net drug costs are the sum of 'net payment' of all eligible claims in a 
given year. For patients who had no prescription claims, or had negative total amount of 
costs, their gross and net drug costs are set to zero. All payments incurred in each calendar 
year from 2005 to 2009 are adjusted with annual inflation rates for medical care to reflect the 
value expressed in 2010 US dollars ($). 
  Given the adequate sample size with around 3,000 eligible patients in both early and 
late biological user groups, prescription drug costs can be consistently estimated for patients 
in each disease severity classification.  
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4.4.6  Transition Probability 
 For budget impact analysis conducted in the first year of CD, the probabilities of each 
outcome under both scenarios are estimated by the proportion of biological therapy users in 
each category of disease severity in their first year of disease. For example, the probability of 
biological users having mild to moderate disease in the first year of disease will be 0.117 if 
there were 11.7% of biological users who experienced mild to moderate disease in their first 
year after diagnosis from 2005 to 2009 (see Table 4.3).  In calculation of the probabilities for 
the first year CD patients, the proportions of biological users are based on distribution of all 
biological users, instead of early or late biological users. Sensitivity analyses are needed to 
address the difference in two biological user groups if their distribution on disease categories 
are significantly different.   
 
Table 4.3   Distribution of Biological Therapy Users in the First Year of Crohn’s Disease 
 Remission Mild- Moderate 
Moderate-
Severe 
Severe/ 
Fulminant 
Early users (N=3,082) 1,299 (42.2.%) 221 (  7.2%)    946 (30.7%)    616 (20.0%) 
 
 
   
Late users (N=2,986)    136 (   4.6%) 487 (16.3%) 1,542 (51.6%)    821 (27.5%) 
 
 
   
Biological users  (N=6,068) 1,435 (23.6%) 708 (11.7%) 2,488 (41.0%) 1,437 (23.7%) 
 
 For BIA conducted in the second year of CD,  the transition probabilities from the 
first year to the second year are calculated by the shift patterns of disease severity for CD 
patients from 2005 to 2009. The transition probability from initial disease severity in the first 
year of disease (e.g., mild to moderate) to present disease severity in the second year of 
disease (e.g., moderate to severe) is based on the proportion of patients who had mild-
moderate disease in the first year, then have moderate and severe disease in the second year. 
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For example, if there were 104 CD patients among the bottom-up users with mild to 
moderate disease in the first year, and 44.2% of them (46 patients) had disease progressed to 
moderate and severe, then the transition probability from mild/moderate to moderate/severe 
is 0.442 (see Table 4.4). The transition probabilities for late and early users are calculated 
separately because of different effect from two treatment strategies.  
 Similarly, transition probabilities from the second year to the third year of disease are 
calculated based on the disease severity data in the second and third years of Crohn's disease.  
 
Table 4.4   Transition Distribution of Biological Therapy Users in Three Years of Crohn’s 
Disease 
 n* Remission Mild- Moderate 
Moderate-
Severe 
Severe/ 
Fulminant 
Late biological users (n=2,986) 
 1st year                                              ===>                           2nd year 
   Remission  104   27 (26.0%) 
  14 (13.5%)   46 (44.2%)   17 (16.3%) 
   Mild-Moderate  368   63 (17.1%) 136 (37.0%) 106 (28.8%)   63 (17.1%) 
   Moderate-Severe  992 111 (11.2%) 
  76 (  7.7%) 634 (63.9%) 171 (17.2%) 
   Severe/Fulminant 497   64 (12.9%) 
  61 (12.3%) 182 (36.6%) 190 (38.2%) 
 
  
   
 2nd year                                             ===>                           3rd year 
   Remission  181   79 (43.6%) 
  34 (18.8%)   48 (26.5%)   20 (11.1%) 
   Mild-Moderate  156   23 (14.7%) 
  64 (41.0%)   44 (28.2%)   25 (16.1%) 
   Moderate-Severe  456   41   (9.0%) 
  37 (  8.1%) 315 (69.1%)   63 (13.8%) 
   Severe/Fulminant 190   20 (10.5%) 
  17 (  8.9%)   69 (36.3%)   84 (44.3%) 
   
   
Early biological users (n=3,082) 
 1st year                                              ===>                           2nd year 
   Remission  816 563 (69.0%) 
  44 (  5.4%) 123 (15.1%)   86 (10.5%) 
   Mild-Moderate  114   33 (28.9%) 
  44 (38.6%)   26 (22.8%)   11 (  9.7%) 
   Moderate-Severe  543 136 (25.0%) 
  40 (  7.4%) 298 (54.9%)   69 (12.7%) 
   Severe/Fulminant 391 116 (29.7%) 
  21 (  5.4%)   82 (21.0%) 172 (43.9%) 
 
  
   
 2nd year                                             ===>                           3rd year 
   Remission  480 298 (62.1%) 
  35 (  7.3%) 108 (15.1%)   39 (10.5%) 
   Mild-Moderate  
  54   11 (20.4%) 
  16 (29.6%)   17 (31.5%)   10 (18.5%) 
   Moderate-Severe  209   35 (16.7%) 
  13 (  6.2%) 128 (61.2%)   33 (15.9%) 
   Severe/Fulminant 152   41 (27.0%) 
    6 (  3.9%)   38 (25.0%)   67 (44.1%) 
* number of patients with full-year claims data in both starting and ending years of disease 
(e.g., 1st and 2nd, or 2nd and 3rd) 
 79 
 
4.4.7  Model Assumptions 
Several important assumptions are made for the budget impact analysis: 
1. The prevalence of Crohn's disease will not increase or decrease significantly in the 
study time frame in the coming three years; 
2. Annual inflation rates for medical care services is  4.0% in 2005, 4.4% in 2006, 3.8% 
in 2007, 3.3% in 2008, 3.6% in 2009 (The rate of increase in the Consumer Price 
Index for medical care service, Bureau of Labor Statistics).[70]  All costs are 
expressed in 2010 US dollar ($). 
3. No new drugs for the treatment of Crohn's disease will enter the drug market in the 
next three years.  
4. No major pharmaceutical policies will be implemented so that payers do not need to 
change their current policy in the coming three years. Current clinical practice 
guidelines for CD treatment will remain the same with the exception that biological 
therapies are preferably used in the early stage of disease. 
 
4.4.8  Base Case Analysis 
 In decision analysis, the base case is defined as 'status quo or keep safe and operating' 
without implementing alternate intervention. In the decision tree model for the current study, 
base case describes an average CD patient who uses biological therapy and other treatment 
following conventional bottom-up strategy in adopting biological therapy later in disease 
course. A patient in the base case has the same likelihood of having different disease severity 
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at the end of each year like other late biological adopters from 2005 to 2009, and incurs the 
same amount of prescription drug costs like others in previous years. 
 The alternative case refers to a scenario where new top-down treatment strategy is 
implemented in the clinical practice for CD patients. A patient in the alternative case follows 
early adoption treatment approach when biological therapies are included in their initial 
treatment. An alternative case patient has the same disease progression as other early 
biological users from 2005 to 2009, and uses the same amount of prescriptions as others. 
 Base case analysis compares the prescription drug costs between an alternative case 
patient with a base case patient, and determines the incremental cost of prescription drug 
costs of the alternative case by applying the estimated values of drug cost and probabilities 
for patients with different disease severity. 
 
4.4.9  Sensitivity Analysis 
 In the base case analysis described above, there is considerable uncertainty with input 
parameters in the model due to a lack of or inaccurate information. Specifically, those 
uncertain parameters are: a) prescription drug costs for patients with different disease 
severity, and b) transition probabilities for patients with disease severity shifting from one 
year to its following year.  Since no detailed cost information for CD patients with specific 
disease severity was available in the literature, we estimated the prescription drug costs and 
transition probabilities for patients classified in different disease severity according to their 
pharmaceutical and medical utilization of CD patients from 2005 to 2009. Point estimates of 
these parameters can not accurately represent their true values without taking into account 
the variation of healthcare utilization of an individual patient in the source data for this study. 
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Sensitivity analysis is a technique used to examine the uncertainties pertaining to the 
variation of prescription costs and transition probabilities. When presenting budget impact 
analysis results to decision makers, it is important to be specific about variation associated 
with all input parameters. Therefore, both base case analysis and sensitivity analysis are 
conducted in the budget impact model. While base case analysis demonstrates the 
incremental prescription drug costs due to the treatment strategy shift to early aggressive 
treatment, sensitivity analysis is performed to verify the robustness and variation of the 
estimation on budget impact. 
 Two types of sensitivity analyses are commonly applied in decision modeling: 
deterministic sensitivity analysis (DSA) and probabilistic sensitivity analysis (PSA). In this 
dissertation, only PSA is chosen for decision analysis. DSA is often a one-way sensitivity 
analysis, which accounts for variation from a single input parameter under an assumption that 
the effect of each input variable is independent from others. However, most decision models 
involve multiple input parameters in combination so that their effects are not additive.  The 
complexity of the budget impact model (e.g., multiple branches at each chance node) raises 
more concerns about the validity of DSA.  On the other hand, PSA allows specifying 
variation of all input parameters simultaneously. In practice, a simple method to perform 
PSA is to use Monte Carlo simulations, which runs the model many iterations (e.g. 2000 
trials) using randomly sampled values from distributions that are pre-specified for input 
parameters. The results from Monte Carlo simulations quantify the effect of variations on the 
uncertainty of the model.  We use the 95% confidence interval of the simulation results to 
present the uncertainty estimated by PSA.  
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 For PSA, distributions are selected to fit the input parameters for the budget impact 
analysis. Gamma distribution is recommended to fit prescription drug cost data, because cost 
data are highly skewed from normal distributions, and are constrained on the interval zero to 
infinity.[71]  Dirichlet distribution is used to fit multinomial data for transition probabilities 
for each disease severity classification (remission, mild-moderate, moderate-severe, and 
severe/fulminant) at each chance node on the decision tree. Although beta distribution is 
often chosen to represent parameters with binomial data (constrained in the interval of 0 to 1), 
however, it is not applicable when the data are multinomial. As a conjugate prior of the 
parameters of multinomial distribution, Dirichlet distribution is frequently used to describe 
transition probabilities with more than two categories.[72] Details for parameter 
specifications for both gamma and Dirichlet distributions are provided in Table 4.5.  All 
sensitivity analyses are conducted with TreeAge Pro 2011 (TreeAge Software Inc., 
Williamstown, MA).  
 
Table 4.5   Parameters Specification in Sensitivity Analysis 
Model Parameter Base Case Value Distribution Specifications  
Prescription drug costs for 
patients classified to 
certain disease severity 
category (e.g. remission) 
Mean of prescription drug costs 
of CD patients by treatment 
strategy (early or late adoption), 
disease severity, and time of 
disease (e.g., 1st year) 
Gamma(κ, θ),  
    where κ =ū2/s2, θ =s2/ū 
     
  
 
Probabilities (in 1st year) 
or transition probabilities 
( in 2nd and 3rd years) of 
patients in certain disease 
severity category 
Proportion of patients in a given 
disease severity, eg. a/(a+b+c+d) 
for disease remission where a, b, 
c and d stand for percentages of 
patients in each of four disease 
categories, respectively 
Dirichlet (a; b; c; d), 
 where a is percentage of 
patients with remission, b 
for mild-moderate disease, 
c for moderate-severe 
disease, and d for 
severe/fulminant disease 
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4.5 Study Methods for Aim 3 (cost study) 
 A cost analysis is conducted to more comprehensively evaluate the financial impact 
of the new treatment approach in CD treatment from payers' perspective. The cost analysis in 
the dissertation estimates the difference in costs incurred in all medical care services between 
two scenarios of treatment strategy, rather than the costs limited to prescription drugs in 
budget impact analysis. In addition to prescription drugs, other medical services, including 
hospitalization, emergency department visit, and outpatient visit, are reimbursed by payers, 
and are accounted for in total cost calculation. The algorithm for the identification of these 
different types of medical care services in the claims database is shown in Table 4.6. The 
total costs of all of these medical services can better represent the financial burden imposed 
to payers. A stable or modest decrease of total medical costs on payers because of the long-
term impact of CD treatment paradigm change from bottom-up to top-down approach is ideal 
for payers to sustain the current benefit policy. On the contrary, a substantial increase of total 
medical costs can likely lead to a major formulary policy change to shift a larger portion of 
costs shared by patients. Therefore, the results from the cost analysis can provide evidence of 
long-term financial impact from the treatment strategy change. Although the cost analysis 
considers the costs from a larger scope of medical resource use, it shares the same analytic 
framework with the budget impact analysis in the previous section. The cost analysis also 
employs the same decision tree, and time horizon. The transition probabilities are identical, 
and sensitivity analyses are constructed similarly to budget impact analysis. 
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Table 4.6   Claims of Medical Services for Cost Analysis 
Service Type Description Claims 
Inpatient services Claims associated with 
inpatient admissions, 
including hospital claims, 
physician claims, surgeon 
claims and claims from 
independent labs 
All claims in Inpatient Services Table except the 
ones for emergency room services of 
MarketScan database 
Outpatient 
services 
Claims for services in a 
doctor's office, hospital 
outpatient facility, and 
other outpatient facilities 
All claims in Outpatient Services Table 
except the ones for emergency room services  
Emergency Room 
services 
Claims for services in 
emergency room 
All claims in both Inpatient and Outpatient 
Services Tables for emergency room facility. 
Selection criteria*: 
• STDPLAC=23; 
• STDPLAC=21,22,28 and 
(STDPROV=220 and STDSVC≠104 or 
STDSVC=77) 
• PROCGRP=110,111, and 114 
Prescription 
Drugs 
Claims for outpatient 
pharmaceutical use 
All claims in Outpatient Pharmaceutical 
Claims Table 
  
 
* Emergency room claims defined in MarketScan User Guide 
 
4.5.1  Time horizon 
 Cost analysis is conducted in a three-year time frame from CD diagnosis to provide 
information of long-term financial consequences of health care costs because of the treatment 
paradigm change from late to early adoption treatment approach.  
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4.5.2  Decision Tree 
 A decision tree model in Figure 4.3 is constructed as the analytical framework for the 
cost analysis. The model compares health care costs (including prescription drug cost) of CD 
patients on an annual basis under two treatment strategies of disease management: bottom-up 
approach (the reference scenario) and top-down approach (the new scenario). In each year 
under either scenario, CD patients are allocated into four outcome levels according to disease 
severity: remission, mild/moderate, moderate/severe, and severe/fulminant. Each outcome (a 
branch on the decision tree) is assigned with a transition probability, and certain amount of 
healthcare costs.  The calculation about the probability and costs for each outcome (branch) 
is elaborated in the sections below. The total costs of each scenario (choice) is the summation 
of the costs with each branch (outcome event) multiplying the corresponding transition 
probability. The difference of healthcare costs between two scenarios demonstrates the long-
term financial impact of the treatment paradigm shift for CD management. 
 
4.5.3  Healthcare Costs 
 Costs of a broader scope of healthcare services, including prescription drug, inpatient 
services, outpatient services and emergency room services, are taken into consideration in the 
cost analysis. Medical and pharmaceutical claims for different type of services in 
MarketScan claims database are classified by the algorithms in Table 4.6. The total cost on 
all four types of healthcare services is the primary economic outcome variable in the cost 
analysis. The analysis results based on the total healthcare cost can be used to demonstrate
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Figure 4.3   Decision Tree for Cost Analysis 
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whether or not the treatment paradigm change is cost-saving. Meanwhile, costs on different 
types of healthcare services are considered as secondary economic outcomes. The results by 
service type (inpatient, outpatient, and prescription services) can be used to demonstrate the 
contribution to the saving of overall cost from each type of healthcare services. 
 On the decision tree, the cost associated with each branch (disease severity) is 
estimated by the average cost of CD patients with the same disease severity in previous years 
from 2005 to 2009. The estimation of total healthcare cost is obtained from the multivariate 
regression analysis in the cohort studies in Aim 1. For example, to predict the total cost of 
CD patients with mild disease in the first year of disease under the late adoption scenario, a 
multivariate linear regression analysis is performed by using the total cost of the same cohort 
of CD patients (mild disease under the late adoption approach) in the years from 2005 to 
2009, and adjusted by the covariates (e.g. age, gender) in the previous sections. 
 All medical costs in previous years are adjusted by the annual inflation rate to reflect 
the present value, expressed in 2010 US dollar ($) as described in Section 4.4.7.  
 
4.5.4  Transition Probability 
 The probability of each branch on the decision tree in the first year is based on the 
proportion of CD patients at the specific disease severity level from 2005 to 2009. For 
example, if 30% of biological users, under either bottom-up or top-down approach, were 
classified as mild disease, then the probability of mild disease in the first year is 0.3. 
 The transition probability of each branch on the decision tree in the second and third 
years is based on the average transition probabilities from the same severity levels in the 
previous year and following year. For example, the transition probability of a CD patient 
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under the bottom-up approach shifting from mild disease in the first year to moderate-severe 
disease in the second year is estimated by the proportion of CD patients under the bottom-up 
approach who shifted from mild disease in the first year to moderate disease in the second 
year of CD. 
 
  
 
 
 
 
CHAPTER V: 
 
HEALTHCARE UTILIZATION AND COSTS FOR 
COMMERCIALLY INSURED PATIENTS WITH CROHN'S 
DISEASE 
  
  
Background: The treatment strategy for Crohn's disease (CD) is currently shifting from the 
conventional 'bottom-up' approach that reserves biological therapy as the last medical resort 
to a more aggressive 'top-down' approach that endorses early use of biological therapy. The 
impact of this shift in treatment on healthcare utilization and costs is unknown.  
Objectives: This study sought to describe healthcare utilization and costs in patterns of 
treatment for Crohn's disease in a commercially insured population. Specifically, the purpose 
was to document healthcare utilization and costs for CD patients who adopted biological 
therapies early or late in their disease course. 
Methods:  The MarketScan Commercial Claims and Encounter database (2005-2009) was 
utilized as source data.  CD patients who used biological therapies were grouped into early 
biological users if biological therapy was used as first-line treatment, and late biological 
users if other conventional medications were initially used in patients' course of treatment. 
We described the trend and pattern of healthcare services, including inpatient, outpatient, 
emergency room visits and prescription drug use. Total medical costs and costs of each 
individual service were summarized from the perspective of third-party payers. Multivariate 
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logistic regression and Generalized Estimating Equations were used to compare the 
utilization and costs of patients who underwent the two different treatment approaches. 
Results:  From 2005 to 2009, 18.2% of CD patients received at least one infusion or injection 
of biological therapy. Compared to late biological users, early biological users had 34% 
fewer inpatient visits and 17%  fewer emergency room visits, and filled 50% fewer outpatient 
prescriptions. The annual costs of inpatient services for early adopters were also 32.2% lower 
than late biological users. However, prescription drug costs for early adopters were 26.4% 
higher. Overall, total medical costs for early adopters were 7.7% (95% CI: 3.0%-12.5%) 
more than later biological users. Factors contributing to these differences include patient age, 
employment status (e.g. large employer or not, full-time or part-time job status), and 
comorbid conditions.  
Conclusion: Early aggressive treatment with biological therapies does not appear to be 
associated with significant changes in the overall costs for treating Crohn's disease.   
 
 
5.1 Introduction 
 
 Crohn's disease (CD) affects approximately one half million Americans.[1] CD is 
characterized by diarrhea, abdominal pain, fatigue, fever, bowel obstruction and passage of 
blood and mucus, and associated with enormous financial burden to both patients and 
society.[2]  The direct medical cost of CD to the U.S. health care system has been estimated 
at over $10 billion in 2006. [3] At present, Crohn’s disease is neither medically nor surgically 
curable.[11] Conventional medical therapies, including aminosalicylates (5-ASA), antibiotics, 
corticosteroids and immunomodulators, have a relatively low response rate and are 
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associated with many side effects. [29, 73] Biological therapies, mainly anti-tumor necrosis 
factors (a-TNF), have emerged as new therapeutic options based on their proven efficacy for 
CD in clinical trials, as well as success in treating other inflammatory conditions, such as 
rheumatoid arthritis and psoriasis.[32] However, these novel biological therapies cost five to 
ten times more than conventional drugs.[3, 74] 
Historically, CD management guidelines recommended that patients begin treatment 
with conventional drugs, such as 5-ASA, oral steroids, and antibiotics, because of their better 
toxicity and safety profile than immunosuppressive medicines.[69] Under these guidelines, 
biological therapies are generally reserved as the last medical resort. This so-called ‘bottom-
up’ treatment strategy has been traditionally accepted in clinical practice, and relies on the 
initial use of inexpensive conventional treatments with more expensive biological therapies 
reserved for patients who are refractory or intolerant to conventional drugs . Recently, 
however, a more aggressive treatment approach, referred to here as the ‘top-down’ approach, 
has received considerable attention because it promotes treatment with expensive biological 
therapy early in the course of treatment before conventional drugs are ever attempted. This 
top-down treatment approach is now thought to change the natural course of disease 
progression by reducing complications of stricturing and fistulization, which often require 
surgery.[37] Indeed, two newly completed clinical trials suggest that the top-down regimen 
results in more rapid and frequent remission.[12, 13]  
Four biological therapies have been approved by the FDA (i.e. Infliximab in 1998, 
Adalimumab in 2007, Natalizumab and Certolizumab pegol in 2008) to treat CD. These new 
therapeutic options, combined with evidence for their effectiveness early in the course of CD, 
have likely shifted treatment patterns for CD. However, there is limited information about 
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utilization patterns and costs of various healthcare services for CD patients over time. Feagan 
et al. examined the costs of different medical services in a claims database (1994-1995), and 
reported that the annual cost was $12,417 for a CD patient.[5] Gibson et al. found that annual 
total medical cost increased to $18,962, based on claims data from 1999 to 2005.[42] More 
recently, Kane et al. and Kappelman et al. compared healthcare utilization and costs between 
biological and non-biological users, and found that biological users incurred substantially 
higher prescription drug costs.[6, 44] However, findings from both studies were based on 
data prior to 2006, and do not capture trends in utilization resulting from the approval of 
newer biological therapies.   
 For the current study, a large administrative database containing medical and 
pharmacy claims was analyzed to describe the use of biological therapies and direct medical 
costs to payers among CD patients from 2005 to 2009. The objectives of this study were to: a)  
describe recent annual trends in the prevalence of biological therapy use among patients with 
CD; and b) summarize the utilization and costs of inpatient, outpatient, and emergency room 
services, as well as prescription drugs for CD patients who initiated biological therapy using 
different treatment strategy. The results of this study will provide third-party payers, 
providers, and CD patients with important financial information regarding recent trends in 
the utilization and costs of healthcare services for Crohn's disease, and the potential influence 
of different strategies for CD treatment on these variables. Study results can also be used to 
predict future use and costs of biological therapies to help facilitate more extensive economic 
evaluations on these biological therapies under different treatment approaches. 
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5.2 Methods 
 
Data Source 
 The data source for this study was the MarketScan Commercial Claims and 
Encounter (CCAE) database (Thomson Reuters, Ann Arbor, Michigan) comprised of patient 
data from January 1, 2005 to December 31, 2009. This database captured person-specific 
clinical utilization, expenditures, and enrollment across inpatient, outpatient, prescription 
drug, and carve-out services from approximately 100 payers including large employers and 
health plans. From 2005 to 2009, there were data from nearly 73 million insured individuals 
in the MarketScan CCAE database. 
 
Patient Selection 
 The process of patient selection was illustrated in Figure 5.1.  The source population 
for the study was comprised of individuals from a MarketScan CCAE database meeting the 
following inclusion criteria: a) a diagnosis of Crohn's disease (ICD-9 code: 555.x); b) 
between 18 and 64 (inclusive) years of age at initial diagnosis; c) a minimum of one year of 
continuous enrollment after the diagnosis of Crohn's disease; d) who were enrolled in 
managed care organizations; and e) who were incident CD patients with no CD history. We 
restricted the sample to incident users following a new user design to avoid selection bias due 
to under-ascertainment of early events and to control for risk factors that may be altered by 
the intervention.[75] Therefore, patients were required to have no CD diagnostic claims or 
prescription treatment for CD for a minimum of six months before the index date of the first 
CD treatment. To eliminate patients with diagnostic claims related to symptoms of CD who 
did not have a confirmed diagnosis of CD, we required patients to have both a diagnosis 
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claim for CD and at least one prescription for medications used to treat CD, including non-
biological drugs (mesalamine, sulfasalazine, metronidazole, ciprofloxacin, rifaximin, 
azathioprine, methotrexate, mercaptopurine, budesonide (Entocort only), cyclosporine, and 
tacrolimus), and biological agents (adalimumab, infliximab, natalizumab, and certolizumab 
pegol). Oral steroids (i.e. prednisone, prednisolone) were not included in the patient selection 
algorithm due to their relatively low specificity.[6] We further restricted our sample to 
exclude patients diagnosed with the following conditions since these conditions can be 
treated with the same biological therapies used to treat Crohn's disease: a) ulcerative colitis 
(ICD-9 codes: 556.xx inclusive); b) rheumatoid arthritis (ICD-9 codes: 714.0, 714.1, 714.2, 
714.30, 714.31, 714.32, 714.33, 714.4, 714.81, 714.89, 714.9); c) ankylosing spondylitis 
(ICD-9 code: 720.0); d) psoriatic arthritis (ICD-9 code: 696.0); e) plaque psoriasis (ICD-9 
code: 696.1);  and f) juvenile idiopathic arthritis (ICD-9 code: 714.3).  Among nearly 73 
million individuals in the MarketScan CCAE database, 33,428 patients met eligibility criteria 
for the study (see Figure 5.1).  
 The study cohort was grouped into either biological users or non-biological users. 
Biological users were defined as patients who used any biological therapy during the disease 
course from the initial diagnosis to the end of enrollment or the last day of follow-up on 
December 31, 2009. There were 6,068 patients who used at least one dose of biological 
therapy. 
 Biological users were further classified into either early or late biological users 
according to their initial medical treatment. If one of the biological therapies was included in 
the patients' initial medical treatments, those patients were categorized as early biological 
users. Late biological users were those patients who used biological therapies after 
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attempting other conventional drugs. Among all biological users, 3,082 of them included 
biologics in their initial CD treatment, and 2,986 patients used biologics later. 
 
Outcome Variable Definitions 
 Outcomes for this study include a series of variables that describe the utilization and 
costs of healthcare services used by CD patients in different healthcare service areas, 
including inpatient, outpatient, and emergency room as well as prescription drugs. Utilization 
and costs were examined for all causes, regardless of whether the service was targeted at CD, 
because diagnosis codes associated with claims may not reflect the exact medical cause.    
 Binary variables were used to categorize patients as having received either inpatient 
or emergency room services during the entire disease course from the date of diagnosis to the 
end of enrollment. Five continuous numeric variables were defined to quantitatively 
represent the annual utilization of healthcare services, including the number of inpatient, 
outpatient, and  emergency room visits,  number of prescriptions filled and  length of 
inpatient stays (number of days). For patients enrolled in more than one year, the utilization 
variables were annualized by first calculating the monthly rate (the amount of utilization 
divided by duration of disease in months), then multiplying by twelve.  
 Healthcare costs consisted of payments from the following three parties: a) out-of-
pocket payments made by patients (i.e. deductibles, copayments, and coinsurance); b) 
payments made by third-pay payers (i.e. net payment); and c) payment coordination of 
benefits (i.e. COB, or other savings). The total payment from all three parties represents the 
direct medical cost to society, where net payment denotes the costs incurred by payers. Both 
total payment and net payment were summarized according to patient groups. In addition to 
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the sum of costs for all health care services, four separate variables were defined to depict 
costs for inpatient, outpatient, emergency room services, and prescription drugs. For each 
patient, cost variables consisted of the average costs for all healthcare services or individual 
healthcare service across all enrolled years. All costs were adjusted to the value of the U.S. 
dollar in 2010 using the medical consumer price index.  
 
 
Independent Variables 
Healthcare utilization and costs for patients with chronic illness can be explained by a 
wide range of internal factors (e.g., patient characteristics) and external variables (e.g., 
provider specialty).[76] We characterized patients on the basis of Andersen's model for 
healthcare utilization, which posits that healthcare utilization is dependent upon predisposing 
factors (the predisposition of the patient to use healthcare services), enabling factors 
(patient's ability secure services), and need factors (disease severity).[60]  In the current 
study, predisposing variables included patient age at initial diagnosis of Crohn's disease, 
gender and calendar year of disease diagnosis (i.e., 2005, 2006, 2007, 2008, and 2009). 
Enabling factors included health plan type (e.g., preferred provider organizations (PPO) or 
others), employment status (e.g., active full time employee or others), relationship with 
employee (e.g.,employee or spouse/dependents), geographic region (e.g., northeast, north 
central, south, or west), urban residence (e.g., metropolican statistical area or not), and 
employer size (e.g., large employers or smaller firms under health plans). Need factors 
included provider specialty at initial diagnosis (e.g., gastroenterologist or not), comorbid 
conditions (e.g., Charlson comorbid index score based on utilization information in the six-
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month 'washout' period prior to the initial diagnosis),[77]  and prescription use in the washout 
period (e.g., number of prescriptions filled in the past six months prior to the initial 
diagnoses). 
 
Statistical Analysis 
Descriptive statistics for both outcomes and independent variables were conducted on 
all eligible CD patients and subgroups, including biological and non-biological users. Among 
biological users, characteristics and outcomes of early biological users were compared with 
late users by applying two-way ANOVA tests for numerical variables (e.g., age) and the 
Cochran-Mantel-Haenszel test for categorical variables (e.g., health plan type). Descriptive 
statistics for these variables in each patient cohort are provided. 
A logistic regression model was used to estimate the effect of patient characteristics 
in predicting the preference in treatment approach for patients when biological therapies were 
included in the treatment algorithm. In this model, the response variable was coded to '1' for 
patients who used the top-down treatment, and coded to '0' for patients following the bottom-
up strategy. Two logistic regression models were used to demonstrate differences in the 
likelihood of using both inpatient services and emergency room services between top-down 
and bottom-up biological users, controlling for patient characteristics. 
Generalized estimating equation (GEE) regression was used to estimate the 
differences in utilization and cost variables between top-down and bottom-up biological 
users, controlling for patient characteristics as covariates. The GEE models are specified as 
follows in a general form where the response variable can be one of the utilization outcome 
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variables, such as average number of inpatient visit per year or average net cost of 
prescription drugs per year. 
εββββββββ ++++++++= yearnprovidermemplinskhealthjdemogiEarly XXXXXXXY 10  
where, Y represents an outcome variable, XEarly is the key independent variable that indicates 
whether a patient is an early biological user (coded to '1'), or a late biological user (coded to 
'0'). Covariates used in the model include: a) Xdemog represents a group of demographic 
variables, including age, gender, urban residency, and region; b) Xhealth represents health 
status, indicated by the Charlson Comorbidity Index (CCI) and total number of prescriptions 
in the washout period; c) Xins denotes the type of benefit plan (PPO, POS, FFS, and other); d) 
Xemp represents employment status (e.g., full-time or not),  relationship to employee (e.g., 
employee or spouse/dependent) and employer size (e.g., large firm vs. small firm); e) Xprovider 
represents characteristics of the provider (e.g., specialty); and f) Xyear represents a given 
calendar year from 2005 to 2009. 
 All analyses were performed with SAS, version 9.1.3 (SAS® Cary, NC). The study 
was approved by the Institutional Review Board (IRB) at the University of North Carolina at 
Chapel Hill. 
 
  
5.3 Results 
 
Study Patients 
Among 33,428 eligible Crohn's disease patients whose data comprised the MarketScan 
database from 2005 to 2009, 18.2% (n=6,068) received at least one infusion or injection of 
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any biological therapy, including Infliximab, Adalimumab, Natalizumab, or Certolizumab 
pegol. In each year from 2005 to 2009, the percentage of biological users among prevalent 
CD patients persistently increased from 7.0% in 2005 to 15.4% in 2008, and 18.% in 2009 
(not including CD patients who were diagnosed after January 1, 2009). The notable growth in 
2008 and 2009 is likely related to the FDA’s approval for new biological therapies (see 
Appendix Tables 5.1, 5.2 and Figure 5.2). 
Compared to non-biological users, biological users were significantly younger (biological 
users: 37.9 vs. non-biological users: 43.1, p< 0.001), more likely employed by smaller firms 
than large employers (56.7% vs. 41.5%,  p<0.001), had fewer comorbid conditions measured 
by the Charlson comorbidity index (0.05 vs. 0.18, p<0.001), and used fewer prescriptions in 
the past six months prior to their diagnosis of Crohn's disease  (1.61 vs. 5.32, p<0.001) (see 
Table 5.1). Logistic regression confirmed that these patient characteristics were significant 
predictors for biological therapy use (see Appendix Table 5.5). 
Among 6,068 biological therapy users, 50.8% (n=3,082) of patients used biological 
therapies as their initial medical treatment, and 49.2% (n=2,986) of patients used other non-
biological therapies as first-line medical treatment. Compared to the late biological users, 
early adopters had similar characteristics, for example, age at diagnosis (38.0 vs. 37.7), 
proportion of females (53.1% vs. 55.0%), percentage of urban residents (86.7% vs. 85.4%),  
the likelihood of being diagnosed by a gastroenterologist (28.2% vs. 32.8%), and comorbid 
conditions measured by the Charlson Comorbidity index (0.03 vs. 0.06). These two groups of 
patients were also categorically different in many aspects. For example, early biological users 
were  more likely enrolled in health plans offered by smaller firms than those covered large 
employers (71.7% vs. 41.2%, odds ratio=2.10, CI: 1.69-2.60), and less likely employed as 
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active full-time employees (27.0% vs. 55.1%, OR=0.73, CI: 0.59-0.91). In addition, early 
biological users consumed fewer prescriptions in the past six months prior to their CD 
diagnosis (0.55 vs. 2.71, OR=0.83, CI: 0.80-0.85) (see Table 5.1 and Appendix  Table 5.4). 
 
Healthcare Utilization 
The descriptive statistical summary showed differences between the early and late 
biological users in inpatient visits, length of inpatient stays, outpatient visits, emergency 
room visits, and number of prescription drugs (see Table 5.2). Generalized estimating 
equations (GEE) models estimated statistically significant differences in healthcare 
utilization between these two biological user groups. When compared to the late biological 
users, early users had 34% (95% confidence interval: 25%-43%) fewer inpatient visits per 
year (0.32 vs. 0.47), had 28% (CI: 24%-32%) fewer days of inpatient stays per year (1.61 vs. 
2.27), had 17% (CI: 5%-28%) fewer emergency room visits per year (0.85 vs. 0.97), and 50% 
(CI: 45%-54%) fewer prescriptions filled per year (16.94 vs. 31.72). The difference in 
number of outpatient visits per year between early and late biological users was not 
statistically significant (see Appendix Table 5.6 and Appendix Figure 5.1). 
 
Healthcare Costs 
Total costs to the healthcare system and net costs to payers for all services and service 
areas are summarized in Table 5.2. The annual total costs of all healthcare services were 
$32,820 (standard deviation: $28,788) for biological users, and 92% of the total costs, or 
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$30,213 per year (SD: $27,538) were paid by third-party payers. Among the total net cost, 
51.0% was attributable to prescription drug costs, equivalent to $15,410 per year (SD: 
$12,672).  
Comparisons of healthcare costs were also made between the early and late biological 
users. The total net costs for early adopters was $30,785 per year (SD: $29,137), which is 7.7% 
(95% confidence interval: 3.0%-12.5%) higher than late biological users, whose costs were 
$29,623 per year (SD: $25,775). When comparing net costs for each healthcare service area, 
the results showed that early biological users incurred 26.4% higher costs for prescription 
drugs ($17,209 vs. $13,554, CI: 22.1%-30.7%), but had 32.2% lower costs for inpatient 
services ($4,942 vs. $6,934, CI: 15.6%-48.9). Differences in the annual net costs of 
outpatient and emergency room services between early and late users were not statistically 
significant. GEE regression results showed that age at diagnosis, provider specialty of initial 
diagnosis, employment status, and comorbid conditions were the factors that contributed 
most to the total net cost difference between the two biological user groups (see Table 5.3, 
Figure 5.3 and Appendix Table 5.7). 
 
5.4 Discussion  
Our results suggest that the use of biological therapy for Crohn's disease has 
increased significantly over the past five years from 7.0% in 2005 to 18.4% in 2009.  Despite 
the economic recession from December 2007 to June 2009, the annual increase of biological 
therapy use is steady because of the market diffusion of individual biological therapies, and 
the expansion of the biological drug class with three biological therapies approved by the 
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FDA in 2007 and 2008. When more biological therapies are under investigation in clinical 
trials [32] and the US economy is continuously recovering, it is projected that more than 20% 
of CD patients would be receiving biological therapies in 2010. The increasing use of 
biological therapies can result in substantial financial pressure on payers, particularly 
managed care organizations, because of the high cost of these drugs. While managed care 
organizations have made an effort toward cost containment, [78] the expansion of biological 
therapies as treatment for CD patients could increase budgetary pressures to control CD 
healthcare spending. In response, aggressive measures may be taken by managed care 
organizations to contain costs, which would reduce access to advanced treatment that may 
benefit patients. In fact, more and more insurance plans adopted co-insurance, instead of flat-
fee co-payment, as the cost-sharing method of choice for biological agents for patients with 
rheumatoid arthritis.[79] 
Our results suggest that the use of biological treatment for Crohn's disease differs 
according to several patient characteristics and healthcare system factors. Although the 
demographic characteristics differentiate who receives biological treatment overall, they 
explain less clearly how early or aggressively biological therapy is initiated among biological 
users. Biological users were, on average, five years younger than non-biological users. 
However, the average age of early biological users was not significantly different from late 
biological users. This suggests that there is a lack of evidence to support the contention that 
biological users are different in age at onset of CD, thus, biological users can be considered 
as a homogeneous group. This can simplify cost-effectiveness modeling without stratifying 
patients into different age groups. Other patients’ demographic characteristics, including 
gender, geographic region, urban residence, and year of initial diagnosis, did not appear to be 
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notably different between two biological user groups. However, we noticed that they were 
different in several important aspects. Early biological users had much lower comorbidity 
scores, and filled smaller number of prescriptions during six months before the diagnosis of 
Crohn's disease. These were the indicators that early biological users may have better general 
health condition than late users.  
Another difference was patient employment status, which showed that early 
biological users were less likely to be full-time employees and less likely to be employed by 
large employers. It is believed that health benefits provided by larger employers are more 
generous than those provided by small firms.[80] Counter-intuitively, patients with less 
generous healthcare coverage are more likely to use advanced treatments, which may be 
related to awareness of expiration of their employment based insurance. Biological therapies 
are associated with high costs, average wholesale prices (AWP) are $754.50 for infliximab 
100 mg (Remicade®), $865.58 for adalimumab 40 mg (Humira®) and $822.30 for 
certolizumab pegol 200 mg (Cimzia®). It is natural for patients to be prone to use more 
expensive treatment options when they have health insurance coverage, but are concerned 
about the continuity of their employment and/or healthcare benefit plans while working at 
small firms. Therefore, patients from small employers use biological therapies earlier in the 
disease course when they have milder disease. Given that specific information about the 
generosity of health plans was not available in the source dataset, further study is needed to 
confirm whether or not employers' size is a valid indicator of a health plan's generosity of 
coverage.  
It was interesting to note that early biological users were less likely to be full-time 
employees than late biological users. Employment status (i.e., active full-time or part-time 
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job status) and healthcare benefits are highly associated with firm size.[81] Large firms offer 
more full-time positions, and provide health insurance to employees with better coverage.[82] 
It may be reasonable to assume that employment status is associated with the health status of 
patients. Patients with severely active CD that experience frequent flare-ups may have 
greater disability preventing them from working at full-time jobs. Due to a lack of 
information in our source data about employment status and disability conditions, it is 
unknown about their effect in predicting healthcare utilization and costs.    
The total medical costs in this analysis are consistent with findings from previous 
studies. The average total cost of medical services for all CD patients was $18,880 (standard 
deviation: $32,228), which is higher than results reported by Kappelman and colleagues 
($10,952 in 2004).[6] The increase in total medical costs reflect the trend that more Crohn's 
disease patients are using biological therapies. The average total cost for biological users was 
$32,820 (standard deviation: $28,788), which is lower than Kane and Sandborn’s calculation 
based on the planned dose schedule. This difference may be attributable to non-compliance 
among some patients in our source data.  
The most striking finding in the cost analysis when comparing the two biological user 
groups is that the overall medical costs paid by third-party payers for early biological users 
($30,785) were only 3.9% higher than those paid for late users ($29,623).  These results 
suggest to payers that the new treatment strategy change for CD patients toward early 
aggressive biological therapy use had not incurred a dramatic surge in overall payments. It 
was also found that total medical costs, including the net payments by payers, out-of-pocket 
payments by patients, and coordination of benefits (COB) and other savings, were $33,263 
for early and $32,362 for late biological users. The differences between total medical costs 
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and net payment by payers for early and late users were $2,478 and $2,739, respectively. 
This indicates that out-of-pocket costs of prescription drugs for CD patients is nearly the 
same, regardless of the treatment approach. Furthermore, our results demonstrate that the 
cost pattern shifted from inpatient services to prescription drugs when utilization and costs 
were analyzed by healthcare service area. Compared to the late biological users, early users 
incurred higher costs for prescription drugs, and lower costs for inpatient services, when 
compared to costs for outpatient and emergency room services. As biological therapy use 
becomes more common and is implemented earlier in the course of CD treatment, managed 
care organizations are concerned about the expense of these treatments. Further research is 
needed to demonstrate the short-term budgetary impact from increased drug costs due to the 
treatment strategy shift toward more aggressive biological therapies, and the long-term cost-
effectiveness of this aggressive treatment approach for CD patients.  
We used a dichotomized approach and classified biological therapy users into early 
and late user groups according to whether or not biological therapies were used within three 
days after their first CD treatment. We used the general consensus about top-down and 
bottom-up strategy in defining patient cohorts since there is no unified definition for both 
top-down and bottom-up therapy from clinical perspective. In practice, medical therapy for 
CD patients is often individualized according to disease severity, location, and health 
condition. Meanwhile, the claims data used in this study do not contain comprehensive 
medical and clinical information. Although top-down treatment suggests patients to start with 
biological therapy immediately after their diagnosis, some clinicians would include patients 
who used biological therapies right after steroids. We examined patients who used steroids as 
the first medical therapy, and found their utilization and healthcare costs were homogenous 
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to other late biological users. Therefore, we included steroid users in the late user group. The 
bottom-up strategy requires patients to start with less potent therapies. We found the order of 
therapies was diversified, and only a small portion of patients strictly followed the disease 
management guidelines. Given the complexity of treatment pattern for CD patients, we 
consider early users using top-down and late users using bottom-up treatment strategy, 
respectively.    
The results of this study must be interpreted in light of the study's limitations. First, 
the study results were based on a well-defined patient population with strict selection criteria. 
Eligible patients were enrollees of managed care organizations in a large commercial claims 
database. Patient groups were required to meet age criteria, continuous enrollment status, and 
were newly diagnosed with a clean six-month washout period. Although these patients can 
represent a large portion of the US population, especially in people under 65, they may be 
categorically different from patients insured by other government programs, such as 
Medicaid and Medicare. External validity needs to be assessed further before extrapolating 
findings from this study to other patient population.  
Second, patient group classification in this study was largely based on pharmacy and 
medical claims instead of medical records. Although claims data contains comprehensive 
healthcare service utilization information, medical information within claims data may lack 
accuracy. For example, the diagnosis code related to many medical procedures can not 
confirm whether a visit truly resulted in a diagnosis or served as a means of ruling out other 
conditions. In the study methodology, some measures were taken to remedy the issues 
concerning the accuracy of the diagnosis by requiring all CD patients to have filled at least 
one prescription for medication used to treat Crohn’s disease. Furthermore, claims data only 
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captures pharmacy or medical utilization where insurance claims were filed. Free or self-paid 
drug samples/procedures were not included in the claims database, which could lead to 
misclassification. In particular, some early biological users might be misclassified if they 
received medications that were not in the claims data prior to FDA approval of biological 
therapies. Inaccurate and incomplete claims data could threaten the internal validity of this 
study. 
 
5.5 Summary  
Biological therapies were increasingly used among Crohn’s disease patients from 
2005 to 2009. From comparisons of healthcare utilization between early and late biological 
users, we found that both user groups utilized a similar amount of outpatient services, but 
early users utilized less inpatient and emergency room services, and filled a fewer number of 
prescriptions. Compared to the late users, early users incurred more costs for prescription 
drugs, but fewer expenses for both inpatient and emergency room services. Despite 
differences in costs for each service area, the total healthcare costs paid by third-party payers 
were not categorically different between two biological user groups. This indicates that 
increased drug costs for top-down users could be offset by the reduction in inpatient and 
emergency room services. These results suggest that early aggressive treatment of CD with 
biological therapy may not incur significant additional expense to health insurers. Further 
studies are needed to investigate the budgetary impact and cost effectiveness of incorporating 
biological treatments early into CD treatment regimens. 
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Figure 5.1   Study Sample Selection 
 
All patients in MarketScan database 
 from 2005 to 2009 
(N = 72,871,157) 
Patients with Crohn's Disease  diagnosis 
(ICD-9 code: 550) 
 (N = 141,883) 
Patients with no diagnosis of RA and other 
co-indicated conditions 
(N = 100,508) 
Patients with at least one year continuous 
enrollment after CD diagnosis 
(N = 63.631) 
Non-biological users  
(N = 27,360) 
Biological users 
(N = 6,068) 
Early biological users 
(N = 3,082) 
Late biological users 
(N = 2,986) 
Cohort  
Comparison 1 
Cohort  
Comparison 2 
Patients at age of 18 under or 65 above 
 (N = 6,977) 
Patients with less than one year 
continuous enrollment after CD diagnosis 
(N = 40,547) 
Patients with no diagnoses of Crohn's 
Disease 
 (N = 72,729,274) 
Patients with diagnosis of RA or other co-
indicated conditions 
 (N =34,398) 
Patients between 18 and 64 years of age 
 (N = 134,906) 
New CD patients with six-month clean 
washout period 
(N = 59,961) 
Patients without six-month clean washout 
period 
(N = 3,670) 
Managed Care Organization Enrollees 
(N = 54,833) 
Non-MCO enrollees 
(N = 5,128) 
Essential CD prescription users 
(N = 33,428) 
Rule-out with no CD prescription used 
(N =21,405) 
  
 
109 
 
Table 5.1   Characteristics of Crohn’s Disease Patients 
Characteristics Non-biological Users Biological Users P-value* 
Early Biological 
Users 
Late Biological 
Users P-value* 
Total number of patients    27,360      6,068 
 
    3,082     2,986 
 
Year of disease diagnosis,% 
  
<0.001 
  
<0.001 
 2005   5,863 (21.4%)       920 (15.2%) 
 
      290  (9.4%)      630 (21.1%) 
 
 2006   6,640 (24.3%)   1,689 (27.8%) 
 
  1,038 (33.7%)      651 (21.8%) 
 
 2007   4,966 (18.2%)      916 (15.1%) 
 
     405 (13.1%)      511 (17.1%) 
 
 2008   9,471 (34.6%)   2,480 (40.9%) 
 
  1,321 (42.9%)   1,159 (38.8%) 
 
 2009       420 ( 1.5%)        63  ( 1.0%) 
 
       28 (  0.9%)        35  ( 1.2%) 
 
Age at diagnosis, mean (SD)     43.1 (12.5)    37.9 (12.2) <0.001     38.0 (12.3)     37.7 (12.2)   0.364 
Age at 40 years or above, % 16,826 (61.5%)   2,609 (43.0%) <0.001   1,327 (43.1%)   1,282 (42.9%)   0.923 
Female, % 16,080 (58.8%)  3,281 (54.1%) <0.001   1,638 (53.1%)   1,643 (55.0%)   0.143 
Diagnosed by GI specialist, %   7,667 (28.0%)   1,846 (30.4%) <0.001      868 (28.2%)      978 (32.8%) <0.001 
Region,% 
  
<0.001 
  
<0.001 
 Northeast   3,591 (13.1%)      733 (12.1%) 
 
     365 (11.8%)     368 (12.3%) 
 
 North Central   8,567 (31.3%)   2,004 (33.0%) 
 
  1,102 (35.8%)     902 (30.2%) 
 
 South 11,502 (42.0%)   2,675 (44.1%) 
 
  1,336 (43.3%)   1,339 (44.8%) 
 
 West, or unknown   3,700 (13.5%)      656 (10.8%) 
 
      279  (9.0%)      377 (12.6%) 
 
MSA, % 23,164 (84.7%)   5,221 (86.0%)   0.007   2,671 (86.7%)   2,550 (85.4%)   0.155 
Large employers, % 25,999 (58.5%)   2,628 (43.3%) <0.001      872 (28.3%)   1,756 (58.8%) <0.001 
PPO, % 19.261 (70.4%)   4,487 (73.9%) <0.001   2,460 (79.8%)   2.027 (67.9%) <0.001 
Fulltime employee, % 14,187 (51.9%)   2,479 (40.9%) <0.001      833 (27.0%)   1,646 (55.1%) <0.001 
Non-dependent employee, % 17,351 (63.4%)   3,824 (63.0%)   0.560   1,946 (63.1%)   1,878 (62.9%)   0.842 
CCI, mean (SD)     0.18 (0.70)     0.05 (0.28) <0.001     0.03 (0.22)     0.06 (0.33) <0.001 
Rx prior to diagnosis, mean (SD)     5.32 (9.14)     1.61 (4.57) <0.001     0.55 (1.87)     2.71 (6.05) <0.001 
* P values were obtained from a Cochran-Mantel-Haenszel test for categorical variables (eg. year of diagnosis), and from a two-way ANOVA test for numerical   
   variables (eg. age) while comparing the characteristics between early and late biological users. 
SD: standard deviation; MSA: metropolican statistical area; GI: gastroenterologist; PPO: preferred provider organization; CCI: Charlson comorbidity index 
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Table 5.2   Summary of Healthcare Utilization and Costs 
Outcomes All Eligible CD Patients 
Non-biological 
Users Biological Users 
Early Biological 
Users 
Late Biological 
Users 
Total number of patients     33,428    27,360      6,068     3,082     2,986 
      
Patients with any inpatient visit, %   11,724 (35.1%)    9,239 (33.8%)     2,485 (41.0%)       1,041 (33.8%)     1,444 (48.4%) 
Inpatient visits per year     0.32 (0.76)     0.30 (0.75)     0.39 (0.80)     0.32 (0.78)     0.47 (0.82) 
Days of inpatient stays per year     1.55 (6.02)     1.46 (6.10)     1.93 (5.62)     1.61 (5.93)     2.27 (5.26) 
Total payment of inpatient services   $5,361 (21,251)   $5,150 (21,661)   $6,313 (19,267)   $5,248 (20,170)   $7,412 (18,226) 
Net payment of inpatient services   $5,029 (20,632)   $4,831 (21,108)   $5,922 (18,308)   $4,942 (19,304)   $6,934 (17,164) 
      
Patients with any outpatient visit, % 33,235 (99.4%) 27,195 (99.4%)  6,040 (99.5%)  3,080 (99.9%)   2,960 (99.1%) 
Outpatient visits per year    18.16 (16.38)    17.44 (16.22)    21.44 (16.20)    21.47 (16.71)    21.42 (15.66) 
Total payment of outpatient services   $7,451 (13,880)   $7,118 (14,429)   $8,951 (10,947)   $8,587 (10,866)   $9,327 (11,019) 
Net payment of outpatient services   $6,543 (13,334)   $6,160 (13,765)   $8,269 (11,020)   $8,083 (11,223)   $8,460 (10,804) 
      
Patients with any ER visit, %   17,674 (52.9%)   14,171 (51.8%)     3,503 (57.7%)     1,658 (53.8%)     1,845 (61.8%) 
ER visits per year     0.78 (2.18)     0.75 (2.23)     0.91 (1.92)     0.85 (1.83)     0.97 (2.00) 
Total payment of ER services      $621 (2,446)      $601 (2,499)      $709 (2,190)      $646 (2,324)      $774 (2,040) 
Net payment of ER services      $540 (2,999)      $523 (2,385)      $613 (1,859)      $551 (1,874)      $676 (1,842) 
      
Number of Rx per year    24.77  (23.43)    24.89 (23.57)    24.21 (22.78)     16.94 (18.35)   31.72 (24.41) 
Total payment of Rx services   $5,447 (8,809)   $2,919 (4,521) $16,848 (13,288) $18,782 (14,953) $14,850 (10,964) 
Net payment of Rx services   $4,766 (8,288)   $2,406 (4,199) $15,410 (12,672) $17,209  (14,191) $13,554 (10,568) 
      
Total payment of all services  $18,880 (32,228)  $15,788 (32,133)  $32,820 (28,788)  $33,263 (30,329)  $32,362 (27,104) 
Net payment of all services 
 $16,878 (31,010)  $13,921 (30,960)  $30,213 (27,538)  $30,785 (29,137)  $29,623 (25,775) 
ER: emergency room, Rx: prescription 
All costs are adjusted to 2010 US dollar ($) with annual CPI inflation rate of medical care. 
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Table 5.3   Comparison of Outcomes Between Early and Late Biological Users 
 
Early vs. Late Biological Users 
Outcome Variables Estimate (95% CI) Model specifications 
Net payment of all services, $ 
    7.7% (3.0%,12.5%)* GEE, gamma, log link 
Net payment of inpatient services, $ -32.2% (-48.9%, -15.6%)§ GEE, gamma, log link 
Net payment of outpatient services, $ 
  -3.6% (-10.5%, 3.4%) GEE, gamma, log link 
Net payment of ER services, $ -15.9% (-32.3%, 0.5%)  GEE, gamma, log link 
Net payment of prescription services, $ 
 26.4% (22.1%, 30.7%)§ GEE, gamma, log link 
   
Any use of inpatient services 0.57 (0.51, 0.64)§ Logistic regression  
Any use of emergency room services 0.77 (0.69, 0.86)§ Logistic regression 
   
Number of inpatient visits  -34% (-43%, -25%)§ GEE, Poisson, log link 
Number of days of inpatient stay  -28% (-32%, -24%)§ GEE, Poisson, log link 
Number of ER visits  -17% (-28%, -5%)† GEE, gamma, log link 
Number of outpatient visits -0.3% (-4%, 3%) GEE, gamma, log link 
Number of prescriptions  -50% (-54%, -45%)§ GEE, gamma, log link 
§: p<0.001, †: p<0.01, *: p<0.05 
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Figure 5.2   Proportion of Biological Users from 2005 to 2009 
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Figure 5.3   Comparison of Healthcare Costs for Early and Late Biological Users  
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APPDENDIX 
 
Appendix Table 5.1   Prevalent Biological Users among Crohn’s Disease Patients 
Year Eligible CD Patients Biological Users Percentage 
2005   6,783    477   7.0% 
2006 15,044 1,688 11.2% 
2007 19,973 2,463 12.3% 
2008 29,438 4,521 15.4% 
2009 26,546 4,873 18.4% 
    
Total 33,428 6,068 18.2% 
 
 
 
 
Appendix Table 5.2   Use of Biological Agents from 2005 to 2009 
 Number of infusions or injections 
Year All biologics Infliximab Adalimumab Natalizumab 
Certolizumab 
pegol 
2005   1,910   1,881 (98.5%)        29 (   1.5%)     n/a     n/a 
2006   7,206   7,033 (97.6%)      173 (   2.4%)     n/a     n/a 
2007   9,675   8,206 (84.8%)   1,469 (15.2%)     n/a     n/a 
2008 20,946 13,329 (63.6%)   7,322 (35.0%) 120 (0.6%)    175 (0.8%) 
2009 23,775 12,692 (53.4%)   9,804 (41.2%) 124 (0.5%) 1,155 (4.9%) 
      
Total 63,512 43,141 (67.9%) 18,797 (29.6%) 244 (0.4%) 1,330 (2.1%) 
n/a= not available. Both Natalizumab and Certolizumab pegol were approved by the FDA in 2008. 
 
 
 
 
Appendix Table 5.3   Use of Biological Agents for Early and Late Biological Users 
Biological Agent Early Biological Users (N=3,082) 
Late Biological Users 
(N=2,986) 
Total 
(N=6,068) 
Infliximab 2,669 (86.6%) 1,763 (59.0%) 4,432 (73.0%) 
Adalimumab   638 (20.6%) 1,348 (45.1%) 1,982 (32.7%) 
Natalizumab   15 (0.5%)     12 (0.4%)    27 (0.4%) 
Certolizumab pegol  76 (2.5%)   210 (7.0%)  286 (4.7%) 
 
   
Two biological agents 289 (9.4%) 311 (10.4%) 600 (9.9%) 
Three biological agents   10 (0.3%)  18 (0.6%) 
  28 (0.5%) 
Four biological agents   1 (<0.1%) 
   0 (0.0%)    1 (<0.1%) 
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Appendix Table 5.4   Odds Ratios Estimated  by Logistic Regression Models  
 
Binary Variables 
Independent Variables 1= Biological Users  0=Non-biological Users 
1=Early Biological Users  
0=Late Biological Users 
Age at diagnosis (numeric) 0.97 (0.97, 0.98)§ 1.01 (1.00, 1.01)† 
Female vs. male 0.94 (0.89, 1.00)* 1.00 (0.89, 1.11) 
Diagnosis by GI specialist vs. non-specialist 1.13 (1.06, 1.21)§ 0.97 (0.85, 1.09) 
Geographic region 
  
 Northeast vs. South 0.88 (0.80, 0.96)† 1.12 (0.94, 1.34) 
 North Central vs. South 0.90 (0.84, 0.97)† 1.03 (0.90, 1.17) 
 West or unknown vs. South 0.88 (0.80, 0.97)† 1.00 (0.83, 1.22) 
MSA vs. non-MSA 1.10 (1.01, 1.20)* 1.24 (1.06, 1.46)† 
Health plan vs. Large employers 1.33 (1.20, 1.47)§ 2.10 (1.69, 2.60)§ 
PPO vs. other benefit plans 1.01 (0.94, 1.08) 1.21 (1.06, 1.38)† 
Fulltime employee vs. others 0.86 (0.78, 0.96)† 0.73 (0.59, 0.91)† 
Employee vs. spouse/dependent 0.96 (0.91, 1.03) 0.90 (0.80, 1.01) 
CCI (numeric) 0.71 (0.64, 0.79)§ 1.04 (0.84, 1.29) 
Rx prior to diagnosis (numeric) 0.91 (0.90, 0.92)§ 0.83 (0.80, 0.85)§ 
Year of diagnosis 
  
 2006 vs 2005 1.34 (1.23, 1.47)§ 2.05 (1.70, 2.47)§ 
 2007 vs 2005 1.04 (0.93, 1.15) 1.31 (1.06, 1.61)* 
 2008 vs 2005 1.33 (1.21, 1.44)§ 1.72 (1.45, 2.06)§ 
 2009 vs 2005 0.78 (0.59, 1.03) 1.25 (0.70, 2.24) 
MSA: metropolican statistical area, GI: gastroenterologist, PPO: preferred provider organization, CCI: Charlson 
comorbidity index 
§: p<0.001, †: p<0.01, *: p<0.05  
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Appendix Table 5.5   Odds Ratios Estimated by Logistical Regression Models on Healthcare 
Utilization 
 
Binary Outcome Variables 
Independent Variables Any use of inpatient services 
Any use of  
emergency room services 
Early vs. Late use 0.57 (0.51, 0.64)§ 0.77 (0.69, 0.86)§ 
Age at diagnosis (numeric) 1.00 (1.00, 1.01) 1.00 (0.99, 1.00) 
Female vs. male 1.28 (1.15, 1.43)§ 1.26 (1.13, 1.40)§ 
Diagnosis by GI specialist vs. non-specialist 0.74 (0.66, 0.83) § 0.81 (0.72, 0.90)§ 
Geographic region 
  
 Northeast vs. South 0.82 (0.69, 0.98) * 1.31 (1.10, 1.56)† 
 North Central vs. South 0.98 (0.86, 1.10) 0.97 (0.86, 1.10) 
 West or unknown vs. South 0.81 (0.67, 0.97)* 1.00 (0.83, 1.20) 
MSA vs. non-MSA 1.01 (0.87, 1.18) 0.98 (0.84, 1.14) 
Health plan vs. Large employers 1.05 (0.85, 1.29) 0.97 (0.79, 1.18) 
PPO vs. other benefit plans 0.95 (0.83, 1.07) 1.00 (0.88, 1.13) 
Fulltime employee vs. others 1.02 (0.83, 1.25) 0.92 (0.75, 1.11) 
Employee vs. spouse/dependent 0.94 (0.84, 1.05) 0.97 (0.87, 1.09) 
CCI (numeric) 1.49 (1.21, 1.83) § 1.46 (1.10, 1.94)† 
Rx prior to diagnosis (numeric) 1.03 (0.02, 1.04) § 1.04 (1.02, 1.05)§ 
Year of diagnosis 
  
 2006 vs 2005 0.93 (0.78, 1.11) 0.98 (0.82, 1.17) 
 2007 vs 2005 0.77 (0.63, 0.93)† 0.88 (0.73, 1.07) 
 2008 vs 2005 0.59 (0.50, 0.69)§ 0.70 (0.59, 0.82)§ 
 2009 vs 2005 0.46 (0.27, 0.81)† 0.64 (0.38, 1.08) 
MSA: metropolican statistical area, GI: gastroenterologist, PPO: preferred provider organization, CCI: Charlson 
comorbidity index 
§: p<0.001, †: p<0.01, *: p<0.05 
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Appendix Table 5.6   Effects Estimated  by GEE Regression Models on Costs for Biological Users 
 
Outcome Variables 
Independent Variables Net payment of all 
services, $ 
Net payment of 
inpatient services, $ 
Net payment of 
outpatient services, 
$ 
Net payment of ER 
services, $ 
Net payment of 
prescription 
services, $ 
Early vs. Late use 0.077 (0.030, 0.125)* -0.322(-0.489,-0.156)§ -0.036(-0.105, 0.034) -0.159(-0.323,0.005)  0.264(0.221, 0.307)§ 
Age at diagnosis (numeric)  0.005(0.003, 0.007)§   0.003(-0.003, 0.010)   0.01 (0.01, 0.01)§ -0.01 (-0.02, -0.00)§ 0.004 (0.002, 0.006)§ 
Female vs. male -0.04 (-0.09, 0.01)    0.01(-0.14, 0.17)   0.10 (0.03,0.16)†   0.20 (0.05, 0.35)* -0.13 (-0.17, -0.09)§ 
Diagnosis by GI vs. non-specialist -0.16 (-0.20, -0.11)§ -0.50 (-0.67, -0.33)§ -0.30 (-0.37, -0.22)§ -0.18 (-0.35, -0.02)*   0.02 (-0.01, 0.07) 
Geographic region      
     Northeast vs. South   0.07 (-0.0, 0.15) -0.13 (-0.38, 0.12)   0.01 (-0.10, 0.12)   0.01 (-0.23, 0.25)   0.17 (0.10, 0.24)§ 
     North Central vs. South   0.01 (-0.03, 0.07) -0.12(-0.30, 0.06)   0.04 (-0.04, 0.11) -0.14 (-0.31, 0.04)   0.04 (-0.01, 0.08) 
     West or unknown vs. South   0.08 (-0.0, 0.15)   0.04 (-0.23, 0.30)   0.05 (-0.06, 0.16)   0.31 (0.05, 0.56)*   0.10 (0.03, 0.17)† 
MSA vs. non-MSA   -0.02(-0.08, 0.05)  -0.001(-0.22, 0.22)  -0.09 (-0.18, 0.00)  -0.001(-0.22, 0.22)   0.04 (-0.02, 0.10) 
Health plan vs. Large employers   0.02(-0.07, 0.10)   0.26 (-0.02, 0.55) -0.05 (-0.17, 0.08)   0.23 (-0.06, 0.50) -0.02 (-0.09, 0.06) 
PPO vs. other benefit plans -0.03 (-0.08, 0.03) -0.07(-0.25, 0.12) -0.004 (-0.08, 0.07)   0.05 (-0.14, 0.23) -0.03 (-0.07, 0.02) 
Fulltime employee vs. others   0.09 (0.01, 0.17)*    0.19 (-0.08, 0.46) -0.002 (-0.12, 0.12)   0.07 (-0.19, 0.34)   0.13 (0.05, 0.20)† 
Employee vs. spouse/dependent   0.02(-0.03, 0.06)   0.01 (-0.15, 0.17) -0.008 (-0.08, 0.06)  -0.09 (-0.25, 0.06)   0.04(-0.00, 0.08) 
CCI (numeric)   0.14 (0.06, 0.22)*   0.40 (0.10, 0.71)*   0.18 (0.08, 0.29)†   0.27 (-0.02, 0.57) 0.003 (-0.07, 0.08) 
Rx prior to diagnosis (numeric)  0.011(0.006, 0.016)§   0.02(0.00, 0.04)*   0.011(0.004, 0.019)†   0.037 (0.02, 0.06)§ 0.002(-0.002, -0.007) 
Year of diagnosis      
 2006 vs 2005   0.01 (-0.06, 0.09) -0.24 (-0.50, 0.01) -0.04 (-0.14, 0.08)   0.01 (-0.23, 0.25)   0.15 (0.08, 0.21)§ 
 2007 vs 2005   0.07 (-0.01, 0.15) -0.07 (-0.35, 0.21) -0.06 (-0.18, 0.06)   0.25 (-0.02, 0.53)   0.17 (0.10, 0.25)§ 
 2008 vs 2005   0.21 (0.14, 0.28)§ 0.04 (-0.20, 0.28)  0.14 (0.04, 0.24)†    0.35 (0.11, 0.58)†   0.30 (0.24, 0.37)§ 
 2009 vs 2005   0.09 (-0.14, 0.31) -0.25(-1.02, 0.53)  0.03 (-0.29, 0.36)   0.35 (-0.41, 1.10)   0.21 (0.01, 0.41)* 
Intercept   9.97 (9.83, 10.12)§   8.68 (8.20, 9.16)§   8.74 (8.54, 8.94)§   6.52 (6.05, 6.99)§   9.07(8.93, 9.20)§ 
GEE model: variance function: 
                    link function: 
Gamma 
log 
Gamma 
log 
Gamma 
log 
Gamma 
log 
Gamma 
log 
All costs are adjusted to 2010 US dollar ($) with annual CPI inflation rate of medical care. 
MSA: metropolican statistical area, GI: gastroenterologist, PPO: preferred provider organization, CCI: Charlson comorbidity index 
§: p<0.001, †: p<0.01, *: p<0.05  
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Appendix Table 5.7    Effects Estimated by GEE Regress Model on Healthcare Utilization of Biological Users 
 
Estimation (95% confidence interval) of Outcome Variables 
Independent Variables # of inpatient visits # of days of inpatient stay # of ER visits 
# of outpatient 
visits # of prescriptions 
Early vs. Late use -0.34 (-0.43, -0.25)§ -0.28 (-0.32, -0.24)§ -0.17 (-0.28, -0.05)† -0.003 (-0.04, 0.03) -0.50(-0.54, -0.45)§ 
Age at diagnosis (numeric) 0.001 (-0.002, 0.004) 0.005 (0.003, 0.006)§ -0.008(-0.012, -0.003)† 0.01(0.01,0.01)§ 0.014(0.012,0.016)§ 
Female vs. male 0.10 (0.02, 0.18)† 0.07 (0.04, 0.11)§   0.14 (0.03, 0.25)* 0.24 (0.20, 0.27)§   0.21(0.16, 0.25) § 
Diagnosis by GI vs. non-specialist -0.35 (-0.44, -0.25)§ -0.44 (-0.48, -0.39)§ -0.19 (-0.30, -0.07)† -0.07(-0.11,-0.03)§  -0.003 (-0.05, 0.05) 
Geographic region      
 Northeast vs. South -0.11 (-0.25, 0.03) -0.21 (-0.27, -0.16)§   0.15(0.03, 0.32) 0.12 (0.06, 0.18)§ -0.15 (-0.21, -0.08)§ 
 North Central vs. South -0.06(-0.15, 0.03) -0.18 (-0.22, -0.13)§ -0.22 (-0.34,-0.10)§ 0.04(0.001, 0.8)* -0.06(-0.11, -0.01)* 
 West or unknown vs. South -0.22 (-0.37, -0.08)† -0.35 (-0.41, -0.28)§ -0.04 (-0.22, 0.14) 0.05 (-0.01, 0.11) -0.04 (-0.12, 0.03) 
MSA vs. non-MSA -0.11 (-0.22, 0.01) -0.05(-0.10, 0.003) -0.08 (-0.24, 0.07) 0.04 (-0.01, 0.09) -0.01(-0.08, 0.05) 
Health plan vs. Large employers  0.09 (-0.07, 0.25)   0.06 (-0.01, 0.13)   0.17 (-0.04, 0.37) 0.08(0.01, 0.14)* -0.23 (-0.31, -0.15)§ 
PPO vs. other benefit plans -0.003 (-0.10, 0.09)  0.0003(-0.04, 0.04)   0.07 (-0.06, 0.20) 0.03(-0.01, 0.07)  -0.06(-0.11,-0.004)* 
Fulltime employee vs. others  0.08 (-0.07, 0.24)   0.02 (-0.05, 0.09) -0.06 (-0.26, 0.13) 0.02 (-0.05, 0.08)   0.07 (-0.01, 0.14) 
Employee vs. spouse/dependent -0.09 (-0.17, 0.001) -0.05 (-0.08,-0.01)* -0.11 (-0.22,-0.01)* -0.02 (-0.06, 0.01) -0.03 (-0.07, 0.02) 
CCI (numeric)  0.25 (0.17, 0.33)§   0.24 (0.20, 0.28)§   0.24 (0.04, 0.44)* 0.19 (0.12, 0.25)§   0.07 (-0.005, 0.14) 
Rx prior to diagnosis (numeric)  0.02 (0.02, 0.03)§   0.02 (0.02, 0.03)§   0.03 (0.02, 0.04)§ 0.02 (0.01, 0.02)§   0.04 (0.03, 0.04)§ 
Year of diagnosis      
 2006 vs 2005  0.02 (-0.11, 0.16) -0.12 (-0.19,-0.06)§   0.10 (-0.07, 0.28) 0.14 (0.08, 0.20)§ -0.05 (-0.12, 0.03) 
 2007 vs 2005  0.14 (-0.005, 0.29)   0.05 (-0.02, 0.12)   0.22(0.03, 0.42)* 0.12 (0.06, 0.19)§   0.23 (0.15, 0.31)§ 
 2008 vs 2005  0.19 (0.06, 0.31)†   0.15 (0.10, 0.21)§   0.36 (0.20, 0.53)§ 0.17 (0.11, 0.22)§   0.21 (0.15, 0.28)§ 
 2009 vs 2005  0.25 (-0.12, 0.63) -0.07 (-0.26, 0.12)   0.30 (-0.33, 0.35) 0.15(-0.03,0.33)   0.17 (-0.05, 0.39) 
Intercept -0.83 (-1.10, -0.56)§  0.73 (0.61, 0.85)§ 0.01 (-0.33, -0.35) 2.19 (2.08, 2.31)§   2.72 (2.58, 2.86)§ 
GEE model: variance function: 
                     link function: 
Poisson 
log 
Poisson 
log 
Gamma 
log 
Gamma 
log 
Gamma 
Log 
MSA: metropolican statistical area, GI: gastroenterologist, PPO: preferred provider organization, CCI: Charlson comorbidity index 
§: p<0.001, †: p<0.01, *: p<0.05  
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Appendix Figure 5.1   Comparison of Healthcare Utilization between Early and Late Biological 
Users 
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CHAPTER VI:   
 
BUDGET IMPACT OF TREATMENT STRATEGY CHANGE ON 
PATIENTS WITH CROHN'S DISEASE FROM PAYERS' 
PERSPECTIVE 
 
Background: The treatment strategy for Crohn’s Disease (CD) has recently undergone a 
significant shift toward a 'top-down' strategy by adopting biological therapies early to 
aggressively manage this disease.  This shift in treatment strategy may challenge pharmacy 
benefits management organizations (PBMOs) managing prescription drug costs for these 
expensive treatments. 
Objectives: This study seeks to predict the budgetary impact of the change in prescription 
drug costs resulting from the top-down treatment approach to PBMOs. 
Methods:  A decision tree model was constructed to compare prescription drug costs of top-
down versus bottom-up strategy for biological therapies in the first, second, and third year 
following CD diagnosis. Top-down therapy was defined as a treatment approach where 
biological therapy was included in the first-line treatment for CD patients. Bottom-up therapy 
referred to use of novel biological therapies after conventional non-biological drugs were 
attempted. Transition probabilities and  prescription drug costs  were modeled by disease 
severity using claims data of biological users in the MarketScan Commercial Claims and 
Encounter database from 2005 to 2009. 
Results:  In the first year of CD diagnosis, top-down therapy resulted in an increase of $9,235 
in prescription drug costs, compared with the bottom-up approach. The difference in 
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prescription drug costs was reduced to $2,064 in the second year and $1,576 in the third year. 
Meanwhile, in the second and third years, a higher percentage of patients following the 
bottom-up approach experienced more severe disease. 
Conclusion: The top-down treatment strategy for CD management resulted in a higher 
prescription drug costs during the first year of treatment. These results diminished over the 
second and third years as bottom-up users began using biological therapies. Further study is 
needed to demonstrate whether or not the top-down treatment approach is cost-saving when 
total healthcare costs are accounted for.   
 
6.1 Introduction 
 
 The treatment strategy for Crohn's disease (CD) is currently changing in clinical 
practice.[83] A new treatment approach that promotes early use of biological therapies in the 
CD treatment algorithm has been suggested to have greater therapeutic benefits than 
conventional treatments for CD management.[12, 13] Previously, CD patients were treated 
with aminosalicylates, antibiotics, corticosteroids, and immunomodulators before being 
initiated on biological therapies.[11] However, response rates from these conventional drugs 
were low, and most CD patients underwent surgeries or became steroid dependent.[29] 
Biological drugs have many therapeutic benefits when compared to conventional medications 
in the treatment of CD, including a higher response rate, more rapid onset of clinical 
response, greater effectiveness in maintaining long-term remission, and significant 
improvement in health related quality of life.[7, 8, 29, 84, 85] Due to their high costs, 
biological therapies are typically reserved as the last medical resort for patients who are 
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refractory or intolerant to conventional drugs.  This treatment strategy, referred to as 'bottom-
up' approach, advocates that patients start with less expensive drugs, and gradually move to 
more advanced therapies. Recently, clinical studies have shown that biological therapies have 
a more rapid remission and higher remission rate if they are introduced into the treatment 
algorithm early in the disease course. Thus, a new treatment strategy, referred to as 'top-
down' approach, suggests that patients start with biological therapy as first-line treatment, 
either in combination with immunomodulators or as mono-therapy. The top-down approach 
has become the preferred treatment approach for CD disease management and, as a result, the 
use of biological therapies is expected to increase. This raises concerns about a surge in drug 
expenditures for both patients and payers in treating CD.  
 One group that is particularly interested in the changing treatment strategy for CD is 
pharmacy benefit management organizations (PBMOs). In the U.S. healthcare system, 
PBMOs play a pivotal role in negotiating price with manufacturers, purchasing discounted 
drugs, and distributing and administering drugs to patients. Today more than 95% of  
consumers receive pharmaceutical drug benefits though a PBMO.[86]  PBMOs can be 
separate organizations, or affiliated with managed care organizations (MCOs), which are 
major payers in the private insurance sector. As healthcare becomes more complex and costly, 
PBMOs have expanded their functions from drug vendors to collaborative partners with 
MCOs in the effort to improve quality of care and safety and to control expenses for 
prescription drugs.[87] In the past decade, the rapid expansion of biological drugs in the 
pharmaceutical market poses extraordinary challenges for PBMOs mainly because of high 
costs associated with biological drugs. Additionally, biological drug therapies raise complex 
issues in drug distribution, administration and access, so that specialty pharmacy programs 
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are developed within PBMOs to provide extended services for payers, who are mostly MCOs 
in the private insurance sector. More importantly, MCOs are facing challenges to manage 
rising drug costs as biological drugs cost anywhere from $10,000 to $200,000 per member 
per year.[67]  
 CD is a chronic disease that incurs substantial medical costs to patients. In our 
previous study, we found that the annual costs for prescription drugs averaged $16,848 for 
each patient who used any biological therapies (see Chapter 5). The treatment strategy 
change for CD patients is anticipated to escalate the costs for PBMOs because biological 
therapies are introduced earlier in the course of the disease.[88] The budgetary impact of the 
change in prescription drug costs resulting from aggressive top-down therapy in CD 
treatment strategy to PBMOs is unknown.   
 In this study, a decision tree was modeled to compare prescription drug costs between 
patients who use top-down and bottom-up approaches.  The budget impact was represented 
by the difference in drug costs for CD patients who initiated biological therapy following 
either the top-down or bottom-up approach three years after their initial diagnosis of Crohn's 
disease. Predictions from the decision model were based on empirical, real-world data 
estimates from a prior cohort study using MarketScan Commercial Claims and Encounter 
database from 2005 to 2009. Finally, sensitivity analysis was conducted to test the robustness 
of the predicted budget impact on pharmacy benefit programs. Results from this study 
provide important information for pharmacy benefit managers to consider when making 
formulary decisions. 
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6.2 Methods 
Decision Modeling 
 A decision tree was developed to compare prescription drug costs for CD patients 
who used biological therapies following the top-down and bottom-up treatment approaches 
(see Figure 6.1).  The perspective of this analysis was a broader view of PBMOs, so 
prescription drug costs included both: a) drug payments that were made by PBMOs, on 
behalf of payers, to pharmacies; and b) drug payments that were directly paid by payers 
under medical benefit because biological therapies can be administered other places (e.g. 
infusion center). Given our perspective on payers, out-of-pocket (OOP) costs to patients and 
coordination of benefit (COB) payments from other payers were excluded.  
 Disease severity is a key factor that prompts medical and surgical treatment decisions 
in CD management, and further determines the amount of healthcare services for CD patients. 
Changes in disease severity also reflect the outcomes of the medical treatments that patients 
received previously.  A time frame of three years following CD diagnosis was included in the 
model. Disease severity was evaluated on an annual basis. In each year, disease severity was 
assessed according to patients' healthcare utilization records, and classified into one of four 
categories: a) remission; b) mild to moderate; c) moderate to severe; or d) severe or 
fulminant. Initial pathways depicted on the decision tree for each treatment strategy show 
disease severity in the first year following CD diagnosis. Disease severity for CD patients 
was either changed from the first year to the second year, or remained the same. A transition 
in disease severity from the first year to the second year is demonstrated by the pathways in 
the second layer of the decision tree. To populate the decision model, cohort analyses were 
conducted to estimate prescription drug costs (payoff value) and the transition probabilities 
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for all pathways. Under top-down scenario, the probability of severity allocation and cost 
assignment of each classification of severity were based on the estimation from patients who 
adopted biological therapies in their initial CD treatment in a large claims database from 
2005 to 2009. For patients under bottom-up scenario, their model parameters were estimated 
from patients who used biological therapies later than conventional drugs in the same 
database. Probabilistic sensitivity analysis (PSA) using Monte Carlo simulation was 
performed to quantify the impact of uncertainties in input parameters on the uncertainty in 
model output. Both base-case and sensitivity analyses were conducted in TreeAge Pro 2011 
(TreeAge Software Inc., Williamstown, MA). The study was approved by the Institutional 
Review Board (IRB) at the University of North Carolina at Chapel Hill. 
 
Data Source and Patient Cohorts 
 The MarketScan Commercial Claims and Encounter (CCAE) database (Thomson 
Reuters, Ann Arbor, Michigan) served as the primary data source for this study. CCAE data 
are comprised of pharmacy and medical claims from January 1, 2005 to December 31, 2009. 
The CCAE database captured person-specific clinical utilization, expenditures, and 
enrollment across inpatient, outpatient, prescription drug, and carve-out services from 
approximately 100 payers, including large employers and health plans.  
 In the CCAE database, a total of 33,428 CD patients met the following inclusion 
criteria: age between 18 and 64; a minimum of one year enrollment after CD diagnosis; a six-
month washout period prior to diagnosis; managed care organization enrollee; and at least 
one CD-related prescription fill. Among these eligible CD patients, 18.2% (n=6,068) 
received at least one infusion or injection of an FDA-approved biological agent, including 
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infliximab, adalimumab, natalizumab, or certolizumab pegol. There were 3,082 patients who 
included biological therapy early as first-line treatment in their disease course, and 2,986 
patients who used biological agents later after attempting other non-biological therapies. 
These early and late biological therapy users were considered using top-down and bottom-up 
treatment strategy, respectively. All cost parameters and probabilities in the decision analyses 
were estimated based on the utilization and cost information for CD patients in these two 
study cohorts: early and late biological users. 
 
Disease Severity Classification 
 Disease severity in the first year of diagnosis and the following two years was 
imputed indirectly according to each patient's healthcare utilization. Disease severity was 
approximated given a lack of relevant clinical information in the claims database. In clinical 
practice, CD is often classified according to the Crohn's Disease Activity Index (CDAI), an 
instrument used to quantify disease symptoms (e.g., the number of liquid or soft stools each 
day for seven days)  through weighted numeric scores. This classification algorithm is 
commonly referred to in disease management guidelines, but not readily available in claims 
databases. The MarketScan CCAE database contains a broad spectrum of person-specific 
clinical utilization and financial information, but includes limited medical information, such 
as diagnosis. In pursuit of a practical approach, Malone et al. developed an algorithm that 
used pharmaceutical and medical claims to classify CD patients into four severity categories. 
The pharmacy and medical information that was used to classify disease severity were based 
on the American College of Gastroenterology (ACG) criteria (See Appendix Table 6.1).    
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 In this study, disease severity was evaluated annually according to Malone et al.'s 
algorithm by reviewing all pharmacy and medical claims incurred in a given year (see 
Appendix Table 6.1). Claims were examined for criteria in each severity category from the 
highest (severe/fulminant) to lowest (remission) severity. For patients with multiple claims, 
disease severity was determined by those ones in the definition of the highest severity. When 
no claims matched the criteria for a higher severity category, the next lower category was 
considered. Patients who had no claims filed in a given year were assumed to have achieved 
disease remission. 
 
Probabilities  
 Probabilities for disease severity in the first year of CD were based on proportions of 
biological users in different severity categories classified according to their claims data in the 
first year following diagnosis. From 2005 to 2009, 23.7% of biological users (N=6,068), 
including both early (N=3,082) and late biological users (N=2,986), had severe/fulminant 
disease in the first year following diagnosis, 41.0% were classified with moderate-severe 
disease, 11.7% had mild-moderate disease, and 23.6% were in disease remission (see Table 
6.1). 
Transition probabilities for disease severity from the first year of CD to the second 
year were estimated by transition patterns of biological users who had at least two years of 
follow-up data. For example, among late biological users, 1,961 CD patients had two or more 
years of claims data, including 497 patients with severe/fulminant disease in the first year of 
CD diagnosis. Of these patients, 64 (12.9%) achieved disease remission, 61 (12.3%) patients 
had mild-moderate disease, 182 (36.6%) had moderate-severe disease, and 190 (38.2%) 
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continued to experience severe/fulminant disease in the second year.  Therefore, under 
bottom-up scenario, the transition probabilities of disease severity from the first year to the 
second year are 0.129 for patients changing from severe/fulminant to remission, 0.123 from 
severe/fulminant to mild-moderate, 0.366 from severe/fulminant to moderate-severe  and 
0.382 for patients remaining to have severe/fulminant disease (see Table 6.1). Similarly, 
transition probabilities for disease severity from the second year of CD to the third year were 
estimated by transition patterns of biological users with complete data in the second and third 
year. In the calculation of transition probabilities, patients were required to have valid 
enrollment in both start and end years. 
 
Prescription Drug Costs  
Prescription drug costs for patients in each year following their diagnosis of CD were 
calculated by accumulating all payments made by payers directly through medical benefit 
reimbursement, or indirectly via PBMOs under pharmacy benefit. For conventional non-
biological drugs, payers usually use a 'carve-out' model and contract with one or more 
PBMOs to manage their prescription benefit. Under the carve-out model, PBMOs make 
payments to pharmacies on behalf of payers. Pharmacy claims are adjudicated with NDC 
numbers, which are unique identifiers for each drug. Therefore, payments of all claims in the 
CCAE database with valid NDC numbers of all drugs, including CD- and non-CD-related 
drugs, represent the overall costs of pharmacy benefits for conventional drugs. Biological 
therapies, however, can be reimbursed under either the pharmacy benefit or medical benefit 
depending on the site and method of administration. All biological therapies for CD are 
office-administered injectables used intravenously (infliximab and natalizumab), or 
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subcutaneously (adalimumab and certolizumab pegol). If a biological therapy was 
administered at outpatient or inpatient visits, the claim is usually submitted with a healthcare 
common procedure coding system (HCPCS) 'J' code and reimbursed under medical benefits. 
Some specialty pharmacy management companies may be contracted to reimburse those 
claims through pharmacy benefits. But they were more often charged directly by providers 
using the 'buy and bill' model.[67]. 
The annual prescription cost is the average amount that payers reimbursed patients for 
prescription drugs used in each 12-month period after the CD diagnosis.  For patients who 
were partially enrolled in MCOs during the second and third years of CD, their annual drug 
costs were annualized according to the length of enrollment. The annualized rate was 
calculated according to the proportion of prescription drug costs in each month over a one-
year period for patients with a full-year of claims data. The annualized rate was not a fixed 
rate at 1/12, but instead, varied from month to month according to the incremental pattern of 
prescription drug costs for patients with complete one-year data. For example, if a patient 
only had 3 months of data available in the second year of disease, prescription drug cost of 
the second year for this patient was extrapolated by dividing the rate of drug cost in the first 
three months out of the entire second year for patients with two years of continuous 
enrollment. Prescription drug costs occurring in each calendar year were adjusted to the value 
of the U.S. dollar in 2010, and then calculated annually according to patients' treatment 
strategy and disease severity classification (see Table 6.2). 
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Base Case Analysis 
The base case in the decision model refers to a new Crohn's disease patient who uses 
biological therapies following conventional 'bottom-up' strategy. The alternative case is the 
patient who instead uses biological therapies following new 'top-down' approach. Regardless 
of case scenario, the patient was assumed to have the same severity of disease as an average 
biological user during  the first year of disease from 2005 to 2009. The prescription drug cost 
was estimated accordingly by disease severity and treatment strategy adapted during the 
disease course. In the second and third year of disease, patients were allocated transition 
probabilities for different disease severities. Base case analysis compared the prescription 
drug costs of the base case patient with the alternative case patient in the first three years of 
disease. The difference in costs of prescription drugs demonstrates the economic effect of 
new top-down treatment strategy. 
 
Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA) using Monte Carlo simulation was performed 
to estimate the impact from uncertainty regarding input parameters in the decision model. 
The input parameters, both transition probabilities and prescription drug costs, were each 
specified with different distributions. Given the complexity of multiple categories for disease 
severity, the Dirichlet distribution was used to represent the pattern of multinomial parameter 
probabilities. Although a series of conditional beta distributions could describe multinomial 
data, the Dirichlet distribution has been successfully implemented to ease in fitting 
multinomial probabilities in decision modeling. [71] For prescription drug costs, a gamma 
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distribution was used to describe its distribution given that costs are constrained on the 
interval 0 to positive infinity (see Appendix Table 6.2).  
 The probabilities for all classifications of  disease severity are quite different between 
early and late biological users in their first year of disease. Compared to early biological 
adopters, late biological users are more likely to have moderate and severe disease. In the 
base case analysis, the probabilities for disease severity were based on the classification of all 
biological users pooled together. Considering both early and late biological users in the 
previous year as two extreme cases, scenario analyses were conducted to test whether or not 
study results are heavily determined by disease severity of the initial cohort. In Case Scenario 
1, the probabilities for disease severity categories in the first year were based on the 
proportion of patients with different severities among late biological users in previous years. 
Probabilities for patients to have disease remission, mild-moderate disease, moderate-severe 
disease, and severe/fulminant disease in the first year after CD diagnosis were 0.046, 0.163, 
0.516, and 0.275 respectively. In Case Scenario 2, the probabilities in the first year were 
based on patient distribution by severity among early biological users. Those probabilities for 
different disease severity categories, i.e., remission, mild, moderate-severe, and 
severe/fulminant, were 0.421, 0.072, 0.307 and 0.200, respectively.  
 
6.3 Results 
Base Case Analysis 
 In the first year following CD diagnosis,  prescription drug costs were estimated at 
$18,166 if patients used the top-down treatment approach, and $8,945 if they used the 
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bottom-up approach. The new top-down treatment approach is associated with higher 
prescription drug costs, and was 103.8% higher than the costs for bottom-up patients with 
CD in the first year.   
 Prescription drug costs for CD patients in the second and third years are predicted at 
$17,109 and $15,752, respectively, if a patient used the top-down treatment strategy. These 
predicted values are 13.8% and 10.4% higher in the second and third year, respectively, than 
the costs for patients using the bottom-up treatment approach. The difference in prescription 
drug costs between the two treatment approaches is projected to lessen significantly in the 
second year of disease (see Table 6.3). 
Sensitivity Analysis 
 Results of the probabilistic sensitivity analysis confirmed the findings that inform the 
base case analysis. The prescription drug costs for patients following top-down treatment 
approach were $9,235 higher than the costs for bottom-up therapy users in their first year of 
disease. The difference in prescription drug costs between the top-down and bottom-up 
biological users rapidly reduced to $2,064 and $1,476 in the second and third years, 
respectively (see Table 6.3). 
 Scenario analyses compared the results from two extreme cases, where disease 
severity in the first year was based on the data of either late biological users (Case Scenario 1) 
or early biological users (Case Scenario 2) in previous years. The difference in prescription 
drug costs between two treatment strategies was $7,720 in the first year of CD for Case 
Scenario 1, and $10,768 for Case Scenario 2. In the second and third year of CD, the 
differences in prescription drug costs decreased to $2,197 and $1,606 respectively for Case 
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Scenario 1, which were comparable to the results of Case Scenario 2 ($1,974 in the second 
year and $1,470 in the third year) and the results of base case ($2,064 and $1,476) (see 
Appendix Table 6.4). 
 
6.4 Discussion  
Our results suggest that new top-down treatment strategy with biological therapy is 
associated with substantially higher prescription drug costs than the conservative bottom-up 
treatment approach in the first year of CD. The dramatic difference in prescription drug costs 
can be attributed to the time preference for initiating biological therapies between the two 
treatment approaches. Patients that adopted biologics early by following top-down approach 
initiated biological therapy on average 89 days after CD diagnosis. However, patients 
following the bottom-up approach initiated their first biological therapy 365 days after CD 
diagnosis on average (data not shown).  
  The perspective of this analysis is PBMOs, who manage the pharmacy benefits for 
health plans, and reimburse drug costs to pharmacies on behalf of payers. Traditionally, 
PBMOs are only responsible for costs of the prescriptions that are delivered at the pharmacy.  
The rapid increase in the use of specialty drugs, (e.g., biological therapies), has changed the 
practice of PBMOs because specialty drugs are administered differently (e.g., intravenous 
infusion and subcutaneous injection) and at different sites (e.g., physician's office, infusion 
center, outpatient hospital department, and home). PBMOs have developed or acquired 
specialty pharmacy programs to cope with this change in the market place. Most payers 
include self-administered injectables (e.g., adalimumab and certolizumab pegol) in the 
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pharmacy benefit, and office-administered injectables (e.g., infliximab and natalizumab) in 
the medical benefit.[89] However, a small portion of biological drugs for CD did not follow 
the convention above due to a lack of a uniform coding system for drugs across pharmacy 
and medical benefits (see Appendix Table 6.3). Therefore, this study took a broader view of 
PBMOs, and included drug costs that were covered under both the pharmacy and medical 
benefit.  
 Our results showed that the difference in prescription drug costs between the two 
treatment approaches significantly reduced from $9,235 in the first year to $2,064 in the 
second year, and further fell to $1,476 in the third year of disease. This change was primarily 
caused by the rapid increase in prescription drug costs incurred by the bottom-up biological 
users, who began using biological therapies in the second and third years. It is worth noting 
that the prescription drug costs of top-down biological users decreased each year. Additional 
analyses were conducted to determine how much biological and non-biological therapies 
have contributed to the reduction in overall prescription drug costs. As shown in the 
summary of prescription drug costs for non-biological therapies in Appendix Table 6.4, it 
was found that top-down biological users incurred lower costs for non-biological drugs than 
bottom-up biological users in each of three years of CD. This could be explained by the 
cohort difference that late biological users had more comorbid conditions than early adopters. 
While conventional drug costs for top-down biological users remained unchanged in the first 
three years of disease, the conventional drug costs increased steadily for bottom-up 
biological users. The increased use of conventional drugs among bottom-up biological users 
may prevent prescription costs from decreasing as rapidly as top-down biological users. This 
could result in a reduction in the drug cost difference between these two treatment strategies 
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from the first year to third year and could result in the top-down treatment approach being 
cost saving to prescription drug budgets in the long term. 
 In this study, disease severity was used as an instrument to assess the outcome of 
medical treatments for CD, including biological therapies. Comparing allocation of CD 
patients by disease severity, we found that patients were more likely to have disease 
remission and less likely to have moderate to severe disease after the first year of CD if they 
followed the top-down treatment approach. From the transition probability matrix, the 
probability of having moderate-severe disease at the end of the first year was 0.41 for all 
biological users. At the end of the second and third years, the probability of moderate or 
severe disease decreased to 0.34 and 0.37 respectively for patients using top-down treatment 
approach. On the contrary, this probability increased to 0.49 and 0.50 for bottom-up users 
(see Figure 6.2). At the mean time, the probabilities of disease remission changed in a 
reversed pattern, while the probabilities of mild and severe/fulminant disease remained 
nearly unchanged between patients who used top-down and bottom-up treatment strategy.  
Subsequently, the current study demonstrates that patients who followed the top-down 
treatment approach had higher prescription drug costs in the first year than those using the 
bottom-up approach. These results suggest that, for patients using top-down approach, higher 
prescription drug costs were exchanged for positive clinical outcomes. In theory, positive 
clinical outcomes can improve patients' quality of life, and reduce health care utilization and 
overall healthcare costs in the long term. Further study is needed to demonstrate whether or 
not cost savings can be achieved with lower total healthcare costs for the top-down treatment 
approach. 
While constructing the budget impact model, we made several assumptions: 
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First, we assumed that patients' characteristics, including age, gender, region, 
employment status, and insurance type, had no effect on patients' preference for treatment 
strategy. In a previous study conducted on this same population (see Chapter 5), we found 
that there was considerable difference in some patient characteristics, such as employment 
status, between the early and late biological users, but none of these variables were consistent 
predictors for healthcare utilization. These factors were not accounted for in our modeling 
because there was no adequate information in the claims database regarding detailed 
employment status (e.g., salary, and benefit plan). 
Second, we assumed that health status and comorbid conditions had no effect on 
patients' choice of treatment strategy. According to CD management guidelines, biological 
therapies are recommended for patients with severe or refractory disease. However, we found 
more than half of biological therapy users included a biological therapy in their first-line 
treatment. This suggests that factors other than disease status and overall health condition 
may be responsible for treatment decisions. We noticed that disease severity was quite 
different between early and late biological users in the first year. For example, the probability 
of moderate-severe disease for late biological users is higher than early biological users 
(0.516 vs. 0.307). This difference may be caused by more prevalent use of immuno-
modulators (e.g., azathioprine) among late users because the use of those drugs is an 
indicator of moderate-severe disease in the disease severity definition by Malone et al. To 
test the robustness of results in disease severity at baseline, we conducted case scenario 
analyses, and found that baseline disease severity has little effect on the difference in 
prescription drug costs in the second and third years between the early and late adoption 
treatment approaches (see Appendix Table 6.5). 
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Third, we assumed that disease severity does not frequently change for CD patients, 
and can be approximated by their healthcare utilization records. We used an empirical 
method developed by Malone et al. to classify patients into four different severity categories 
by using patients' medical and pharmacy claims. This method has not been verified in an 
actual patient population. It is unknown how accurate the definition of disease severity is 
when compared with standard way in clinical practice. There is likely a potential 
misclassification, particularly for patients with milder disease symptom. [68] However, the 
criteria used in the Malone algorithm for disease severity classification reflect current 
treatment practice in the US. Therefore, it is more relevant to actual CD management than 
previously published models, which were often based on patients in other healthcare 
systems.[52, 54]  Our results showing patient allocation in each disease severity category is 
consistent Malone et al.'s results. Due to the lack of direct medical information to more 
precisely evaluate patients' disease progression, the algorithm proposed by Malone et al. was 
used as a reasonable proxy for severity classification in this study. 
6.5 Summary  
For newly diagnosed CD patients, top-down treatment approach resulted in an 
increase of $9,235 in prescription drug costs during patients' first year of CD, potentially 
having a substantial impact on pharmacy budgets to PBMOs. The incremental costs of 
prescription drugs was reduced to $2,064 in the second year and $1,476 in the third year. It is 
believed that higher prescription drug costs for patients who use the top-down treatment 
strategy could result in better clinical outcomes in the long term. Further study is needed to 
demonstrate whether or not the top-down biological strategy is cost-saving when total 
healthcare costs are accounted for.  
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Figure 6.1   Decision Tree (2-year model) 
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Figure 6.2   Comparison of Probabilities of Disease Severity in Three Years 
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Table 6.1   Transition Probabilities 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
 
Biological users: 
1st year after diagnosis 0.236 0.117 0.410 0.237 
     
Late biological users: 
1st year  2nd year 
     Remission 0.260 0.135 0.442 0.163 
     Mild-moderate 0.171 0.370 0.288 0.171 
     Moderate-severe 0.112 0.077 0.639 0.172 
     Severe/Fulminant 0.129 0.123 0.366 0.382 
     
2nd year 3rd year 
     Remission 0.436 0.188 0.265 0.111 
     Mild-moderate 0.147 0.410 0.282 0.161 
     Moderate-severe 0.090 0.081 0.691 0.138 
     Severe/Fulminant 0.105 0.089 0.363 0.443 
     
Early biological users: 
1st year 2nd year 
     Remission 0.690 0.054 0.151 0.105 
     Mild-moderate 0.289 0.386 0.228 0.097 
     Moderate-severe 0.250 0.074 0.549 0.127 
     Severe/Fulminant 0.297 0.054 0.210 0.439 
     
2nd year 3rd year 
     Remission 0.621 0.073 0.225 0.081 
     Mild-moderate 0.204 0.296 0.315 0.185 
     Moderate-severe 0.167 0.062 0.612 0.159 
     Severe/Fulminant 0.270 0.039 0.250 0.441 
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Table 6.2   Prescription Drug Costs by Disease Severity and Time after Diagnosis 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
     
Late biological users (bottom-up strategy): 
1st year    $579( $3,438)   $8,312($11,063) $12,244($11,630) $11,882($11,355) 
2nd year $8,359($12,452) $15,280($21,743) $17,199($15,188) $14,900($13,052) 
3rd year  $8,961($13,234) $14,682($17,759) $16,664($13,739) $12,194($11,280) 
     
Early biological users (top-down strategy): 
1st year $16,755($15,219) $21,446($14,770) $19,584($14,914) $15,498($14,124) 
2nd year $14,718($17,347) $18,241($15,415) $19,938($17,525) $16,149($16,477) 
3rd year $12,430($17,876) $15,655($15,516) $18,402($16,816) $16,927($17,598) 
Mean and standard deviation, in parentheses, were calculated after adjusting to 2010 US$. 
Costs incurred in a partial year were annualized.   
 
 
 
 
 
 
Table 6.3   Budget Impact Analysis Results 
Year Analysis Top-down Biological User 
Bottom-up 
Biological User Difference 
1st year Base-case Analysis     $18,166     $8,945 $9,221 
 
Sensitivity Analysis     $18,135     $8,900 $9,235 (CI: $9,027 - $9,443) 
     
2nd year Base-case Analysis      $17,109     $15,038 $2,071 
 
Sensitivity Analysis      $17,097     $15,033 $2,064 (CI: $1,951 - $2,178) 
     
3rd year Base-case Analysis      $15,752     $14,268 $1,484 
 
Sensitivity Analysis      $15,792     $14,316 $1,476 (CI: $1,355 - $1,597) 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
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APPDENDIX 
Appendix Table 6.1   Crohn’s Disease Severity Classification Criteria 
Disease Severity Claims for Classification* Coding details (CPT, ICD-9, and HCPCS) 
Severe/Fulminant Hospitalization admission CD diagnosis; Primary diagnosis: 555.x 
 
Diagnosis: obstruction, acute suppuration, 
perforation, refractory disease;  
Obstruction: 537.3, 560, 560.8, 560.81, 560.89, 560.9, 574.11, 997.4 
Acute suppuration: 461.x, 473.x 
Perforation: 530.4, 531.1, 532.1, 533.1, 534.1 
 
Procedures: hyperalimentation; Hyperalimentation: 278.8, 783.6 
 
CD related procedures: surgical resection, 
stricturoplasty, colectormy ileostomy; 
Surgical resection: 44202, 44203, 45.51, 45.61, 45.62, 45.71, 46.02, 
46.04, 48.4, 48.41, 48.49, 48.5, 48.6, 48.62, 48.63, 48.64, 48.65 
Stricturoplasty: 44615 
Colectomy:  45.x, 44140, 44141, 44143, 44144, 44145, 44146, 
44147, 44150, 44151, 44152, 44153, 44155, 44156, 44160, 44204, 
44205, 44206, 44207, 44208, 44210, 44211, 44212 
Ileostomy: V44.2, V55.2, 44310, 44312, 44314, 44316, 45136 
Colectomy/Eleoctomy: 46.x, v44.4, v44.3 
 
Rx drugs: immunosuppressant, IV steroid Generic drug names: cyclosporine, tacrolimus 
Cyclosporine: J7502, J7503, K0121, K0122, C9438, K0418, 80158, 
J7515, J7516 
Tacrolimus: 80197, J7507, J7508, J7525, C9006 
IV steroid: J7506 
   
Moderate-severe Diagnosis: fistulas, abdominal mass, 
haemorrhage; 
Fistula: 565.1, 569.69, 569.81, 575.5, 576.4, 685.x  
Abdominal mass: 789.3  
Hemorrhage: 530.7, 530.82, 537.83, 562.02, 562.03, 562.12, 562.13, 
569.3, 569.85, 578, 578.9, 772.4  
 
Procedures: abscess drainage; Abscess/abscess drainage: 75989, 47010, 47011, 49.01, 54.19, 
54.91, 55.12  
  
(To be continued) 
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Disease Severity Claims for Classification* Coding details (CPT, ICD-9, and HCPCS) 
Moderate-severe Rx drugs: aTNF (>2 doses), Prednisone, 
azathioprine, mercaptopurine, methotrexate; 
Prednisone: J7506 J7510 K0125  
Methotrexate: J8610 J9250 J9260 
Mercaptopurine: S0108  
Azathioprine: J7500 J7501 K0119 K0120  
Anti-TNF: J1745,  J0135, J0718, C9249 
Generic Drug names: azathioprine, methotrexate, mercaptopurine, 
infliximab, adalimumab, natalizumab, certolizumab pegol 
 
Symptoms: high fever, significant weight loss, 
abdominal pain/tenderness, anaemia 
Abdominal pain/tenderness: 789.0, 789.6  
Fever: 780.6  
Anemia: 280.x, 281.x, 283.x, 285.x, V78.0, V78.1 
Nausea/vomitting: 536.2, 564.3, 787.0, 787.01, 787.02, 787.03 
weight loss: 783.2 
   
Mild-Moderate Rx drugs: mesalazine, sulfasalzine, 
metronidazole, ciprofloxaxin, budesonide, 
rifaximin, and aTNF (1 dose only) 
Generic Drug names: mesalazine, sulfasalzine, metronidazole, 
ciprofloxaxin, budesonide, rifaximin, infliximab, adalimumab, 
natalizumab, certolizumab pegol 
HCPCS codes: J1745, J0135, J0718, C9249, J7506, J7510, K0125, 
J8610, J9250, J9260, S0108, J7500, J7501, K0119, K0120 
   
Remission Does not meet criteria for severe/fulminant, 
Moderate-severe, and Mild-moderate 
 
   
* Source: Malone et al. 2010 
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Appendix Table 6.2   Parameters for Sensitivity Analysis 
Parameter Base-case value Distribution Specification 
Probability of a CD patient 
assessed with different 
disease severity in the 1st 
year after diagnosis 
Remission: 0.236 
Mild-mod.: 0.117 
Mod.-sev.:  0.410 
Sev./Fulm.: 0.237 
Dirichlet Dirichlet(236;117;410;237) 
Prescription drug cost of a 
late biological user with 
different disease severity in 
the 1st year  
Remission: $579 
Mild-mod.: $8,312 
Mod.-sev.:  $12,244 
Sev./Fulm.: $11,882 
Gamma(κ, θ) 
κ =0.028, θ=20,413 
κ =0.565, θ=14,723 
κ =1.108, θ=11,047 
κ =1.095, θ=10,852 
Prescription drug cost of a 
late biological user with 
different disease severity in 
the 2nd year 
Remission: $8,359 
Mild-mod.: $15,280 
Mod.-sev.:  $17,198 
Sev./Fulm.: $14,900 
Gamma(κ, θ) 
κ =0.451, θ=18,549 
κ =0.494, θ=30,938 
κ =1.282, θ=13,413 
κ =1.303, θ=11,433 
Transition probability of a 
late biological user with 
remission disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.265 
Mild-mod.: 0.139 
Mod.-sev.:  0.390 
Sev./Fulm.: 0.206 
Dirichlet Dirichlet(265;139;390;206) 
Transition probability of a 
late biological user with mild 
disease in the 1st year to 
different disease severity in 
the 2nd year 
Remission: 0.171 
Mild-mod.: 0.370 
Mod.-sev.:  0.288 
Sev./Fulm.: 0.171 
Dirichlet Dirichlet(171;370;288;171) 
Transition probability of a 
late biological user with 
moderate disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.112 
Mild-mod.: 0.077 
Mod.-sev.:  0.639 
Sev./Fulm.: 0.172 
Dirichlet Dirichlet(112;77;639;172) 
Transition probability of a 
late biological user with 
severe disease in the 1st year 
to different disease severity 
in the 2nd year 
Remission: 0.129 
Mild-mod.: 0.123 
Mod.-sev.:  0.366 
Sev./Fulm.: 0.382 
Dirichlet Dirichlet(129;123;366;382) 
Prescription drug cost of a 
early biological user with 
different disease severity in 
the 1st year 
Remission: $16,755 
Mild-mod.: $21,456 
Mod.-sev.:  $19,584 
Sev./Fulm.: $15,498 
Gamma(κ, θ) 
κ =1.212, θ=13,823 
κ =2.108, θ=10,172 
κ =1.724, θ=11,357 
κ =1.204, θ=12,871 
Prescription drug cost of a 
early biological user with 
different disease severity in 
the 2nd year 
Remission: $14,718 
Mild-mod.: $18,241 
Mod.-sev.:  $19,938 
Sev./Fulm.: $16,150 
Gamma(κ, θ) 
κ =0.720, θ=20,446 
κ =1.400, θ=13,027 
κ =1.294, θ=15,405 
κ =0.961, θ=16,811 
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Parameter Base-case value Distribution Specification 
Transition probability of a 
early biological user with 
remission disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.690 
Mild-mod.: 0.054 
Mod.-sev.:  0.151 
Sev./Fulm.: 0.105 
Dirichlet Dirichlet(690;54;151;105) 
Transition probability of a 
early biological user with 
mild disease in the 1st year 
to different disease severity 
in the 2nd year 
Remission: 0.289 
Mild-mod.: 0.386 
Mod.-sev.:  0.228 
Sev./Fulm.: 0.097 
Dirichlet Dirichlet(289;386;228;97) 
Transition probability of a 
early biological user with 
moderate disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.250 
Mild-mod.: 0.074 
Mod.-sev.:  0.549 
Sev./Fulm.: 0.127 
Dirichlet Dirichlet(250;74;549;127) 
Transition probability of a 
early biological user with 
severe disease in the 1st year 
to different disease severity s 
in the 2nd year 
Remission: 0.297 
Mild-mod.: 0.054 
Mod.-sev.:  0.210 
Sev./Fulm.: 0.439 
Dirichlet Dirichlet(297;54;210;439) 
1.Parameters for Gamma distributions are approximated by mean and standard deviation: κ =ū2/s2, θ =s2/ū 
2.Prescription drug costs in the 3rd year and transition probability from the 2nd to the 3rd year for both 
early and late biological users are similarly specified with Gamma and Dirichlet distributions. Detailed 
specifications for each parameter are not included in the table above.
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Appendix Table 6.3   Prescription Drug Costs by Biological Drug by Claim Type 
Claim Type 2005 2006 2007 2008 2009 
Biologics for intravenous use, including infliximab and natalizumab 
  Medical benefit $6,152,045 $24,247,237 $28,131,469 $44,929,533 $43,858,861 
  Pharmacy benefit $342,871 $670,609 $581,837 $1,285,359 $1,258,710 
      
Biologics for subcutaneous use, including adalimumab and certolizumab pegol 
  Medical benefit n/a $18,610 $165,289 $731,150 $553,299 
  Pharmacy benefit n/a $370,813 $3,504,359 $16,057,968 $22,656,426 
Prescription drug costs under pharmacy benefit are the total costs of the claims with the following NDC numbers: 
57894003001for infliximab; 50474070062, 50474071079, and 50474071081 for certolizumab pegol; 00074379901, 
00074379902, 00074433902, 00074433906, 00074433907, 00074937402, 54569552400, 54868482200 for 
adalimumab; 59075073015 for natalizumab. 
Prescription drug costs under medical benefit are the total costs of the claims with the following HCPCS codes: 
J1745 for infliximab; J0135 for Adalimumab; J2323 for natalizumab; J0718 and C9249 for certolizumab pegol. 
All prescription costs were adjusting to 2010 US$. 
 
 
 
 
 
 
 
 
 
Appendix Table 6.4   Comparison of Prescription Drug Costs of Non-biological Drugs 
Year Analysis Top-down Biological User 
Bottom-up 
Biological User Difference 
1st year Base-case Analysis     $1,073     $2,239 $1,166 
 
Sensitivity Analysis     $1,078     $2,252 $1,175 (CI: $1,147 - $1,202) 
     
2nd year Base-case Analysis      $1,124     $2,597 $1,473 
 
Sensitivity Analysis      $1,106     $2,571 $1,465 (CI: $1,425 - $1,505) 
     
3rd year Base-case Analysis      $1,113     $2,677 $1,564 
 
Sensitivity Analysis      $1,120     $2,646 $1,526 (CI: $1,493 - $1,560) 
Sensitivity analysis results were based on Monte Carlo simulation with 2000 iteration trials. 
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Appendix Table 6.5   Case Scenario Sensitivity Analysis Results 
Year Analysis Top-down Biological User 
Bottom-up 
Biological User Difference 
Case Scenario 1: Probabilities in the first year were based on late users' data in previous years 
1st year Base-case Analysis     $18,634     $10,967 $7,667 
 
Sensitivity Analysis     $18,736     $11,016 $7,720 (CI: $7,567 - $7,873) 
     
2nd year Base-case Analysis      $17,442     $15,227 $2,215 
 
Sensitivity Analysis      $17,441     $15,244 $2,197 (CI: $2,096 - $2,299) 
     
3rd year Base-case Analysis      $15,932     $14,317 $1,615 
 
Sensitivity Analysis      $15,916     $14,310 $1,606 (CI: $1,490 - $1,722) 
     
Case Scenario 2: Probabilities in the first year were based on early users' data in previous years 
1st year Base-case Analysis     $17,711     $6,966 $10,745 
 
Sensitivity Analysis     $17,712     $6,944 $10,768(CI:$10,542-$10,994) 
     
2nd year Base-case Analysis      $16,785     $14,854 $1,931 
 
Sensitivity Analysis      $16,751     $14,777 $1,974 (CI: $1,849 - $2,099) 
     
3rd year Base-case Analysis      $15,576     $14,220 $1,356 
 
Sensitivity Analysis      $15,607     $14,137 $1,470 (CI: $1,344 - $1,596) 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
 
  
 
 
 
CHAPTER VII:  
 
EARLY ADOPTION OF BIOLOGICAL THERAPIES BY 
PATIENTS WITH CROHN'S DISEASE: COST ANALYSIS FROM 
THIRD PARTY PAYERS' PERSPECTIVE 
 
Background: As more patients with Crohn's disease (CD) adopt biological therapies early in 
their disease course, the economic impact of this treatment strategy on third party payers 
becomes increasingly important.  
Objectives: This study sought to evaluate whether or not the top-down treatment approach is 
cost-saving for payers when considering potential improvements in spending for non-
prescription healthcare services. 
Methods:  A decision tree model was constructed to compare total healthcare costs for 
biological therapy users during the first three years following a CD diagnosis when using two 
different treatment strategies, top-down and bottom-up approach. Parameters for the decision 
model, including transition probabilities and  healthcare costs, were derived from cohort 
analyses based on claims data from CD patients who used biological therapies early or late in 
their disease course. Study cohorts were selected from the MarketScan Commercial Claims 
and Encounter database from 2005 to 2009. 
Results:  Total healthcare costs were predicted at $33,025 in the first year for CD patients 
who used top-down treatment approach, which was $9,073 (CI: $8,716-$9,429) more than 
the costs for bottom-up therapy users. The difference in total healthcare costs decreased to 
$1,299 (CI: $1,005-$1,593) in the second year, and further reduced to $900 (CI: $660-$1,140) 
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in the third year. The cost neutrality between the two treatment strategies for CD 
management was primarily attributed to the cost reduction for both inpatient and outpatient 
services. A sub-group analysis on CD patients who used biological therapies more frequently 
in the three months after their initial dose demonstrated a saving of $564 (CI: $268-$862) in 
healthcare costs in the third year of disease if the top-down strategy was used.   
Conclusion: Compared to conventional bottom-up therapy, the top-down treatment approach 
is cost neutral, and potentially cost saving for payers. It is recommended that payers balance 
the short-term burden of increased drug costs and long-term gain of savings from total 
healthcare services when evaluating their health plans. 
 
 
7.1 Introduction 
 
 Crohn's disease (CD) is a major inflammatory bowel disease (IBD) that affects the 
gastrointestinal tract with symptoms of diarrhea, abdominal pain, fatigue, fever, bowel 
obstruction, and passage of blood and mucus.[1] CD substantially impairs quality of life for 
patients and entails great financial burden to the US society.[2] In 2006, total direct medical 
costs were estimated at $18,000 per patient and over $10 billion to the US healthcare 
system.[3] Medical costs for Crohn's disease may have increased even more in recent years 
because novel biological therapies were more frequently prescribed to CD patients. 
 Four biological agents (including infliximab, adalimumab, natalizumab and 
certolizumab pegol) have been approved by the FDA to treat CD. Compared to conventional 
drug therapies, these biological therapies have many therapeutic benefits, including a higher 
response rate, more rapid onset of clinical response, greater effectiveness in maintaining 
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long-term remission, and significant improvement in health related quality of life.[7-9] As a 
result, the treatment strategy for CD is currently shifting toward the adoption of biological 
therapy as a first-line treatment regimen.  Conventionally, biological therapies were reserved 
as the last medical resort for patients who are refractory or intolerant to conventional drugs, 
which include aminosalicylates, antibiotics, steroids, and immunomodulators.  This strategy, 
referred to as 'bottom-up' therapy, advocates that patients start with less expensive drugs, and 
gradually move to more advanced biological therapies. Recently, clinical studies have shown 
that biological therapies result in a more rapid remission and higher remission rate if they are 
introduced into the treatment algorithm early in the disease course.[12, 13] Thus, a new 
treatment regimen, known as the 'top-down' approach, suggests that patients start with 
biological therapy as first-line treatment, either in combination with immunomodulators or as 
mono therapy.  
 The adoption of biological therapy as a first line treatment can significantly increase 
medication costs.  However, if these medications are proven to be more effective, they may 
result in lower health care spending for other services. This study takes an important step in 
the effort to conduct effectiveness research on biological therapies by comparing healthcare 
costs that incurred by CD patients who use either the top-down or bottom-up approach when 
adopting novel biological therapies into treatment regimen. More specifically, we aim to 
determine costs that are paid by managed care organizations (MCOs) for all health care 
services utilized by CD patients, including inpatient, outpatient, and emergency department 
services as well as prescription drugs. In this study, the targeted population is patients who 
are commercially insured. This population is thought to be representative of the majority of 
Crohn's disease patients as this condition is most common in people of working age who 
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often obtain health insurance through their employer.[90] In the private sector of the US 
healthcare system, more than 95% of insured persons are enrolled in MCOs, who not only 
manage the use of healthcare services, but control their costs. Increasing healthcare 
expenditures in recent years can be partly attributed to the adoption of novel technologies and 
therapies.[91] Biological therapies for CD treatment provide unprecedented medical benefits 
to patients, however, they also impose a substantial financial burden to payers because they 
cost five to ten times more than conventional drugs.[3, 74] In a previous unpublished study, 
we showed that the annual drug cost for biological users was $16,848 which is significantly 
higher than drug costs for non-biological users which averaged $2,919 (see Chapter 6). 
Increasing prescription drug spending leads to heightened awareness of medication 
expenditures by managed care organizations (MCOs) charged with managing drug costs. 
MCOs have a number of cost-containment strategies available, including prior authorization, 
quantity limits, and care management.[92] A thorough understanding of medication and 
health expenditures resulting from the shift in prescribing from the bottom-up to top-down 
approach would help inform MCO’s about the potential benefits that might result from 
increasing prescription expenditures for biological treatments.  
 As with all medication treatments, the benefits from treatment are only achieved in 
patients who use medication appropriately.  For conventional small-molecule drugs, 
medication adherence plays an important role in optimizing their treatment effect.[93]  
Literature about adherence to biological therapies, however, is scarce due to technical 
barriers in measuring and calculating medication adherence and persistence, including 
diverse administration methods (i.e., intravenous infusion and subcutaneous injection) and 
different distribution channels (i.e., physician office visit and pharmacy retail).[94] For 
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biological therapies, discontinuation rate and dose frequency are commonly used as crude 
adherence measurements. Among CD patients treated with infliximab, 68% of them 
discontinued treatment twelve months following initiation, and up to 80% discontinued 
infliximab after thirty-six months.[40] This high treatment discontinuation rate was also 
observed among patients with rheumatoid arthritis.[95]  Evidently, CD patients with more 
frequent use of infliximab as maintenance therapy in the first year had a lower rate of 
hospitalization and increased medical costs.[44]  
 In this study, a decision analytical model is employed to predict the cost difference to 
MCOs when the CD treatment strategy changes from the conservative bottom-up to 
aggressive top-down approach. We further evaluate the economic impact of this treatment 
strategy change on a subgroup of CD patients who used biological therapies more 
persistently to examine the role of patient adherence on health care costs.  The results from 
this study will enrich the literature with information regarding potential reductions in  
healthcare costs for CD patients from the adoption of a shift in treatment strategy from late to 
early adoption. 
 
7.2 Methods 
Sample Selection 
 The study sample was selected from the MarketScan Commercial Claims and 
Encounter (CCAE) database (Thomson Reuters, Ann Arbor, Michigan). These data 
comprised of data from January 1, 2005 to December 31, 2009. Patients were eligible for 
inclusion in our study sample if they met the following criteria: a) a confirmed diagnosis of 
Crohn's disease; b) age between 18 and 64; c) enrollment in an MCO; d) a minimum of one 
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year of continuous enrollment after CD diagnosis; e) a 6-month, disease free period before 
the first CD treatment; and f) at least one infusion/injection of an FDA-approved biological 
therapy (namely, infliximab, adalimumab, natalizumab, certolizumab pegol). Given the 
potential for these medications to be used for other FDA approved conditions, patients were 
excluded from the study sample if they were also diagnosed with ulcerative colitis, 
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenile idiopathic 
arthritis. In total 6,068 patients were identified as eligible biological users for this study. 
Among them, 3,082 patients initiated biological therapy as their initial treatment for Crohn's 
disease. These patients were categorized as early adoption biological users, and considered as 
top-down therapy users. The remaining patients (n=2,986), who used other CD treatments 
(aminosalicylates, corticosteroids, antibiotics, and immunomodulators) prior to biological 
therapies, were defined as late adoption biological users, and deemed as bottom-up therapy 
users. While early adopters started to use biological therapies three months on average after 
CD diagnosis, late adopters waited twelve months to initiate biological treatment. 
 
Decision Modeling 
 A decision tree was developed to compare total healthcare costs for CD patients who 
followed top-down or bottom-up treatment approaches for biological therapies (see Figure 
6.1).  A three-year time frame was built into the model to predict annual healthcare costs 
following the initial diagnosis of CD. Disease severity was assessed using a claims based 
algorithm developed by Malone et al.[68] According to patients' healthcare utilization 
records in each year,  disease severity was classified into one of four categories: a) remission; 
b) mild to moderate; c) moderate to severe; or d) severe or fulminant (See Appendix Table 
 154 
 
6.1 for detailed classification criteria for each severity category). Initial pathways depicted on 
the decision tree for each treatment strategy show disease severity in the first year following 
CD diagnosis. Disease severity for CD patients was either changed, or remained the same, 
from the first year to the second year. A transition in disease severity from the first year to 
the second year is demonstrated by the pathways in the second layer of the decision tree. To 
populate the decision model, cohort analyses were conducted to estimate healthcare costs 
(payoff value) and the transition probabilities for all pathways. Under the top-down scenario, 
the probability of severity allocation and cost assignment of each classification of severity 
were based on the estimation from patients who adopted biological therapies in their initial 
CD treatment in a large claims database from 2005 to 2009. For patients under the bottom-up 
scenario, their model parameters were estimated from patients who used biological therapies 
later than conventional drugs in the same database. Algorithms for disease severity 
classification and transition probability calculation were described in another study (see 
Chapter VI for details). 
  
Healthcare Costs 
 Total healthcare costs were of primary interest in this study. For CD patients who 
used top-down or bottom-up treatment strategy, total healthcare costs were comprised as the 
sum of costs for four individual healthcare services, including inpatient, outpatient, 
emergency department services and prescription drugs. In each year following the diagnosis 
of CD, healthcare costs were estimated based on claims from 2005 to 2009. Annual 
healthcare costs were the average amount that payers reimbursed patients for all healthcare 
services, including prescription drugs, in each 12-month period following the CD diagnosis. 
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Healthcare costs occurring in each calendar year were adjusted to the value of the U.S. dollar 
in 2010, then calculated annually according to patients' treatment strategy and disease 
severity classification (see Table 7.1).  In addition, the costs for each of the four individual 
healthcare services (e.g., inpatient services) were similarly estimated based on claims data for 
each specific service area (see Appendix Table 7.1). 
 In the cost summarization for total healthcare or individual healthcare services, only 
patients with a full year of enrollment in MCOs were included. In the first year of disease, all 
eligible patients automatically had a one-year enrollment period as required by the previously 
defined inclusion criteria. Patients who were partially enrolled in MCOs were not taken into 
consideration when calculating the annual healthcare costs for the second and third year. For 
example, if a patient had continuous enrollment for 27 months (2 years and 3 months) 
following CD diagnosis, then this patient was only eligible for cost summarizations in the 
first and second years.  
 Examining the distribution of health care costs, we found a small number of patients 
with outlier expenditures for inpatient services. Among CD patients eligible for cost 
summarization (6,068 in the first, 3,825 in the second and 1,878 in the third year of CD),  17 
patients in one of three years, or 0.1% of 11,771 patient-years, incurred annual inpatient costs 
exceeding $250,000 per year. A review of claims data showed that these high inpatient costs 
were attributable to lengthy inpatient stays and non-CD related therapies or procedures (e.g., 
chemotherapy for cancer treatment). To account for potential inflation of our cost estimates 
on the basis of these outlier observations, we truncated inpatient costs at $250,000. 
Examining annual costs for other healthcare services, i.e., outpatient, emergency department 
services, and prescription drugs did not reveal concerns regarding outlier observations. 
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 Base Case Analysis 
The base case in the decision model refers to a new Crohn's disease patient who uses 
biological therapies following the conventional 'bottom-up' strategy. The alternative case is 
the patient who instead uses biological therapies following the new 'top-down' approach. 
Regardless of case scenario, the patient was assumed to have the same severity of disease as 
an average biological user  had during  the first year of disease from 2005 to 2009. Total 
healthcare costs were estimated accordingly by disease severity and treatment strategy 
adapted during the disease course. In the second and third year of disease, patients were 
allocated transition probabilities for different disease severities. Base case analysis compared 
total healthcare costs of the base case patient with the alternative case patient in the first three 
years of disease. The difference in total healthcare costs demonstrates the economic effect of 
new top-down treatment strategy. 
 
Sensitivity Analysis 
Probabilistic sensitivity analysis (PSA) using Monte Carlo simulation was performed 
to estimate the impact of uncertainty regarding input parameters in the decision model. The 
input parameters, both transition probabilities and healthcare costs, were each specified with 
different distributions. Given the complexity of multiple categories for disease severity, the 
Dirichlet distribution was used to represent the combination of multinomial parameter 
probabilities. Although a series of conditional beta distributions could describe multinomial 
data, the Dirichlet distribution has been successfully implemented to ease in fitting 
multinomial probabilities in decision modeling.[71] For healthcare costs, a gamma 
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distribution was used to describe its distribution given that costs are constrained on the 
interval 0 to positive infinity (see Appendix Table 7.3).  
 Probabilistic sensitivity analysis (PSA) using the Monte Carlo simulation was 
performed to quantify the impact of input parameters on the uncertainty in model output. 
Both base case and sensitivity analyses were conducted in TreeAge Pro 2011 (TreeAge 
Software Inc., Williamstown, MA). The study was approved by the Institutional Review 
Board (IRB) at the University of North Carolina at Chapel Hill. 
 
Subgroup Analysis 
 From the study sample (n=6,608 CD patients), more persistent biological users were 
selected for a subgroup analysis. The recommended dosage to treat CD in the first three 
months (12 weeks) are: a) for infliximab, 3 infusions at weeks 0, 2, 6; b) for adalimumab, 7 
injections on days 1, 15, 29, weeks 6, 8, 10, and 12; c) for natalizumab, 4 infusions at weeks 
0, 4, 8, and 12; and d) for certolizumab pegol, 5 injections at weeks 0, 2, 4, 8, and 12. In this 
study, we used the number of doses of biological therapies as the crude measurement of drug 
adherence. Patients who used three or more doses of biological therapies (including the initial 
dose) during the three months following their initial dose were identified as frequent 
biological users. There were 2,404 (39.6% of 6,068) patients who were eligible for the 
subgroup analysis. Their characteristics, including age, gender, and comorbidity, were 
similar to both early and late biological users (see Appendix Table 7.6). 
Total healthcare costs for the subgroup of CD patients were compared by using the 
same decision tree model for base case and sensitivity analyses above (see Figure 6.1). 
Frequent biological users in the subgroup were categorized as early frequent biological users 
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(n=848, or 27.5% of 3,082) if biological therapy was included in their initial treatment, or as 
late frequent biological users (n=1,556, or 52.1% of 2,986) if biological therapies were used 
later in their disease course after other conventional treatments were attempted. We 
considered early frequent biological users followed top-down treatment strategy, and late 
frequent biological users used bottom-up therapy approach. According to the treatment 
strategy of adopting biological therapy and annual assessment of disease severity, total 
healthcare costs and transition probabilities in the first three years of CD for frequent 
biological users were calculated based on their claims data in previous years (see Appendix 
Tables 7.4 and 7.5). 
  
7.3 Results 
Base Case Analysis 
 In the first year of CD, total healthcare costs were estimated at $32,910 for patients 
who followed top-down treatment approach and $23,706 if they used bottom-up approach. 
This difference was mainly explained by the costs of biological therapies incurred to CD 
patients. On average, biological therapies were initiated 89 days after diagnosis if patients 
followed top-down strategy to adopt these expensive therapies early, and 365 days if patients 
used the bottom-up approach. The top-down treatment strategy is associated with 38.8% 
higher total healthcare costs  than bottom-up approach. Total healthcare costs in the second 
and third years were predicted at $28,500 and $26,384, respectively, if patients used the top-
down approach. These predicted values are only 4.2% (second year) and 3.2% (third year) 
higher than those for patients using bottom-up approach (see Table 7.2). 
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 For each of the three years following CD diagnosis, the costs of inpatient services 
were $5,672 (first year), $4,148 (second year), and $4,293(third year) for patients that used 
the top-down strategy. Inpatient service costs were $6,148, $5,387 and $4,941 for patients 
using the bottom-up therapy in the first, second and third years, respectively. Outpatient 
service costs were $8,498 for top-down users in the first year of CD, about 6% higher than 
costs for bottom-up users. However, costs of outpatient services for top-down users were 9% 
and 6% lower than bottom-up users in the second and third year of disease, respectively. 
Prescription drug costs incurred by top-down users were $18,166, twice as much as costs for 
bottom-up users ($8,945) in the first year. Prescription drug costs for bottom-up users 
increased to $13,371 in the second year and remained elevated in the third year ($12,895) of 
CD, the differences in prescription drug costs of patients using two different strategies 
became smaller, even though the costs for top-down users remained 20% (second year) and 
16% (third year) higher. Compared to costs for other healthcare services, emergency room 
services only contributed a small fraction of the total health care costs, totaling $574, $478, 
and $388 for top-down users in the first, second, and third years following CD diagnosis (see 
Figure 7.1 and Appendix Table 7.2). 
 
Sensitivity Analysis 
 Results of the probabilistic sensitivity analysis confirmed findings that informed the 
base case analysis. The incremental costs of total healthcare services from top-down 
treatment startegy rapidly decreased from $9,073 (95% confidence interval: $8,716-$9,429) 
to $1,299 (CI: $1,005-$1,593) from the first year to the second year, and to $900 (CI: $660-
$1,140) in the third year. (see Table 7.2). The differences in the costs of inpatient, outpatient, 
 160 
 
ER services and prescription drugs between the two user groups were statistically significant 
and consistent with the findings from base case analyses (see Appendix Table 7.2). 
 
Subgroup Analysis 
 Total healthcare costs for early and late biological users with greater persistence 
during the first three months of treatment were $34,613 and $23,435, respectively, in the first 
year of CD. Total healthcare costs for patients following two treatment strategies became 
comparable at $29,940 (early) and $29,043 (late) in the second year.  In the third year, total 
healthcare costs for top-down users continuously decreased to $26,601, which was $690 
lower than costs for bottom-up biological users ($27,291). Sensitivity analyses demonstrated 
that the cost-saving of $690 from top-down approach was statistically significant. 
 
7.4 Discussion  
This is the first study using large, real-world data to evaluate the long term economic 
outcomes of biological therapies used by CD patients following different treatment strategies. 
Top-down treatment approach demonstrated cost neutrality for payers after the first year of 
disease.  Although healthcare costs for patients who follow top-down therapy in the first year 
were elevated substantially, their costs became comparable with those using the bottom-up 
approach in the second and third year of CD. This study has demonstrated for the first time 
that the top-down treatment approach can be cost neutral in the long term when compared to 
the conventional bottom-up treatment strategy that recommends to reserve biological therapy 
as last medical resort. 
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The subgroup analyses further showed that top-down treatment strategy can be cost-
saving among CD patients who used biological therapies more aggressively and persistently 
after the initial dose of biological therapy. This suggests that better compliance to biological 
therapies can result in improved economic outcomes, specifically, reduced healthcare costs 
for third party payers. In recent years, payers have been aggressively making efforts to 
contain healthcare costs, especially expenses related to innovative technology and 
medications.[14, 92] The results from our study provide important information to payers 
regarding the long-term value of new biological therapies for Crohn's disease. Our results 
suggest that formulary restrictions for biological treatments in CD patients may not yield cost 
savings and should be considered carefully. More persistent use of biological therapies 
among CD patients should be encouraged to improve adherence, resulting in better clinical 
and economic outcomes.    
Total healthcare services were grouped into the following four categories: a) inpatient 
services, including facility and physician services; b) outpatient services, rendered in a 
doctor's office, hospital outpatient facility, or other outpatient facility; c) emergency room 
services; and d) prescription drugs, including biological therapies and conventional 
medications for CD treatment. As shown in Figure 7.1, total healthcare costs for patients 
using top-down therapy were substantially higher in the first year of disease, and became 
convergent thereafter. In the second and third years, top-down therapy incurred lower costs 
for inpatient, outpatient, and ER services, although drug costs remained higher than those for 
bottom-up therapy users. This indicates that potential cost-savings from top-down treatment 
strategy can be attributed mainly to the decreased cost of non-drug services (i.e., inpatient, 
outpatient and ER services).  
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When a decision tree model was employed to rigorously predict total healthcare costs 
for patients who use top-down and bottom-up treatment strategy of biological therapies, we 
derived all cost parameters and transition probabilities from CD patients in a large claims 
database. This approach for real world data modeling is accompanied by some challenges 
due to imperfection of data. We noticed that there were 17 cases, or 0.1% of 11,771 in total, 
with very high annual costs (more than $250,000 per year) for inpatient services.  For 
example, the highest inpatient expenditures for one patient exceeded $1 million. These 
outliers could significantly distort the cost distribution by elevating the mean and standard 
deviation of certain patient groups when stratified by disease severity (see Appendix Table 
7.7). To avoid the disproportionate influence from these cost outliers, a truncation method 
was applied prior to obtaining cost parameters by substituting extremely high inpatient costs 
with a fixed value of $250,000. Additional decision analyses based on both unadjusted costs 
and adjusted costs with a truncation value of $500,000 showed that these outliers with high 
inpatient service costs inflated the predicted costs for total healthcare, particularly in the third 
year of disease (see Appendix Table 7.8). Because it is not possible to verify all claims 
pertaining to high outlier inpatient costs, the accuracy of claims data can be a potential 
limitation in this study powered by real-world data. 
A lack of patient-level clinical and medical information in the claims database 
introduces another limitation. In order to obtain severity of disease in this study, we used an 
empirical method developed by Malone et al. to classify patients into four different severity 
categories by using patients' medical and pharmacy claims.[68] This method used healthcare 
utilization to approximate disease severity, and could be inaccurate for patients who under- 
or over-utilized healthcare services. Inadequate information about the medical cause of 
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claims prevented us from separating CD-related claims from all claims related to other 
medical causes, even though the diagnosis codes (e.g., ICD-9) were provided in the claims 
database. Additionally, the diagnosis codes were not consistently available across all services 
in a uniform code system. Therefore, it is not practical to differentiate claims by diagnosis 
codes, even though it would be theoretically meaningful to use the difference in CD-related 
healthcare costs to represent the economic outcomes of biological therapies when adopted by 
patients under a different treatment strategy.  
We assumed that patients have equal preference for different treatment strategies. 
Their choices of either early or late adoption of biological therapies into their treatment 
regimen was not affected by patients' characteristics, health status, insurance coverage, and 
comorbid conditions. In a previous unpublished study (see Chapter 5), we did not find a 
significant difference in demographic characteristics (e.g., age and gender) when comparing 
early and late biological users in a large claims database. However we noticed that early 
biological users appeared to have fewer comorbid conditions, used fewer prescriptions in six 
months prior to diagnosis, and were more likely to be working for smaller employers (see 
Table 5.1). This suggests that other factors, such as employment and health insurance 
coverage, could impact a given patient's treatment strategy and resulting economic outcomes. 
This study provided more general information about the economic outcomes for patients 
enrolled in any MCOs. Further research can be conducted on patients enrolled in specific 
health plans to provide more customized information of interest to plan administrators.   
Additionally, long-term side effects of biological therapies were not modeled in this 
three-year study due to lack of long-term safety data. Biological therapies are generally well 
tolerated among CD patient, however, adverse events, including infections, infusion reactions, 
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lymphomas, and demyelinating disease, were reported in clinical studies.[96] Some long-
term side effects, e.g., reactivation of tuberculosis, may have not been captured in the claims 
database. These side effects may undermine clinical benefit of biological therapy, and incur 
extra medical costs. Therefore, long-term healthcare costs may be underestimated for CD 
patients who use biological therapies in their treatment algorithm. 
  
7.5 Summary  
For patients with Crohn's disease, new top-down treatment strategy for biological 
therapy showed a long-term cost-neutrality to Managed Care Organizations (MCOs) when 
compared to conventional bottom-up approach. CD patients who used biological therapies 
more frequently after their initial dose showed that cost savings can be achieved as early as 
the third year after CD diagnosis. The rapid decrease in the incremental costs of total 
healthcare services from the top-down treatment approach was attributed mainly to the 
reduction of costs for non-drug services. This study is the first to demonstrate the long term 
value of biological therapies for CD treatment, and improved economic outcomes when 
adopted early in the initial treatment. 
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Figure 7.1   Comparison of Healthcare Costs of Individual Services 
 
Total Costs
Rx Costs
Outpatient Costs
Inpatient Costs
ER Costs
$0
$5,000
$10,000
$15,000
$20,000
$25,000
$30,000
$35,000
1st year 2nd year 3rd year 1st year 2nd year 3rd year
C
o
s
t
s
 
i
n
 
2
0
1
0
 
U
S
 
D
o
l
l
a
r
Bottom-up  Users                                                                                   Top-down Users
 166 
 
 
Table 7.1   Total Healthcare Costs by Disease Severity 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
     
Late biological users(N=2,986): 
1st year    $6,415($10,655) $16,416($17,936) $23,336($21,708) $45,162($40,116) 
2nd year $10,660($15,102) $21,362($26,589) $25,659($20,010) $46,864($44,390) 
3rd year  $13,568($17,010) $20,668($23,703) $24,879($20,544) $39,857($37,627) 
     
Early biological users (N=3,082): 
1st year $24,904($20,080) $29,467($18,360) $30,100($22,205) $47,444($46,555) 
2nd year $20,389($18,901) $24,316($19,344) $30,051($24,278) $43,570($40,557) 
3rd year $15,383($16,658) $22,720($18,443) $27,875($26,350) $46,189($43,666) 
Mean and standard deviation, in parentheses, were calculated after adjusting to 2010 US$. 
Only costs incurred in a full year were summarized.   
 
 
 
Table 7.2   Comparison of Total Healthcare Costs Between Top-down and Bottom-up Users 
Year Analysis Top-down Biological User  
Bottom-up 
Biological User  Difference 
1st year Base-case Analysis     $32,910     $23,706 $9,204 
 
Sensitivity Analysis     $33,025     $23,952 $9,073 (CI: $8,716 - $9,429) 
     
2nd year Base-case Analysis      $28,500     $27,362 $1,138 
 
Sensitivity Analysis      $28,362     $27,063 $1,299 (CI: $1,005 - $1,593) 
     
3rd year Base-case Analysis      $26,384     $25,563 $821 
 
Sensitivity Analysis      $26,530     $25,630 $900 (CI: $660 - $1,140) 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
 
Table 7.3   Subgroup Analysis Results of Total Healthcare Costs for Frequent Biological Users* 
Year Analysis Top-down Biological User  
Bottom-up 
Biological User  Difference 
1st year Base-case Analysis $34,613 $23,435 $11,178 
 
Sensitivity Analysis $34,585 $23,361 $11,224(CI:$10,850-$11,598) 
     
2nd year Base-case Analysis $29,940 $29,043 $897 
 
Sensitivity Analysis $29,931 $29,184 $746 (CI: $462 - $1,030) 
     
3rd year Base-case Analysis $26,601 $27,291 -$690 
 
Sensitivity Analysis $26,689 $27,253 -$564 (CI: -$862 - -$268) 
*Frequent biological users for subgroup analysis were CD patients who used 3 or more doses of biological therapies 
in the first three months following the initial dose (inclusive). 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
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APPDENDIX 
Appendix Table 7.1   Healthcare Costs for Individual Services by Disease Severity 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
Costs for Inpatient Services 
    Late biological users: 
       1st year $1,226( $5,045) $1,006( $4,355) $2,136($11,860) $20,530($29,297) 
       2nd year    $161( $1,418)    $894( $5,332) $1,807( $9,228) $19,863($32,193) 
       3rd year     $292( $2,437) $1,855( $9,594) $1,993($11,004) $17,856($30,142) 
     
    Early biological users: 
        1st year    $648( $3,911)    $306( $2,691) $1,896( $7,544) $19,858($36,220) 
        2nd year    $550( $3,190) $1,134( $7,963) $2,534($11,074) $15,481($29,419) 
        3rd year    $329( $1,917) $1,050( $4,150) $3,132($17,493) $15,661($29,917) 
     
Costs for Outpatient Services 
    Late biological users: 
       1st year $4,477( $8,217) $6,804($12,513) $8,521($11,964) $11,241($16,984) 
       2nd year $4,407( 9,513) $6,925($11,473) $7,891($11,582) $11,497($18,182) 
       3rd year  $4,815(11,071) $6,600($12,404) $7,212($10,722) $9,557($12,939) 
     
    Early biological users: 
        1st year $7,165($12,276) $7,448($10,643) $8,172($12,794) $10,908($15,010) 
        2nd year $6,186($10,159) $5,931( $7,711) $6,893( $8,431) $10,828($12,498) 
        3rd year $4,198( $8,104) $5,798( $6,470) $6,660( $8,484) $12,565($18,017) 
     
Costs for Prescription Drugs 
    Late biological users: 
       1st year    $579( $3,438) $8,312($11,063) $12,244($11,630) $11,882($11,355) 
       2nd year $5,998( $9,945) $13,298($23,250) $15,555($12,490) $13,876($12,329) 
       3rd year  $8,269($12,326) $11,904($16,530) $15,301($13,512) $11,273( $9,780) 
     
    Early biological users: 
        1st year $16,755($15,219) $21,446($14,770) $19,584($14,914) $15,498($14,124) 
        2nd year $13,288($15,301) $17,085($14,257) $20,274($18,399) $16,182($16,252) 
        3rd year $10,749($13,682) $15,682($16,124) $17,809($16,752) $16,724($17,161) 
     
Costs for Emergent Room Services 
    Late biological users: 
       1st year    $132(   $413)    $294(   $976)    $437( $1,682) $1,510( $3,564) 
       2nd year     $95(   $395)    $245(   $739)    $406( $1,375) $1,628( $4,027) 
       3rd year     $191(   $636)    $309( $1,087)    $380( $1,339) $1,171( $3,063) 
     
    Early biological users: 
        1st year    $336( $2,008)    $267(   $735)    $448( $1,439) $1,179( $2,238) 
        2nd year    $367( $2,746)    $166(   $476)    $350( $1,113) $1,081( $2,688) 
        3rd year    $107(   $366)    $191(   $596)    $274( $1,007) $1,241( $3,434) 
Mean and standard deviation, in parentheses, were calculated after adjusting to 2010 US$. 
Only costs incurred in a full year were summarized.    
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Appendix Table 7.2   Comparison of Healthcare Costs of Individual Services for Top-down and 
Bottom-up Biological Users 
Year Analysis Top-down Biological User  
Bottom-up 
Biological User  Difference 
Costs for Inpatient Services 
  1st year Base-case Analysis     $5,672     $6,148 -$476 
 
Sensitivity Analysis     $5,607     $6,045 -$438 (CI: -$524 - -$352) 
     
  2nd year Base-case Analysis      $4,148     $5,387 -$1,239 
 
Sensitivity Analysis      $4,289     $5,751 -$1,462(CI: -$1,659 - -$1,264) 
     
  3rd year Base-case Analysis      $4,293     $4,941 -$648 
 
Sensitivity Analysis      $4,367     $5,106 -$336 (CI: -$484 - -$187) 
 
Costs for Outpatient Services 
  1st year Base-case Analysis     $8,498     $8,011 $487 
 
Sensitivity Analysis     $8,470     $8,013 $457 (CI: $278 - $636) 
     
  2nd year Base-case Analysis      $7,291     $8,001 -$710 
 
Sensitivity Analysis      $7,300     $7,987 -$687 (CI: -$750 - -$623) 
     
  3rd year Base-case Analysis      $6,808     $7,229 -$421 
 
Sensitivity Analysis      $6,948     $7,291 -$343 (CI: -$430 - -$257) 
 
Costs for Prescription Drugs 
  1st year Base-case Analysis     $18,166     $8,945 $9,221 
 
Sensitivity Analysis     $18,135     $8,900 $9,235 (CI: $9,027 - $9,443) 
     
  2nd year Base-case Analysis      $16,583     $13,371 $3,212 
 
Sensitivity Analysis      $16,638     $13,387 $3,251 (CI: $3,124 - $3,377) 
     
  3rd year Base-case Analysis      $14,895     $12,895 $2,000 
 
Sensitivity Analysis      $14,911     $12,893 $2,017 (CI: $1,899 - $2,136) 
 
Costs for Emergency Room Services 
  1st year Base-case Analysis     $574     $603 -$29 
 
Sensitivity Analysis     $571     $604 -$33 (CI: -$45 - -$22) 
     
  2nd year Base-case Analysis      $478     $603 -$125 
 
Sensitivity Analysis      $471     $602 -$131 (CI: -$148 - -$114) 
     
  3rd year Base-case Analysis      $388     $501 -$113 
 
Sensitivity Analysis      $399     $511 -$112 (CI: -$122 - -$103) 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
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Appendix Table 7.3   Parameters for Sensitivity Analysis in Cost Analysis 
Parameter Base-case value Distribution Specification 
Probability of a CD patient 
assessed with different 
disease severity in the 1st 
year after diagnosis 
Remission: 0.236 
Mild-mod.: 0.117 
Mod.-sev.:  0.410 
Sev./Fulm.: 0.237 
Dirichlet Dirichlet(236;117;410;237) 
Total healthcare cost of a 
late biological user with 
different disease severity in 
the 1st year  
Remission: $6,415 
Mild-mod.: $16,416 
Mod.-sev.:  $23,336 
Sev./Fulm.: $45,162 
Gamma(κ, θ) 
κ =0.362, θ=17,697 
κ =0.838, θ=19,597 
κ =1.156, θ=20,193 
κ =1.267, θ=35,633 
Total healthcare cost of a 
late biological user with 
different disease severity in 
the 2nd year 
Remission: $10,660 
Mild-mod.: $21,362 
Mod.-sev.:  $25,659 
Sev./Fulm.: $46864 
Gamma(κ, θ) 
κ =0.498, θ=21,394 
κ =0.645, θ=33,096 
κ =1.644, θ=15,605 
κ =1.115, θ=42,047 
Transition probability of a 
late biological user with 
remission disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.265 
Mild-mod.: 0.139 
Mod.-sev.:  0.390 
Sev./Fulm.: 0.206 
Dirichlet Dirichlet(265;139;390;206) 
Transition probability of a 
late biological user with mild 
disease in the 1st year to 
different disease severity in 
the 2nd year 
Remission: 0.171 
Mild-mod.: 0.370 
Mod.-sev.:  0.288 
Sev./Fulm.: 0.171 
Dirichlet Dirichlet(171;370;288;171) 
Transition probability of a 
late biological user with 
moderate disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.112 
Mild-mod.: 0.077 
Mod.-sev.:  0.639 
Sev./Fulm.: 0.172 
Dirichlet Dirichlet(112;77;639;172) 
Transition probability of a 
late biological user with 
severe disease in the 1st year 
to different disease severity 
in the 2nd year 
Remission: 0.129 
Mild-mod.: 0.123 
Mod.-sev.:  0.366 
Sev./Fulm.: 0.382 
Dirichlet Dirichlet(129;123;366;382) 
Total healthcare cost of a 
early biological user with 
different disease severity in 
the 1st year 
Remission: $24,904 
Mild-mod.: $29,467 
Mod.-sev.:  $30,100 
Sev./Fulm.: $47,444 
Gamma(κ, θ) 
κ =1.538, θ=16,190 
κ =2.576, θ=11,440 
κ =1.838, θ=16,381 
κ =1.039, θ=45,683 
Total healthcare cost of a 
early biological user with 
different disease severity in 
the 2nd year 
Remission: $20,389 
Mild-mod.: $24,316 
Mod.-sev.:  $30,051 
Sev./Fulm.: $43,570 
Gamma(κ, θ) 
κ =1.164, θ=17,521 
κ =1.580, θ=15,388 
κ =1.532, θ=19,615 
κ =1.154, θ=37,753 
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Parameter Base-case value Distribution Specification 
Transition probability of a 
early biological user with 
remission disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.690 
Mild-mod.: 0.054 
Mod.-sev.:  0.151 
Sev./Fulm.: 0.105 
Dirichlet Dirichlet(690;54;151;105) 
Transition probability of a 
early biological user with 
mild disease in the 1st year 
to different disease severity 
in the 2nd year 
Remission: 0.289 
Mild-mod.: 0.386 
Mod.-sev.:  0.228 
Sev./Fulm.: 0.097 
Dirichlet Dirichlet(289;386;228;97) 
Transition probability of a 
early biological user with 
moderate disease in the 1st 
year to different disease 
severity in the 2nd year 
Remission: 0.250 
Mild-mod.: 0.074 
Mod.-sev.:  0.549 
Sev./Fulm.: 0.127 
Dirichlet Dirichlet(250;74;549;127) 
Transition probability of a 
early biological user with 
severe disease in the 1st year 
to different disease severity s 
in the 2nd year 
Remission: 0.297 
Mild-mod.: 0.054 
Mod.-sev.:  0.210 
Sev./Fulm.: 0.439 
Dirichlet Dirichlet(297;54;210;439) 
1.Parameters for Gamma distributions are approximated by mean and standard deviation: κ =ū2/s2, θ =s2/ū 
2.Total healthcare costs in the 3rd year and transition probability from the 2nd to the 3rd year for both 
early and late biological users are similarly specified with Gamma and Dirichlet distributions. Meanwhile, 
costs of individual services (e.g. inpatient services) can also been similarly specified as total healthcare 
costs. Detailed specifications for those parameters are not included in the table above.
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Appendix Table 7.4   Transition Probabilities of Frequent Biological Users 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
     
Bottom-up biological users: 
1st year  2nd year 
     Remission 0.207 0.069 0.534 0.190 
     Mild-moderate 0.120 0.333 0.344 0.203 
     Moderate-severe 0.094 0.059 0.669 0.177 
     Severe/Fulminant 0.145 0.101 0.347 0.407 
     
2nd year 3rd year 
     Remission 0.373 0.145 0.301 0.181 
     Mild-moderate 0.189 0.405 0.243 0.162 
     Moderate-severe 0.097 0.085 0.691 0.127 
     Severe/Fulminant 0.103 0.075 0.402 0.421 
     
Top-down biological users: 
1st year 2nd year 
     Remission 0.682 0.041 0.206 0.071 
     Mild-moderate 0.417 0.333 0.167 0.083 
     Moderate-severe 0.247 0.071 0.538 0.143 
     Severe/Fulminant 0.285 0.062 0.254 0.400 
     
2nd year 3rd year 
     Remission 0.603 0.078 0.233 0.086 
     Mild-moderate 0.143 0.286 0.357 0.214 
     Moderate-severe 0.164 0.073 0.618 0.145 
     Severe/Fulminant 0.195 0.001 0.267 0.537 
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Appendix Table 7.5   Total Healthcare Costs of Frequent Biological Users 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
     
 Bottom-up biological users: 
1st year $6,063( $9,203) $14,859($17,814) $24,246($24,320) $43,565($31,833) 
2nd year $12,723($16,700) $23,297($34,650) $25,296($19,814) $49,120($45,704) 
3rd year  $17,978($20,007) $22,365($27,248) $25,456($22,218) $41,592($41,382) 
     
Top-down biological users: 
1st year $25,218($22,090) $37,633($20,463) $30,234($21,089) $50,055($44,453) 
2nd year $21,039($19,313) $22,824($23,294) $30,508($24,427) $51,206($53,004) 
3rd year $14,630($15,254) $18,106($15,557) $31,086($36,393) $41,666($33,898) 
Mean and standard deviation, in parentheses, were calculated after adjusting to 2010 US$. 
Only costs incurred in a full year were summarized.   
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Appendix Table 7.6    Characteristics of Biological Users with Crohn’s Disease 
Characteristics Biological Users Early Biological Users 
Late 
Biological Users 
Early Frequent 
Biological Users 
Late Frequent 
Biological Users P-value* 
Total number of patients      6,068     3,082     2,986     848     1,556 
 
Year of disease diagnosis,% 
     
<0.001 
 2005       920 (15.2%)       290  (9.4%)      630 (21.1%) 
   66  (7.8%)   293 (18.8%)  
 2006   1,689 (27.8%)   1,038 (33.7%)      651 (21.8%) 
  269 (31.7%)   348 (22.4%)  
 2007      916 (15.1%)      405 (13.1%)      511 (17.1%) 
  114 (13.4%)   275 (17.7%)  
 2008   2,480 (40.9%)   1,321 (42.9%)   1,159 (38.8%) 
  392 (46.2%)   621 (39.9%)  
 2009        63  ( 1.0%)        28 (  0.9%)        35  ( 1.2%) 
    7  (0.8%)    19  (1.2%)  
Age at diagnosis, mean (SD)    37.9 (12.2)     38.0 (12.3)     37.7 (12.2) 
   37.4 (12.1)    37.9 (12.0)   0.332 
Age at 40 years or above, %  2,609 (43.0%)   1,327 (43.1%)   1,282 (42.9%) 
  341 (40.2%)   684 (44.0%)   0.076 
Female, %  3,281 (54.1%)   1,638 (53.1%)   1,643 (55.0%) 
  474 (55.9%)   851 (54.7%)   0.570 
Diagnosed by GI specialist, %   1,846 (30.4%)      868 (28.2%)      978 (32.8%) 
  241 (28.4%)   531 (34.1%)   0.004 
Region,% 
     
  0.085 
 Northeast      733 (12.1%)      365 (11.8%)     368 (12.3%) 
  109 (12.9%)   186 (12.0%)  
 North Central   2,004 (33.0%)   1,102 (35.8%)     902 (30.2%) 
  287 (33.8%)   508 (32.6%)  
 South   2,675 (44.1%)   1,336 (43.3%)   1,339 (44.8%) 
  375 (44.2%)   663 (42.6%)  
 West, or unknown      656 (10.8%)       279  (9.0%)      377 (12.6%) 
   77  (9.0%)   199 (12.7%)  
MSA, %   5,221 (86.0%)   2,671 (86.7%)   2,550 (85.4%) 
  742 (87.5%)  1332 (85.6%)   0.197 
Health Plan, %   3,440 (56.7%)   2,210 (71.7%)   1,230 (41.2%)   622 (73.3%)   650 (41.8%) <0.001 
PPO, %   4,487 (73.9%)   2,460 (79.8%)   2.027 (67.9%)   676 (79.7%)  1062 (68.3%) <0.001 
Fulltime employee, %   2,479 (40.9%)      833 (27.0%)   1,646 (55.1%)   223 (26.3%)   851 (54.7%) <0.001 
Non-dependent employee, %   3,824 (63.0%)   1,946 (63.1%)   1,878 (62.9%)   521 (61.4%)  1007 (64.7%)   0.111 
CCI, mean (SD)     0.05 (0.28)     0.03 (0.22)     0.06 (0.33)     0.05 (0.25)     0.06 (0.28)   0.502 
Rx prior to diagnosis, mean (SD)     1.61 (4.57)     0.55 (1.87)     2.71 (6.05) 
    0.58 (2.06)     3.18 (6.68) <0.001 
* P values were obtained from a Cochran-Mantel-Haenszel test for categorical variables (eg. year of diagnosis), and from a two-way ANOVA test for numerical   
   variables (eg. age) while comparing the characteristics between early frequent biological users and late frequent biological users. 
SD: standard deviation; MSA: metropolican statistical area; GI: gastroenterologist; PPO: preferred provider organization; CCI: Charlson comorbidity index 
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Appendix Table 7.7   Total Healthcare Costs and Inpatient Service Costs 
Year/Severity Remission Mild-moderate Moderate-severe Severe/Fulminant 
     
Inpatient Service Costs (unadjusted with any truncation) 
Late biological users: 
       1st year $1,226( $5,045) $1,006( $4,355) $2,208($13,585) $20,768($31,489) 
       2nd year    $161( $1,418)    $894( $5,332) $1,807( $9,228) $20,654($39,644) 
       3rd year     $292( $2,437) $1,855( $9,594) $1,993($11,004) $18,076($31,946) 
     
Early biological users: 
        1st year    $648( $3,911)    $306( $2,691) $1,896( $7,544) $20,218($38,887) 
        2nd year    $550( $3,190) $1,134( $7,963) $2,534($11,074) $15,481($29,419) 
        3rd year    $329( $1,917) $1,050( $4,150) $6,365($70,352) $15,661($29,917) 
 
Inpatient Service Costs (with truncation at $500,000) 
Late biological users: 
       1st year $1,226( $5,045) $1,006( $4,355) $2,208($13,585) $20,768($31,489) 
       2nd year    $161( $1,418)    $894( $5,332) $1,807( $9,228) $20,614($39,144) 
       3rd year     $292( $2,437) $1,855( $9,594) $1,993($11,004) $18,076($31,946) 
     
Early biological users: 
        1st year    $648( $3,911)    $306( $2,691) $1,896( $7,544) $20,218($38,887) 
        2nd year    $550( $3,190) $1,134( $7,963) $2,534($11,074) $15,481($29,419) 
        3rd year    $329( $1,917) $1,050( $4,150) $3,991($30,764) $15,661($29,917) 
 
Total Healthcare  Costs (unadjusted with any truncation) 
Late biological users: 
       1st year    $6,415($10,655) $16,416($17,936) $23,408($22,808) $45,401($41,927) 
       2nd year $10,660($15,102) $21,362($26,589) $25,659($20,010) $47,655($50,457) 
       3rd year  $13,568($17,010) $20,668($23,703) $24,879($20,544) $40,077($39,334) 
     
Early biological users: 
       1st year $24,904($20,080) $29,467($18,360) $30,100($22,205) $47,804($49,024) 
       2nd year $20,389($18,901) $24,316($19,344) $30,051($24,278) $43,570($40,557) 
       3rd year  $15,383($16,658) $22,720($18,443) $31,108($73,605) $46,189($43,666) 
 
Total Healthcare Costs (with truncation at $500,000) 
Late biological users: 
       1st year    $6,415($10,655) $16,416($17,936) $23,408($22,808) $45,401($41,927) 
       2nd year $10,660($15,102) $21,362($26,589) $25,659($20,010) $47,615($50,053) 
       3rd year  $13,568($17,010) $20,668($23,703) $24,879($20,544) $40,077($39,334) 
     
Early biological users: 
       1st year $24,904($20,080) $29,467($18,360) $30,100($22,205) $47,804($49,024) 
       2nd year $20,389($18,901) $24,316($19,344) $30,051($24,278) $43,570($40,557) 
       3rd year  $15,383($16,658) $22,720($18,443) $28,734($36,823) $46,189($43,666) 
Mean and standard deviation, in parentheses, were calculated after adjusting to 2010 US$. 
Only costs incurred in a full year were summarized.   
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Appendix Table 7.8   Comparison of Total Healthcare Costs and Inpatient Service Costs 
Year Analysis Top-down Biological User  
Bottom-up 
Biological User  Difference 
Inpatient Service Costs (based on unadjusted cost data) 
1st year Base-case Analysis     $5,757     $6,234 -$477 
 
Sensitivity Analysis     $5,798     $6,269 -$471 (CI: -$577 - -$365) 
     
2nd year Base-case Analysis      $4,148     $5,561 -$1,413 
 
Sensitivity Analysis      $4,308     $5,718 -$1,410 (CI: -$1,609 - -$1,211) 
     
3rd year Base-case Analysis      $5,487     $4,986 $693 
 
Sensitivity Analysis      $5,564     $5,070 $493 (CI: $332 - $655) 
 
Inpatient Service Costs (based on cost data truncated at $500,000) 
1st year Base-case Analysis     $5,672     $6,234 -$477 
 
Sensitivity Analysis     $5,798     $6,269 -$471 (CI: -$577 - -$365) 
     
2nd year Base-case Analysis      $4,148     $5,552 -$1,404 
 
Sensitivity Analysis      $4,257     $5,623 -$1,367 (CI: -$1,571 - -$1,162) 
     
3rd year Base-case Analysis      $4,610     $4,986 -$376 
 
Sensitivity Analysis      $4,705     $5,104 -$400 (CI: -$548 - -$252) 
 
Total Healthcare Costs (based on unadjusted cost data) 
1st year Base-case Analysis     $32,995     $23,792 $9,203 
 
Sensitivity Analysis     $33,075     $23,597 $9,478 (CI: $9,122 - $9,833) 
     
2nd year Base-case Analysis      $28,500     $27,536 $964 
 
Sensitivity Analysis      $28,189     $27,079 $1,110 (CI: $819 - $1,401) 
     
3rd year Base-case Analysis      $27,578     $25,608 $1,970 
 
Sensitivity Analysis      $28,094     $25,778 $2,316 (CI: $2,060 - $2,571) 
 
Total Healthcare Costs (based on cost data truncated at $500,000) 
1st year Base-case Analysis     $32,995     $23,792 $9,203 
 
Sensitivity Analysis     $33,075     $23,597 $9,478 (CI: $9,122 - $9,833) 
     
2nd year Base-case Analysis      $28,500     $27,527 $973 
 
Sensitivity Analysis      $28,352     $27,557 $796 (CI: $506 - $1,085) 
     
3rd year Base-case Analysis      $26,701     $25,608 $1,093 
 
Sensitivity Analysis      $26,677     $25,501 $1,176 (CI: $927 - $1,425) 
Sensitivity analysis results were based on the Monte Carlo simulation with 2000 iteration trials. 
 
  
 
 
 
CHAPTER VIII:  
STUDY FINDINGS AND LIMITATIONS 
 
8.1 Summary of Findings 
 This dissertation sought to evaluate the economic consequences on payers when the 
treatment paradigm for Crohn's disease(CD) management is shifting from the conventional 
and conservative algorithm to a more aggressive treatment strategy.  We examined healthcare 
utilization and costs for CD patients in a large claims database from 2005 to 2009. 
Specifically, we compared CD patients who used novel biological therapies following two 
alternate treatment strategies, 'top-down' and 'bottom-up' approaches. The top-down approach 
endorses early use of biological therapy in initial treatment, and bottom-up approach 
promotes late use of biological therapy after non-biological medical treatments have been 
attempted. Based on empirical data for CD patients, we constructed decision tree models to 
predict the differences in annual costs of prescription drugs and total healthcare services in 
the first three years of CD between patients who use the top-down or bottom-up strategy in 
disease management. To our knowledge, this study is the first to use real-world data to 
demonstrate the financial implications to payers resulting from the shift in CD treatment 
strategy. 
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 In Chapter V, we reported that biological therapies have been increasingly used 
among CD patients in recent years. From comparisons of healthcare utilization between early 
and late biological adopters, we found that both groups of CD patients used a similar amount 
of outpatient services. However, early biological adopters used less inpatient and emergency 
room services, and incurred few expenses for both services. Early adopter also filled a fewer 
number of prescriptions, but had greater drug costs because biological therapies are more 
expensive. Average total healthcare costs per year paid by third party payers were not 
categorically different between early and late biological users from 2005 to 2009. These 
results indicate that the new and more aggressive treatment strategy did not cause a rapid 
increase in overall healthcare costs for CD patients. Further, we compared a broad range of 
patient and provider characteristics between the two CD patient cohorts, and found great 
similarities. For example, both early and late biological users were at similar age at diagnosis, 
gender distribution, urban residence, and provider specialty. We also noticed these two 
groups differed in socioeconomic status (e.g., employment status) and general health 
condition (e.g., comorbidity and prescription use). Multivariate regression models confirmed 
that these variables played a significant role in predicting healthcare utilization and costs 
between the two user groups. Due to lack of detailed information about patient 
socioeconomic information and general health assessment in the source data, it is likely that 
relevant variables were omitted in the analyses. Despite statistical adjustments in the 
multivariable regression models, selection bias could have been introduced into the study 
sample and cohort definition. Therefore, the findings in Chapter 5 were informative rather 
than conclusive. 
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 In Chapter VI, a decision tree model was constructed where top-down approach was 
the base case scenario and bottom-up therapy was the alternative.  The model was used to 
predict annual prescription drug costs in the first, second, and third years of disease for 
patients.  In the decision tree, disease severity was the model for possible outcomes of  CD 
treatment. At each chance node on the decision tree, four separate disease severity categories 
(i.e., remission, mild to moderate, moderate to severe, and severe or fulminant) were used to 
classify patients by symptoms and healthcare utilization records. Based on the decision tree 
model, budget impact analyses were performed from the perspective of Pharmacy Benefit 
Management Organizations (PBMOs) with all model parameters (including costs and  
probabilities) estimated from the claims data. We found that the top-down strategy resulted in 
a substantial increase in prescription drug costs during patients' first year of CD. The 
difference in prescription drug costs was reduced significantly in the second and third years 
of disease. These important findings provide key messages to payers, particularly PBMOs.  
The treatment strategy shift from bottom-up to top-down approach of biological therapy 
would result in a drastic increase in prescription drug costs in the first year of disease, but 
extra drug costs associated with this treatment strategy shift are much lower in the second 
and third years. Within a three-year time frame, it is evident that the treatment strategy shift 
towards the early, more aggressive algorithm would not impose a severe financial burden for 
payers. However, caution needs to be practiced when extrapolating these findings over a 
longer time period. The large difference in drug costs in the first year of disease between 
patients using the two treatment strategies was primarily attributable to the timing of initial 
biological treatment. Whereas top-down user began their first biological treatment, on 
average, three months after diagnosis, bottom-up adopters used their first biotherapy one year 
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after diagnosis. We found that prescription drug costs for top-down users were 15 - 20% 
higher during the first and second years of disease than costs for bottom-up users during the 
same time period. It is unknown if the increase in annual drug costs would titrate over time. 
The top-down strategy might require a long-term budgetary increase for MCOs since CD is 
lifelong for most patients. The decision tree model predicted that CD patients using the top-
down approach were less likely to have severe disease at the end of three years . This is an 
indicator that early adoption of biotherapies resulted in better clinical outcomes, and could 
subsequently affect patients' utilization of healthcare services. 
 In Chapter VII, a cost analysis was conducted to compare a broader scope of 
healthcare costs between patients in the base case (bottom-up approach) and those in the 
alternate case (top-down approach) scenario. We used the same decision model from Chapter 
VI, but expanded costs to include prescription drugs, total healthcare services, and more 
specific services, including inpatient, outpatient, and emergency room services. We found 
that CD patients who followed top-down approach incurred substantially higher costs for 
total healthcare services in the first year of disease. This increase in healthcare costs was 
mainly driven by the difference in the induction time of biological therapies between patients 
using top-down or bottom-up approach. The incremental costs of total healthcare services for 
top-down biological users was significantly reduced in the second and third years of disease. 
The top-down treatment strategy also resulted in long-term cost neutrality as the healthcare 
costs for CD patients became comparable with those costs for bottom-up users over time.  
 We further examined healthcare costs according to the types of services that CD 
patients received, which were grouped into four categories: a) inpatient services; b) 
outpatient services; c) emergency room services; and d) prescription drugs. We found that the 
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convergence of total healthcare costs for CD patients could be explained by a cost shift 
between drug and non-drug services (i.e., inpatient, outpatient, and emergency room 
services). Even though prescription drug costs for top-down users remained elevated and 
were higher than drug costs for bottom-up users in the third year of disease, top-down users' 
costs for outpatient, inpatient, and emergency room services were lower. In addition, we 
conducted subgroup analyses among CD patients who used biological therapies more 
aggressively and persistently after the initial dose of biotherapy. A financial savings was 
achieved in the third year of disease for patients who followed top-down strategy and used 
three or more doses (including the initial dose) of biological therapies in the three months 
following their initial biological dose. Our results suggested that better compliance to 
biological therapies could result in improved economic outcomes and reduced healthcare 
costs for third party payers. 
 In summary, this dissertation showed that novel biological therapies have been 
increasingly used among CD patients, and their choice of treatment strategy can affect 
healthcare costs. From the perspective of third party payers, the new and aggressive top-
down treatment approach incurred higher prescription drug costs than the conventional 
bottom-up treatment strategy, especially in the first year of disease. The top-down treatment 
strategy for CD is projected to be cost neutral because patients incur lower costs for non-drug 
services in the long term. In comparison with the top-down treatment strategy, the bottom-up 
treatment strategy is associated with a 270-day deferral of use of biological therapies. The 
short-term cost reduction of the bottom-up users in the first year of disease cannot be 
converted to a long-term cost saving. On the contrary, the bottom-up treatment strategy can 
lead to worsening clinical outcomes and increased non-drug healthcare costs. Therefore, it is 
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recommended that payers to balance their short-term budget to include more pharmacy-
related benefits and their long-term budget to encompass other medical benefits. Restricting 
early access to biological therapies is unnecessary since the top-down treatment approach 
does not incur greater costs than the bottom-up strategy over time. 
 
8.2 Limitations 
Data Issues  
 Despite the merits of a large claims database in observational studies, there were 
some drawbacks to using the MarketScan Commercial Claims and Encounter (CCAE) 
database as the primary data source in this dissertation. The limitations of this real-world data 
can potentially threaten the internal and external validity of our study results. Therefore, 
caution needs to be practiced when interpreting our findings. 
 In this dissertation, we selected patients diagnosed with Crohn's disease who filed 
claims between 2005 and 2009.  These patients were between 18 and 64 years old with 
commercial insurance coverage, and comprised the majority of enrollees in the MarketScan 
CCAE database. Older patients aged 65 and above were mostly retirees, and eligible for 
Medicare. A large portion of young patients under age 18 were insured by public insurance 
programs (e.g., Medicaid and SCHIP). Therefore, our findings may not be generalizable to 
patients aged 65 and above and under 18 years, even though CD can affect both.[16]  
  The MarketScan database provides rich information about patients' utilization records 
from pharmacy counters or other medical facilities whenever a claim is filed to an insurer. 
When serving as source data for an observational study, the MarketScan database lacks 
personal information about each patient's demographic and socioeconomic status as well as 
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detailed medical and clinical data. When developing the conceptual framework for this study, 
we recognized that education level, annual income, and race were important factors that 
could potentially impact a patient’s choice of treatment strategy. Omitting these variables in 
the analytical models could have introduced selection bias into comparisons of healthcare 
utilization and costs between the two patient cohorts.  
 We also realized that more accurate information about patients' initial diagnosis of 
CD, general health condition, and progression of disease severity was needed to ensure the 
credibility of our study findings. Unfortunately, the MarketScan database does not contain 
detailed clinical and medical histories, so other measurements were developed to 
approximate those variables. For example, we denoted the CD diagnosis date as the date of 
the first claim for a procedure with a CD diagnosis or a prescription for a CD drug. We 
assumed that patients were newly diagnosed with CD if no CD-related claims were filed in 
the six months preceding the diagnosis. We used the Charlson Comorbidity Scores and the 
number of prescriptions filled in six months prior to diagnosis to approximate the general 
health condition at diagnosis. Further, we used a claims-based algorithm developed by 
Malone et al. to define disease severity. This method was considered as a better proxy for 
disease severity classification compared to other algorithms because it reflects the current 
treatment practice in the US. However, this claims-based approach has not been verified in 
an actual patient population. It is unknown how accurate the definition of disease severity is 
when compared with standard way in clinical practice. There is likely a potential 
misclassification, particularly for patients with milder disease symptom and patients who 
under-utilized healthcare services. [68] 
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Modeling Issues 
 A decision tree is a simple and effective form of a decision model. In this dissertation, 
the budget impact analysis for Aim 2 and cost analysis for Aim 3 were based on the same 
decision tree model. Since we took a real-world data approach to predict the incremental 
costs of the new treatment strategy (early adoption), the time frame for the decision tree 
model was set to three years, which was based on availability of claims data for CD patients 
in the MarketScan database. In order to obtain consistent estimates of healthcare costs 
(payoff value) and probabilities at each chance node, we required at least 20 patients in the 
same path for each year of either treatment scenario. From our study cohorts (3,082 early 
biological users and 2,986 late biological users), we could not identify an adequate number of 
patients to empirically estimate model parameters for the fourth year of disease. For example, 
among 26 early biological users with mild to moderate disease in the third year of CD, there 
were 6 patients had mild disease and only 1 patient had severe disease in the fourth year. 
Sample sizes reduction over time due to attrition prevented us from extending the time frame 
of the decision model. Based on the three-year decision tree model, the budget impact 
analysis for Aim 2 and cost analysis for Aim 3 provided positive information about the value 
of biological therapies for CD patients, and the tendency toward financial benefits under the 
new treatment strategy. However, a time frame of 5-10 years would be more desirable to 
demonstrate the long-term value of the new treatment strategy since CD is chronic.  
   Another major methodological issue should be mentioned. The budget impact and 
cost analyses were not the best economic evaluation methods to effectively demonstrate the 
value of a new treatment or technology since both methods focus on costs rather than 
effectiveness (namely, health-related quality of life).  In the decision tree model, disease 
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severity was designated as an outcome of medical treatment. Change in disease severity 
(either improving or worsening) may be correlated to patients' quality of life. However, 
disease severity, often in discreet categories, cannot quantitatively represent quality of life on 
a continuous numeric scale. To account for both costs and effectiveness, cost-effectiveness 
analysis (CEA) is a more appropriate method for economic evaluation. However, lack of 
effectiveness data was the obvious barrier to using CEA. The MarketScan database does not 
contain information about health related quality of life. In the literature, quality of life data 
were only reported in randomized clinical trials (RCTs) according to treatment arms. Without 
patient- level information, the published RCT data cannot be incorporated into the decision 
tree model where patients were stratified by disease severity. Furthermore, RCT data were 
obtained from studies with relatively small sample sizes, so the results may not be 
generalizable to a large patient population. 
  
8.3 Future Research Directions 
 
 The study findings and limitations above suggest directions for future research. First, 
to improve the budget impact analysis and cost-analysis models in predicting the long-term 
financial effect of the new treatment strategy, we will need to construct the decision model 
based on a longer time frame, preferably five years. To overcome the constraint on sample 
size, it is recommended that future studies include claims data from more recent years once 
they become available. For the analyses in this study, the most recent year of the MarketScan 
data was 2009. Claims data from 2010 and 2011 could expand the sample size substantially, 
and extend the follow-up time for more patients. We could also consider combining the 
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MarketScan database with another commercial claims database, such as PharMetrics, to 
further increase the sample size. Both MarketScan and PharMetrics include claims data for a 
similar patient population and have similar data structure. Although some patient data may be 
included in both databases, the combined source data would provide a larger patient pool, 
and allow us extend the time frame to five years or beyond to demonstrate the long-term 
effect of the new treatment strategy on CD patients. 
 Second, we recommend that investigators conduct future research with an older 
patient population to evaluate the financial implications of treatment strategy change for CD 
management.  CD in older people (aged 60 and above) counts for 10%-15% of cases of the 
disease and significantly amount of hospitalizations, [97] and healthcare costs for older CD 
patients are believed to be elevated for payers, mainly Medicare. Compared to younger CD 
patients, older patients have more comorbid conditions, different socioeconomic status (e.g., 
most are retirees), and homogenous health insurance coverage. Therefore, the effect of the 
treatment strategy shift from the late to early adoption on the older patient population is 
likely different from the findings in this dissertation.  
 Third, sub-group analyses are recommended to address more specific research 
questions under certain scenarios. In the economic evaluation in this dissertation, we 
combined all biological agents into one drug therapy without taking into account of 
heterogeneity of treatment effect from individual agent. Future studies can be designed to 
estimate the healthcare costs for patients who use one of biological agents or switch to 
another biological agents due to intolerance or non-response to the initial biological agent.  
 Last but not least, future studies need to be conducted in the framework of CEA or 
CUA.  To show the value of novel biological therapies adopted using different treatment 
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strategies, CEA is an appropriate method since it accounts for both costs and effects 
associated with alternative strategies. Lack of patient-level data reflecting quality of life will 
be a challenge when implementing CEA, and  it may be necessary to use simulated data 
based on previously published studies. Under the framework of CUA, it would be 
meaningful for payers if we can estimate the annual costs per unit change of disease severity 
(e.g., from moderate-severe to mild-moderate disease) when a patient follows either the top-
down or bottom-up treatment strategy. 
 In conclusion, this dissertation found that CD treatment strategy shift from the 
bottom-up to top-down approach will not increase prescription drug costs and total healthcare 
costs for payers in a long term. Future studies are recommended to continue to evaluate these 
novel biological therapies from a broader perspective, and in a greater depth when more 
research data become available.
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